filename,title,date,google_drive_link,folder,file_type,page_count,module,document_type,people_mentioned,tags,has_exemption,has_exclusion,password_protected,processed
~$A-CBER-2021-5683-1712392-1712421_27034_S17_M1_hcp-fact-1450-0-5-pi-lab-1457-0-5-clean.docx,HCP Fact Sheet,2021,https://docs.google.com/document/d/1JPXuTnyUxPoDZkEoY3WSLgGLb5Q7v8eP/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,0,M1,fact sheet,,"CBER, Pharmaceutical, Product Labeling, M1, Dosing, Safety, Administration, Medical Information, Regulatory, Clinical Data, Healthcare Provider, Hcp, Product Information, Efficacy",False,False,False,True
19736_S105_M4_berger-rentsch-m-2011.pdf,Berger-Rentsch M. 2011,2011,https://drive.google.com/file/d/1iOVs-v8Sa1q44YeINg0NX8nu8rFN-gBQ/view?usp=drivesdk,eua-051925,PDF,8,M4,report,"Berger, Rentsch","Pharmaceutical, FDA, M4, Risk Management, Safety Analysis, Quality Control, Drug Development, Regulatory Compliance, Product Lifecycle, Adverse Events, Data Analysis, Clinical Trial, Scientific Research, Efficacy",False,False,False,True
19736_S105_M4_dewit-e-2016.pdf,Emergence of Coronaviruses in the 21st Century,2016,https://drive.google.com/file/d/1N-OXtnj4HOHJ4r3_LFNVsoH4vknsQb9F/view?usp=drivesdk,eua-051925,PDF,12,M4,report,"de Wit, SARS-CoV, MERS-CoV","M4, Global Health, Medical Research, Respiratory Disease, Public Health, Coronavirus, Mers, Emerging Infectious Diseases, Viral Outbreaks, Infection Control, Zoonotic Transmission, Epidemiology, Sars, Pandemic",False,False,False,True
19736_S105_M4_brouwer-pjm-2020.pdf,19736 S105 M4 brouwer-pjm-2020,undated,https://drive.google.com/file/d/1XIhlO7UfDusoohaFpe4hmk3k8dAjOTlQ/view?usp=drivesdk,eua-051925,PDF,8,M4,document,,"Review-needed, Clinical, M4, Vaccine, 2020, COVID-19, Research",False,False,False,True
19736_S105_M4_boone-l-2005.pdf,Boone L. 2005 Regulatory Submission,2005,https://drive.google.com/file/d/1xKskqYcj3ky8xNmPiFEWqwpzCH9Z2H-7/view?usp=drivesdk,eua-051925,PDF,7,M4,regulatory submission,Boone L.,"CBER, FDA, Pharmaceutical, M4, Submission, Quality Control, Drug Development, Needs-review, Regulatory, 2005, Clinical Trial, Product Information, Safety Data, Efficacy Data",False,False,False,True
19736_S105_M4_brooks-mb-2017.pdf,19736 S105 M4 brooks-mb-2017,undated,https://drive.google.com/file/d/1DKeoABs0VaTJBROiucb-0nBJgnyujEke/view?usp=drivesdk,eua-051925,PDF,23,M4,document,,"FDA, Review-needed, M4, Study, Data, Research",False,False,False,True
19736_S105_M4_al-amri-ss-2017.pdf,Regulatory Submission for COVID-19 Vaccine,2020-04-13,https://drive.google.com/file/d/1gnI0JgQUzRWaRYsrKQNFrym0_WTzqmc_/view?usp=drivesdk,eua-051925,PDF,8,M4,report,al-amri-ss,"CBER, FDA, M4, Pandemic Response, Submission, Vaccine, Safety, Public Health, Authorization, COVID-19, Regulatory, Clinical Trial, Immunogenicity, Efficacy",False,False,False,True
19736_S105_M4_cai-y-2020.pdf,COVID-19 Vaccine Candidate Development and Evaluation,2020-08-17,https://drive.google.com/file/d/1hj9RGfKHnTRy2TWw6m1RQgP3f8okIoku/view?usp=drivesdk,eua-051925,PDF,12,M4,report,"Cai, Y.","CBER, FDA, M4, SARS-COV-2, Pandemic Response, Biomedical Research, Safety, Public Health, Clinical Trials, COVID-19, Vaccine Development, Immunogenicity, Regulatory Approval, Efficacy",False,False,False,True
19736_S105_M4_baum-a-2020.pdf,A promising approach to combat the COVID-19 pandemic,2020-06-15,https://drive.google.com/file/d/1A9gw1aLJClS00qjfXHIeRP72G63dKVYs/view?usp=drivesdk,eua-051925,PDF,7,M4,report,A. Baum,"M4, SARS-COV-2, Neutralizing Antibodies, Virus Escape Mutants, Selective Pressure, Antiviral Therapy, COVID-19, Combination Therapy, Drug Resistance, Genetically-humanized Mice, Antibody Cocktail, Convalescent Humans, RBD, Spike Protein",False,False,False,True
19736_S105_M4_engelmann-b-2013.pdf,Thrombosis: Pathological Deviation of Haemostasis,2013,https://drive.google.com/file/d/19H48SzcynRntJ2ih0VILm-LSYKrovte3/view?usp=drivesdk,eua-051925,PDF,12,M4,report,Engelmann,"Arterial Thrombosis, M4, Myocardial Infarction, Physiological Haemostasis, Stroke, Deep Vein Thrombosis, Thrombosis, Haemostasis, Blood Coagulation, Venous Thrombosis, Antithrombotic Approaches, Pulmonary Embolism, Cardiovascular Disease, Platelet Activation",False,False,False,True
19736_S105_M4_hassett-kj-2019.pdf,19736 S105 M4 hassett-kj-2019,undated,https://drive.google.com/file/d/1K_tqwwIMgoChuRYYaWhBQjxj2fNwcCXO/view?usp=drivesdk,eua-051925,PDF,11,M4,document,,"Review-needed, Clinical, M4, Vaccine, Trial",False,False,False,True
19736_S105_M4_ennulat-d-2010.pdf,Diagnostic Performance of Traditional Hepatobiliary Biomarkers of Drug-Induced Liver Injury in the Rat,2010,https://drive.google.com/file/d/1SbpPal6sfuepdnvNj5lq_N84BkoU4F-1/view?usp=drivesdk,eua-051925,PDF,16,M4,research paper,"Daniela Ennulat, Michal Magid-Slav, Sabine Rehm, Kay S. Tatsuoka","M4, Biomarkers, Alkaline Phosphatase, Bile Acids, Alanine Aminotransferase, Hepatobiliary, Diagnostic Performance, Bilirubin, Gamma Glutamyl Transferase, Liver Injury, Toxicology, Rats, Aspartate Aminotransferase, Drug Safety",False,False,False,True
19736_S105_M4_henderson-r-2020.pdf,SARS-CoV-2 Spike Protein Structure and Function,2020,https://drive.google.com/file/d/1i36n0173e_7B1bqPITQnc-rbEi0MXFKV/view?usp=drivesdk,eua-051925,PDF,22,M4,article,"Rory Henderson, Priyamvada Acharya","M4, SARS-COV-2, Receptor Binding Domain, Structural Biology, Viral Fusion, Duke University, Pandemic Response, Molecular Biology, Coronavirus, NIEHS, COVID-19, Vaccine Development, Structural Dynamics, Spike Protein",False,False,False,True
19736_S105_M4_hulswit-rj-2016.pdf,Coronavirus Spike Protein and Tropism Changes,2016,https://drive.google.com/file/d/1QSIMz0Uur2-MxzV9c2ns1Fml7QOiInFF/view?usp=drivesdk,eua-051925,PDF,29,M4,chapter,"R.J.G. Hulswit, C.A.M. de Haan, B.-J. Bosch","M4, Membrane Fusion, Structural Biology, Host Range, Coronavirus, Mers, Tropism, Viral Entry, Evolutionary Adaptation, Zoonotic Transmission, Sars, Spike Protein, Receptor Binding, Molecular Virology",False,False,False,True
19736_S105_M4_hoffmann-m-2020.pdf,19736 S105 M4 hoffmann-m-2020,undated,https://drive.google.com/file/d/1GYilEth0WnupAex4xwNNaWnOIFNPLy6b/view?usp=drivesdk,eua-051925,PDF,18,M4,document,,"FDA, Clinical, Review-needed, M4, Vaccine, 2020, COVID-19, Research",False,False,False,True
19736_S105_M4_hutloff-a-2015.pdf,Regulation of T follicular helper cells by ICOS,2015,https://drive.google.com/file/d/17UPRHztTRUXQnASKo2_RhgAZmbEj4QQx/view?usp=drivesdk,eua-051925,PDF,2,M4,research,Andreas Hutloff,"Immune Response, Sphingosine Phosphate Receptor, M4, Akt, Autoimmune Disorders, B Cells, Cell Homing, Klf, T Follicular Helper Cells, Immunology, Signaling Pathway, ICOS, Foxo, Chemokine Receptors",False,False,False,True
19736_S105_M4_ivens-ia-2015.pdf,19736 S105 M4 ivens-ia-2015,undated,https://drive.google.com/file/d/1z1xRQtC0DM4OKXnJTODePTSMqmsr7D-e/view?usp=drivesdk,eua-051925,PDF,25,M4,document,,"FDA, Clinical, Review-needed, M4, Study, Data, Research",False,False,False,True
19736_S105_M4_jiang-s-2020.pdf,Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses,2020,https://drive.google.com/file/d/1PtkIJopPJI76itYFpXUzaF2wSgAzTVau/view?usp=drivesdk,eua-051925,PDF,5,M4,report,"Shibo Jiang, Christopher Hillyer, Lanying Du","SARS-COV, M4, SARS-COV-2, MERS-COV, Neutralizing Antibodies, Global Health, Treatment Development, Public Health, Virus Research, Coronavirus, COVID-19, Prevention, Zoonotic Transmission, Pandemic",False,False,False,True
19736_S105_M4_kariko-k-2005.pdf,Kariko K. 2005 Presentation,2005,https://drive.google.com/file/d/1RyJVBHUBqmMpQgIScBG7CZ9qe3U4tSZy/view?usp=drivesdk,eua-051925,PDF,11,M4,presentation,"Kariko, K.","Nucleic Acid, M4, Molecular Biology, Medical Technology, RNA, Biotechnology, Pharmaceutical Development, mRNA, Academic Presentation, Immunotherapy, Vaccine Development, Scientific Research, Therapeutic Applications, Drug Delivery, Gene Expression",False,False,False,True
19736_S105_M4_kaushal-d-2015.pdf,19736 S105 M4 kaushal-d-2015,undated,https://drive.google.com/file/d/1SGrcgMl8QZ6ffsox_eCjV8l0FC4tW3L-/view?usp=drivesdk,eua-051925,PDF,14,M4,document,,"FDA, Clinical, Review-needed, M4, Vaccine, Research",False,False,False,True
19736_S105_M4_ke-z-2020.pdf,19736 S105 M4 ke-z-2020,undated,https://drive.google.com/file/d/170ijipuKjwfWfI7nIybTJLeCRVgZ7dIW/view?usp=drivesdk,eua-051925,PDF,22,M4,document,,"M4, FDA, Review-needed, 2020, COVID-19",False,False,False,True
19736_S105_M4_kim-a-2014.pdf,"Red Cells, Iron, and Erythropoiesis",2014,https://drive.google.com/file/d/1joloQB8MX1tYccy4zTWDXkxTFmibG2oo/view?usp=drivesdk,eua-051925,PDF,8,M4,paper,"Airie Kim, Eileen Fung, Sona G. Parikh, Erika V. Valore, Victoria Gabayan, Elizabeta Nemeth, Tomas Ganz","M4, Hypoferremia, Mouse Model, Medical Research, Anemia, Brucella Abortus, Hemoglobin, Erythropoiesis, Iron Metabolism, Hepcidin, Erythrocyte Lifespan, Inflammation, Schistocytes, Red Blood Cells",False,False,False,True
19736_S105_M4_kim-a-2016.pdf,Isocitrate treatment of acute anemia of inflammation in a mouse model,2016,https://drive.google.com/file/d/1h3SBVW2iKqxud66V3jvpzW6xkJTG-hZU/view?usp=drivesdk,eua-051925,PDF,6,M4,research article,"Airie Kim, Eileen Fung, Sona G. Parikh, Victoria Gabayan, Elizabeta Nemeth, Tomas Ganz","M4, Mouse Model, Acute Anemia, Isocitrate, Anemia, Brucella Abortus, Hemoglobin, Erythropoiesis, Hepcidin, Erythropoietin, Inflammation, Reticulocytes, Iron, Severe Anemia",False,False,False,True
19736_S105_M4_kim-jy-2020.pdf,Nonclinical Study Report,2020-08-17,https://drive.google.com/file/d/1bet2UpQfI1k4ZyQ-abjmUlw3JT76ese4/view?usp=drivesdk,eua-051925,PDF,7,M4,report,"Kim, Jy","CBER, FDA, Pharmaceutical, August 2020, M4, Study, Nonclinical, Safety, Drug Development, Final Report, Regulatory, Biotech, Toxicology, Preclinical",False,False,False,True
19736_S105_M4_liu-l-2020.pdf,19736 S105 M4 liu-l-2020,undated,https://drive.google.com/file/d/1_dFCUTrsJ5B4pl9cYTQaEOfz9afw9s1y/view?usp=drivesdk,eua-051925,PDF,26,M4,document,,"Review-needed, Clinical, M4, Vaccine, Study, 2020, COVID-19, Trial, Research",False,False,False,True
19736_S105_M4_middleton-ea-2016.pdf,Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases,2016-08-03,https://drive.google.com/file/d/1v3ONwano7G4CfAfVdDY8EQyLOkKd1-zQ/view?usp=drivesdk,eua-051925,PDF,49,M4,research paper,"Elizabeth A. Middleton, Andrew S. Weyrich, Guy A. Zimmerman","M4, Immune System, Critical Care, Pulmonary Immunity, Hemostasis, Thrombosis, Platelets, Respiratory System, Adaptive Immunity, Lung Inflammation, Innate Immunity, Inflammatory Diseases, Molecular Medicine, Physiology",False,False,False,True
19736_S105_M4_page-mj-2002.pdf,A Champion of Host Defense: A Generic Large-Scale Cause for Platelet Dysfunction and Depletion in Infection,2020,https://drive.google.com/file/d/1bWRhmrc_WI_4rriiqbAxHx_DV1MOrpbG/view?usp=drivesdk,eua-051925,PDF,18,M4,research paper,"Martin J. Page, Etheresia Pretorius","Immune Response, Host Defense, M4, Bacteria, Damage-associated Molecular Patterns, Thrombocytopenia, Hemostasis, Cell-cell Interaction, Stellenbosch University, Physiological Sciences, Platelets, Infection, Pathogen-associated Molecular Patterns, Virus, Inflammation",False,False,False,True
19736_S105_M4_muruato-ae-2020.pdf,A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation,2020,https://drive.google.com/file/d/1RLC-EhDeGmQFzijCFtP67xnXVMiZwICs/view?usp=drivesdk,eua-051925,PDF,6,M4,article,"Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, Mariano A. Garcia-Blanco, Vineet D. Menachery, Xuping Xie, Pei-Yong Shi","Assay, Fluorescence-based, Reopening Communities, M4, Antibody Efficacy, COVID-19, Evaluation, Plaque Reduction Neutralizing Assay, Virus Neutralization, Convalescent Plasma Therapy, High-throughput, Rapid Platform, Gold Standard, SARS-COV-2, Vaccine, Serodiagnosis, Neutralizing Antibody, Diagnosis, Antibody Protection",False,False,False,True
19736_S105_M4_pallesen-j-2017.pdf,19736 S105 M4 pallesen-j-2017,undated,https://drive.google.com/file/d/1bAXiBcvNGNJWTyx5W_ou414q_iPWX6yW/view?usp=drivesdk,eua-051925,PDF,10,M4,document,,"M4, Review-needed, Vaccine, COVID-19, Research",False,False,False,True
19736_S105_M4_pardi-n-2017.pdf,19736 S105 M4 pardi-n-2017,undated,https://drive.google.com/file/d/1hnFJL_df7BcE1S5wWUPo6PjTngcu34MI/view?usp=drivesdk,eua-051925,PDF,12,M4,document,,"Data, M4, Review-needed, Vaccine",False,False,False,True
19736_S105_M4_sahin-u-2014.pdf,Nucleic Acid-Encoded Drugs,2014,https://drive.google.com/file/d/1T9EdI6L4VFurg-L1T1R4QlFzHj0SVuLG/view?usp=drivesdk,eua-051925,PDF,22,M4,research,Wolff et al.,"Nucleic Acid, M4, Infectious Diseases, Gene Therapy, Recombinant Engineering, Technological Advances, mRNA, Drug Development, Cytoplasm, Vaccination, Nuclear Envelope, Cancer, Protein Expression, Preclinical Research",False,False,False,True
19736_S105_M4_pardi-n-2018.pdf,Pardi N-2018 Submission,2018,https://drive.google.com/file/d/1JoGSX5Urth24JLZclB8omJLROXS5cFGW/view?usp=drivesdk,eua-051925,PDF,12,M4,submission,,"CBER, FDA, Pharmaceutical, Clinical, Pardi, M4, Application, Safety, Biologics, Regulatory, Data, N-2018, Review, Efficacy",False,False,False,True
19736_S105_M4_sellers-rs-2020.pdf,2020 Sellers Report,2020,https://drive.google.com/file/d/1MetJC5YaeX-f4ubZHOTenAY1hd8vEyzB/view?usp=drivesdk,eua-051925,PDF,20,M4,report,,"M4, Operations, Metrics, Revenue, Strategy, 2020, Performance, Sales, Business, Forecasting, Analysis, Sellers, Market, Trends",False,False,False,True
19736_S105_M4_slansky-je-2000.pdf,Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands,2000-10,https://drive.google.com/file/d/1eJl1j-daXdpoF0S650q8PRNsrOXIezhf/view?usp=drivesdk,eua-051925,PDF,10,M4,research paper,"Jill E. Slansky, Frédérique M. Rattis, Lisa F. Boyd, Tarek Fahmy, Elizabeth M. Jaffee, Jonathan P. Schneck, David H. Margulies, Drew M. Pardoll","M4, Cancer Vaccines, Molecular Biology, Tumor Immunology, Oncology, Immune System, Antigen Presentation, Mhc-peptide-tcr Complex, T Cell Responses, Tumor Antigens, Antigen Recognition, Vaccine Development, Immunology, Cell Biology",False,False,False,True
19736_S105_M4_usfda-2020.pdf,FDA Submission for COVID-19 Vaccine,2020-09-09,https://drive.google.com/file/d/15gN03UtJwkfi53GV4CGQBHXjw7P-TnAw/view?usp=drivesdk,eua-051925,PDF,24,M4,submission,,"CBER, FDA, Pharmaceutical, Medical Product, Pandemic Response, M4, Vaccine, Submission, Public Health, COVID-19, Regulatory, Clinical Trial, Safety Data, Efficacy Data",False,False,False,True
19736_S105_M4_vogel-ab-2018.pdf,Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses,2018,https://drive.google.com/file/d/1OHiNkH9jRUOvsTu70Ne0dSP6kB1LXKLM/view?usp=drivesdk,eua-051925,PDF,10,M4,research article,"Annette B. Vogel, Laura Lambert, Ekaterina Kinnear, David Busse, Stephanie Erbar, Kerstin C. Reuter, Lena Wicke, Mario Perkovic, Tim Beissert, Heinrich Haas, Stephen T. Reece, Ugur Sahin, John S. Tregoning","M4, Vaccine Efficacy, RNA Vaccines, mRNA, Pandemic Preparedness, Vaccine Dosage, Vaccine Development, Immunology, Influenza, Pharmaceutical Research, Vaccine Platforms, Virology, BioNTech, Self-amplifying RNA",False,False,False,True
19736_S105_M4_wrapp-d-2020.pdf,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,2020,https://drive.google.com/file/d/1Xn2HcxKl4Ys_xEVjYw0aMzcEGECJKIQt/view?usp=drivesdk,eua-051925,PDF,4,M4,research paper,"Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Jory A. Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S. Graham, Jason S. McLellan","M4, 2019-ncov, ACE2, Cryo-em, Vaccine, Exclusion, Therapeutic, Public Health, Coronavirus, Antibody, COVID-19, Diagnostic, Outbreak, Prefusion Conformation, Betacoronavirus, Spike Protein, Pandemic",False,True,False,True
19736_S105_M4_who-2014.pdf,WHO Technical Report Series 987,2014,https://drive.google.com/file/d/1bvbCmK3nBgwKLc6L3zS_zuamVeEteh_I/view?usp=drivesdk,eua-051925,PDF,44,M4,report,,"Technical Recommendations, M4, Biological Standardization, Medical Research, Global Health, WHO, Pharmaceutical Quality, Regulatory Guidelines, Public Health, Regulatory Compliance, Expert Committee, Vaccine Development, Scientific Consensus, International Standards",False,False,False,True
19736_S105_M4_who-2005.pdf,WHO guidelines on nonclinical evaluation of vaccines,2005,https://drive.google.com/file/d/1Sm2lZ8uPXsIWVQURLmHAWkacyHF3Xmup/view?usp=drivesdk,eua-051925,PDF,33,M4,guidelines,,"M4, Biotechnology, WHO, Regulatory Expectations, Alternative Administration, Nonclinical Testing, Toxicity Assessment, Regulatory Guidance, Delivery Devices, Infectious Disease Prevention, Vaccine Development, Adjuvants, Immunogenicity, Vaccine Formulation",False,False,False,True
19736_S105_M4_xie-x-2020.pdf,An Infectious cDNA Clone of SARS-CoV-2,2020,https://drive.google.com/file/d/1wD9WjFKEqcqjGIzDc9t3Y-uohWH9x3lz/view?usp=drivesdk,eua-051925,PDF,12,M4,resource,"Xuping Xie, Antonio Muruato, Kumari G. Lokugamage, Krishna Narayanan, Xianwen Zhang, Jing Zou, Jianying Liu, Craig Schindewolf, Nathen E. Bopp, Patricia V. Aguilar, Kenneth S. Plante, Scott C. Weaver, Shinji Makino, James W. LeDuc, Vineet D. Menachery, Pei-Yong Shi","M4, SARS-COV-2, Infectious Cdna Clone, Mneongreen Reporter, Molecular Biology, Biotechnology, Coronavirus, COVID-19, Antiviral Screening, Reverse Genetic System, Infectious Disease, Recombinant Virus, Virology, Pandemic",False,False,False,True
19736_S105_M4_wu-y-2020.pdf,19736 S105 M4 wu-y-2020,undated,https://drive.google.com/file/d/12DiQXyjdPTKj-0pp22C4pKU-z5V81XxO/view?usp=drivesdk,eua-051925,PDF,5,M4,document,,"Review-needed, Clinical, M4, Vaccine, Study, 2020, COVID-19",False,False,False,True
19736_S105_M4_yuan-m-2020.pdf,A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV,2020,https://drive.google.com/file/d/1HQltNetOvsCIwuascOEJUF9EkkreHcBu/view?usp=drivesdk,eua-051925,PDF,4,M4,research paper,"Meng Yuan, Nicholas C. Wu, Xueyong Zhu, Chang-Chun D. Lee, Ray T. Y. So, Huibin Lv, Chris K. P. Mok, Ian A. Wilson","Antigenicity, SARS-COV, M4, SARS-COV-2, Receptor Binding Domain, Membrane Fusion, Crystal Structure, Coronavirus, COVID-19, Neutralizing Antibody, Molecular Insights, Virus Entry, Spike Protein, Pandemic",False,False,False,True
19736_S105_M4_yong-cy-2019.pdf,Clinical Study Report for Yong-CY-2019,2019,https://drive.google.com/file/d/1VOoWqYS7hBkuFTTliySRQi3htSPB2_73/view?usp=drivesdk,eua-051925,PDF,18,M4,report,Yong,"Pharmaceutical, M4, Medical Research, Yong-cy-2019, FDA Submission, Drug Development, Regulatory Compliance, Clinical Study, Patient Outcomes, Clinical Trial, Efficacy Analysis, Product Development, Safety Data, Investigational Drug",False,False,False,True
19736_S105_M4_zakhartchouk-an-2007.pdf,19736 S105 M4 zakhartchouk-an-2007,undated,https://drive.google.com/file/d/1MTPb7DYctOuqBaBfrSOZFi7TUeo3HKF2/view?usp=drivesdk,eua-051925,PDF,8,M4,document,,"FDA, Review-needed, M4, Vaccine, COVID-19, Research",False,False,False,True
19736_S105_M4_zhou-m-2020.pdf,Coronavirus disease 2019 (COVID-19): a clinical update,2020,https://drive.google.com/file/d/1qxqaFsya7Fyyi1YLUNMqaYrK9GC8a05e/view?usp=drivesdk,eua-051925,PDF,10,M4,report,"Min Zhou, Xinxin Zhang, Jieming Qu","M4, Radiology, Global Health, Medical Research, Public Health, Pathology, Coronavirus, Treatment, Clinical Characteristics, COVID-19, Shanghai Jiao Tong University, Infectious Disease, Epidemiology, Respiratory Illness",False,False,False,True
19736_S105_M4_zou-l-2020.pdf,Correspondence on Vitamin E Acetate and EVALI,2020-03-19,https://drive.google.com/file/d/118r1gSHEIrLqx04rgPGQfcTmUrvJYHks/view?usp=drivesdk,eua-051925,PDF,3,M4,correspondence,"Tariq A. Bhat, Maciej L. Goniewicz, Yasmin M. Thanavala, Blount","Vitamin E Acetate, M4, Lung Injury, E-cigarettes, Case-associated Products, Aerosols, EVALI, Lipophilic Solvents, Nicotine, Bal Fluid, Roswell Park Comprehensive Cancer Center, THC, National Institutes Of Health, Vaping",False,False,False,True
27034_S10_M1_covid19-vax.pdf,PFIZER-BIONTECH COVID-19 VACCINE FACT SHEET FOR HEALTHCARE PROVIDERS,2021,https://drive.google.com/file/d/1GGEGMkiKFL0_kQJhMCLYnfJzQ1QCgne_/view?usp=drivesdk,eua-051925,PDF,36,M1,fact sheet,,"Emergency Use Authorization, Healthcare Providers, M1, Vaccine, Public Health, Coronavirus, Clinical Trials, COVID-19, Medical Information, Vaccination, BioNTech, Pfizer, Immunization, Pandemic",False,False,False,True
27034_S15_M1_vrbpac-presentation.pdf,BNT162b2 Vaccine Candidate Against COVID-19,2020-12-10,https://drive.google.com/file/d/1-b2Ss4lb42MWaOFTrGUZ11UdY2a84i0x/view?usp=drivesdk,eua-051925,PDF,61,M1,presentation,"Kathrin Jansen, William Gruber","FDA Advisory Committee, SARS-COV-2, Pandemic Response, Benefit-risk Analysis, M1, Safety, Public Health, Clinical Trials, COVID-19, Non-clinical Data, Vaccine Storage, Vaccine Development, Pfizer, Efficacy",False,False,False,True
27034_S17_M1_fact-sheet-recipients-lab-1451-0-5.pdf,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/1nQTAinJH5uhftr_iVUghIuvyJWwodT_e/view?usp=drivesdk,eua-051925,PDF,6,M1,fact sheet,,"Emergency Use Authorization, SARS-COV-2, Symptoms, M1, Vaccine, Individuals 16 And Older, Coronavirus, Pandemic, COVID-19, Respiratory Illness, Recipients, EUA, Pfizer-biontech, Caregivers",False,False,False,True
27034_S1_M1_fact-sheet-healthcare-lab-1450-0-4.pdf,Fact Sheet for Vaccination Providers - Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/1enomch7U0EV8gkmaoiqT_1PUnJW68ZXr/view?usp=drivesdk,eua-051925,PDF,10,M1,fact sheet,,"Emergency Use Authorization, Reporting Requirements, SARS-COV-2, Healthcare Providers, Pandemic Response, M1, Public Health, Clinical Trials, COVID-19, Vaccination, Adverse Events, Vaccine Administration, Pfizer-biontech, Immunization",False,False,False,True
27034_S17_M1_hcp-fact-1450-0-5-pi-lab-1457-0-5-clean.pdf,Fact Sheet for Healthcare Providers Administering Vaccine,2020-12,https://drive.google.com/file/d/1-1KXeHNk1d9QCXj0-gMW22-767eMQ7Wk/view?usp=drivesdk,eua-051925,PDF,30,M1,fact sheet,,"Emergency Use Authorization, Healthcare Providers, M1, Vaccine, Public Health, Medical Guidance, Coronavirus, Clinical Trials, COVID-19, Regulatory, Vaccination, Pfizer-biontech, Immunization, Pandemic",False,False,False,True
27034_S1_M1_fact-sheet-recipients-lab-1451-0-4.pdf,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021-01-01,https://drive.google.com/file/d/1Mt8eivBs7WAKiObaQDo3ReAPLqO2QQ6d/view?usp=drivesdk,eua-051925,PDF,6,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Symptoms, M1, Vaccine, Coronavirus, COVID-19, Respiratory Illness, Vaccination, Recipients, Pfizer-biontech, Caregivers, Pandemic",False,False,False,True
27034_S1_M5_5351_bnt162-01_10010.pdf,BioNTech BNT162-01 Clinical Trial,2020-08-26,https://drive.google.com/file/d/1viz_QGyVUX7qyJf6RGPdCrnJQq_GTcuO/view?usp=drivesdk,eua-051925,PDF,75,M5,form,,"Crs Mannheim, Pharmaceutical, Alcohol Breath Test, Medical Research, SARS-COV-2 Antibodies, Part A, Clinical Trial, ECG, Safety Lab, COVID-19, M5, BioNTech, Subject 276-01-0010, Bnt162-01",False,False,False,True
27034_S1_M1_pi-lab-1457-0-3.pdf,PFIZER-BIONTECH COVID-19 VACCINE FULL PRESCRIBING INFORMATION,2021,https://drive.google.com/file/d/1S4LS9RyH1yZcm5DNgDTzPk8Kak2FVVQy/view?usp=drivesdk,eua-051925,PDF,22,M1,prescribing information,,"Emergency Use Authorization, Pharmaceutical, M1, Vaccine, Safety And Precautions, Clinical Trial Results, Patient Counseling, Public Health, Regulatory Compliance, COVID-19, Medical Information, Adverse Events, Storage And Handling, Dosage And Administration",False,False,False,True
27034_S1_M5_5351_bnt162-01_10075.pdf,BioNTech BNT162-01 Clinical Trial,2020-09-23,https://drive.google.com/file/d/1e5ZeA_ySAJJNrJpXx1VjgCaKmMtutfVT/view?usp=drivesdk,eua-051925,PDF,94,M5,form,,"Crs Mannheim, FDA, CBER, Subject 276-01-0075, Vaccine, Clinical Trial, Part A, 2020, COVID-19, Safety Lab, Alcohol Test, M5, BioNTech, ECG, Bnt162-01",False,False,False,True
27034_S1_M5_5351_bnt162-01_20116.pdf,BioNTech BNT162-01 (CRS 049/20) Clinical Trial,2020-09-23,https://drive.google.com/file/d/1aC58H9dYWfzYFquUX_v3K8jUPF7HxkMS/view?usp=drivesdk,eua-051925,PDF,81,M5,form,,"Pharmaceutical, Medical Research, Crs Berlin, Part A, Clinical Trial, Crs 049/20, COVID-19, Safety Lab, Alcohol Test, M5, Vaccine Development, BioNTech, Subject Data, ECG, Bnt162-01",False,False,False,True
27034_S1_M5_azar-kmj-2020.pdf,Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California,2020,https://drive.google.com/file/d/1-QsViyBwe_8HdlrVGbeq9RhICaUnOf3L/view?usp=drivesdk,eua-051925,PDF,10,M5,report,"Kristen M. J. Azar, Zijun Shen, Robert J. Romanelli, Stephen H. Lockhart, Kelly Smits, Sarah Robinson, Stephanie Brown, Alice R. Pressman","Electronic Health Records, Health Disparities, Access To Care, Public Health, Hospitalization Risk, Pandemic, Healthcare System, COVID-19, M5, Comorbidities, California, Racial Disparities, Socioeconomic Disparities, Sutter Health",False,False,False,True
27034_S1_M5_argenziano-mg-2020.pdf,27034 S1 M5 argenziano-mg-2020,undated,https://drive.google.com/file/d/15T8wDcnmCR1QKrWQlCoiKsoBOPV2p0KK/view?usp=drivesdk,eua-051925,PDF,9,M5,document,,"Review-needed, Clinical, Study, 2020, COVID-19, M5, Data",False,False,False,True
27034_S1_M5_anderson-rm-2020.pdf,Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination,2020-11-04,https://drive.google.com/file/d/1fRmdOcyniVZoeVDBCulwc2cTkDax7iki/view?usp=drivesdk,eua-051925,PDF,3,M5,report,,"Herd Immunity, SARS-COV-2, Reinfection, Vaccine, Antibodies, Public Health, Vaccine Hesitancy, Public Acceptance, Clinical Trials, Health Policy, COVID-19, M5, Vaccination Program, Immunity",False,False,False,True
27034_S1_M5_bnt162-01-A-adrg.pdf,Analysis Data Reviewer's Guide,2020-10-22,https://drive.google.com/file/d/1CccZ-1i7y1-KLeTjlRQ2rLTlMGQp_ht_/view?usp=drivesdk,eua-051925,PDF,31,M5,guide,"Pfizer Inc., BioNTech SE","Source Data, Data Review, Data Standards, Data Integrity, Regulatory Compliance, Protocol Design, M5, Confidential Information, BNT162 Study, Vaccine Development, Pharmaceutical Research, Data Analysis, Clinical Trial, Analysis Datasets",False,False,False,True
27034_S1_M5_biggerstaff-m-2015.pdf,Estimating the Potential Effects of a Vaccine Program Against an Emerging Influenza Pandemic —United States,2015,https://drive.google.com/file/d/1AvBHLBCSnVpbTyLZ-ouHZ2UsuSOGhZIc/view?usp=drivesdk,eua-051925,PDF,10,M5,report,"Matthew Biggerstaff, Carrie Reed, David L. Swerdlow, Manoj Gambhir, Samuel Graitcer, Lyn Finelli, Rebekah H. Borse, Sonja A. Rasmussen, Martin I. Meltzer, Carolyn B. Bridges","Preparedness, Disease Control, Public Health, Emerging Infectious Diseases, Vaccine Program, Disease Prevention, M5, Influenza Pandemic, Respiratory Diseases, Epidemiology, Hospitalization, Epidemic Modeling, Mortality, Immunization",False,False,False,True
27034_S1_M5_bnt162-01-S-acrf.pdf,BNT162-01 Clinical Study CRF,2020-04-22,https://drive.google.com/file/d/1d_NCH7MVOvHmO6P9cQ-eEuo2xLkY_d0B/view?usp=drivesdk,eua-051925,PDF,41,M5,form,,"Sponsor Study, Protocol Milestone, Crs 049/20, COVID-19, BNT162, Clinical Study, M5, Demographic Data, Vaccine Trial, BioNTech, Body Mass Index, Vital Signs, Informed Consent, Subject Id",False,False,False,True
27034_S1_M5_bnt162-01-S-csdrg.pdf,BNT162-01 Clinical Study Data Reviewer's Guide,2020-10-20,https://drive.google.com/file/d/1V6GdRJneskATvQEp3ZRez5vAt0_ZNBUM/view?usp=drivesdk,eua-051925,PDF,65,M5,report,,"Medical Product, FDA Submission, Exclusion, Data Standards, Trial Design, Regulatory Review, Clinical Study, BNT162, Confidential Information, M5, Vaccine Development, Pharmaceutical Research, Data Analysis, BioNTech, Pfizer",False,True,False,True
27034_S1_M5_c4591001-A-P-adae-s091-all-2mpd2-p23-saf-sas.pdf,ADAE-S091-ALL-2MPD2-P23-SAF Analysis,2020-11-16,https://drive.google.com/file/d/1OUq6_lby-91_kXtD7Zo7gHPYrYs_9RIr/view?usp=drivesdk,eua-051925,PDF,74,M5,analysis,,"Data Reporting, CDISC, Data Management, Data Processing, SAS Programming, ADAE, Patient Safety, Regulatory Compliance, Data Quality, M5, Adverse Events, Data Analysis, Clinical Trial, Data Subset",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf-sas.pdf,ADAE-S091-ALL-PD2-P3-SAF SAS Program,2020-11-16,https://drive.google.com/file/d/1agnrIXGVzVNTLcm7pH46N0j5MZh2IyBO/view?usp=drivesdk,eua-051925,PDF,71,M5,program,,"Safety Analysis, Data Processing, ADAE, Data Transformation, Regulatory Compliance, Data Quality, M5, Clinical Data, Adverse Events, Data Analysis, Data Standardization, SAS, Data Subset, Data Preparation",False,False,False,True
27034_S1_M5_boehmer-tk-2020.pdf,"Changing Age Distribution of the COVID-19 Pandemic — United States, May–August 2020",2020-10-02,https://drive.google.com/file/d/1bcLd_3HU0I6MBT-p80GimQl5-AtHuaDB/view?usp=drivesdk,eua-051925,PDF,6,M5,report,"Tegan K. Boehmer, Jourdan DeVies, Elise Caruso, Katharina L. van Santen, Shichao Tang, Carla L. Black, Kathleen P. Hartnett, Aaron Kite-Powell, Stephanie Dietz, Matthew Lozier, Adi V. Gundlapalli","United States, SARS-COV-2 Testing, Age Distribution, Emergency Department Visits, Regional Outbreaks, Public Health, Disease Surveillance, COVID-19, M5, May-august 2020, Epidemiology, Confirmed Cases, Demographic Trends, Pandemic",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-s130-ser-vax2-p3-saf-sas.pdf,ADAE-S130-SER-VAX2-P3-SAF Analysis,2020-11-16,https://drive.google.com/file/d/1uXSdfUDw7edYVyIB_o7OzI-wQtw5I6lh/view?usp=drivesdk,eua-051925,PDF,22,M5,analysis,,"S130, Vaccine, Vax2, Safety, P3, ADAE, M5, Saf, Phase 3, Programming, Data Analysis, Clinical Trial, SAS, Ser",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-s130-1md2-ser-p3-saf-sas.pdf,ADAE-S130-1MD2-SER-P3-SAF Analysis,2020-11-16,https://drive.google.com/file/d/1R4xvvgUCQvszAOjLFLRZbYScCWViL7z-/view?usp=drivesdk,eua-051925,PDF,22,M5,program,,"S130, Pharmaceutical, Clinical Trial, Data Processing, P3, ADAE, Data Transformation, M5, Saf, Programming, 1md2, Data Analysis, SAS, Ser, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-s130-1md2-soc-p3-saf-sas.pdf,adae-s130-1md2-soc-p3-saf SAS Program,2020-11-16,https://drive.google.com/file/d/1GQU92zEiAuzSVPRtfzUbBFUGMjx6qRxI/view?usp=drivesdk,eua-051925,PDF,22,M5,program,,"Pharmaceutical, Safety, Data Processing, Clinical Trials, ADAE, Data Transformation, Regulatory Compliance, Data Quality, M5, Programming, Data Analysis, Adverse Events, SAS, Data Subset",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-sas.pdf,ADAE Dataset Creation for Phase 2/3 IA - EUA,2020-11-16,https://drive.google.com/file/d/15kufZovdaHzrDqsDwLt-794QCJ5Miqh2/view?usp=drivesdk,eua-051925,PDF,21,M5,program,,"Regulatory Submission, Phase 2, Emergency Use Authorization, Dataset Creation, CDISC, Statistical Programming, Data Processing, Adverse Event, M5, Phase 3, Programming, Data Analysis, Clinical Trial, Interim Analysis",False,False,False,True
27034_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.pdf,ADAE-VAX-TIER2-P3-SAF Analysis,2020-11-16,https://drive.google.com/file/d/1z7fvyC9No8xE25p0ZaFmBJGUXqUWpYoo/view?usp=drivesdk,eua-051925,PDF,18,M5,report,,"Vaccine, Statistical Programming, Safety, Data Processing, Phase3, ADAE, Regulatory Compliance, Tier2, M5, Adverse Events, Data Analysis, Clinical Trial, Pharmaceutical Research, SAS",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ia-sas.pdf,adc19ef Dataset Creation,2020-11-15,https://drive.google.com/file/d/1yfIssr8SlJJEidOUAqesrEBi6sHBEGEE/view?usp=drivesdk,eua-051925,PDF,33,M5,code,,"Clinical Trial Data, Dataset Creation, Adsympt, Data Management, C4591001 Study, Data Processing, SAS Programming, ADSL, COVID-19, M5, Vaccine Development, Data Analysis, Adc19ef, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-cov-bl-7dpd2-eval-ia-sas.pdf,"COVID-19 Occurrence From 7 Days After Dose 2, by Prior SARS-CoV-2 Status",2020-11-15,https://drive.google.com/file/d/18GhlWQP-R-aab7Vh5Bw1gGGHCTUyqqdE/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"SARS-COV-2, Medical Reporting, Vaccine Efficacy, Statistical Programming, Exclusion, Regulatory Compliance, COVID-19, M5, Prior Infection, Dose 2, Data Analysis, Clinical Trial, Interim Analysis, Pharmaceutical Research, Evaluable Population",False,True,False,True
27034_S1_M5_c4591001-A-P-adc19ef-sev-cov-d1-aai-ia-sas.pdf,Severe COVID-19 Occurrence After Dose 1 - Dose 1 All-Available Efficacy Population - Interim Analysis 1,2020-11-16,https://drive.google.com/file/d/1YtNxIo5-_6_4IPi7rVcf76Tsg3zs-ZXn/view?usp=drivesdk,eua-051925,PDF,3,M5,report,,"Regulatory Submission, Vaccine, Statistical Programming, Safety, Severe Disease, COVID-19, M5, Dose 1, Adverse Events, Data Analysis, Clinical Trial, Interim Analysis, Pharmaceutical Research, Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-14pd2-eval-sas.pdf,Vaccine Efficacy - First COVID-19 Occurrence From 14 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/19pZvfLHjxWnqyj5wVnFBo4Zxr9c4y9jq/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Pharmaceutical, Statistical Reporting, Vaccine Efficacy, Public Health, Regulatory Compliance, COVID-19, M5, Infection Prior, Phase 3, Dose 2, Data Analysis, Clinical Trial, Immunization, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-sas.pdf,adc19ef Dataset Creation,2020-11-18,https://drive.google.com/file/d/1_Zjg5DMF-xH0sutt2M2WvsO6yicObzBe/view?usp=drivesdk,eua-051925,PDF,35,M5,code,,"Adsympt, Dataset Creation, Data Management, Data Processing, SAS Programming, Clinical Trials, ADSL, Data Transformation, M5, Clinical Data, Pharmaceutical Research, Data Analysis, Data Engineering, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-eval-sas.pdf,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/1J1iOfB80nFdtvqH8GzxeS-0UvBWR42Hf/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Pharmaceutical, Pandemic Response, Medical Research, Statistical Reporting, Vaccine Efficacy, Public Health, COVID-19, M5, Infection Prior, Regulatory, Dose 2, Data Analysis, Clinical Trial, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-14pd2-wo-eval-sas.pdf,Vaccine Efficacy - First COVID-19 Occurrence From 14 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/11HrAV4B8vEA5eh2OHLx7hvv0Fyr27Ktb/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Pandemic Response, Disease Control, Statistical Reporting, Vaccine Efficacy, Medical Intervention, Public Health, COVID-19, M5, Dose 2, Pharmaceutical Research, Clinical Trial, Data Analysis, Infection Prevention, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-eval-sas.pdf,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/1gAXbDwb_ay1GbXDMiJv2K9c5MNq6YQQd/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Pharmaceutical, Safety Monitoring, Vaccine Efficacy, Public Health, Regulatory Compliance, COVID-19, M5, Biostatistics, Dose 2, Data Analysis, Clinical Trial, Adverse Events, Epidemiology, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-eval-ia-sas.pdf,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/118-RBti5DYwWg5wsdnTqBTX5e2J9OWPE/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Pharmaceutical, Medical Research, Vaccine Efficacy, Clinical Trial, Public Health, Regulatory Compliance, COVID-19, M5, Infection Prior, Biostatistics, Dose 2, Data Analysis, Evaluable Efficacy Population, Interim Analysis",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.pdf,Vaccine Efficacy Analysis - COVID-19 Occurrence After Dose 2,2020-11-15,https://drive.google.com/file/d/18Ye6irrX2kEssm7gnCMpSQd8m2beT8Ib/view?usp=drivesdk,eua-051925,PDF,10,M5,report,,"Subgroup Analysis, Regulatory Submission, Medical Reporting, Vaccine Efficacy, Statistical Programming, Exclusion, Public Health, COVID-19, M5, Prior Infection, Dose 2, Data Analysis, Clinical Trial, Pharmaceutical Research, Evaluable Efficacy",False,True,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-ia-sas.pdf,"Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2, by Subgroup - Subjects Without Evidence of Infection Prior to 7 Days After Dose 2 - Evaluable Efficacy Population (7 Days) - Interim Analysis 1",2020-11-16,https://drive.google.com/file/d/1KdQxRHEyjnqVUMismmJjZhbv2K3iWZpB/view?usp=drivesdk,eua-051925,PDF,10,M5,report,,"Subgroup Analysis, Pharmaceutical, Medical Research, Vaccine Efficacy, Clinical Trial, Exclusion, Public Health, COVID-19, M5, Dose 2, Data Analysis, Evaluable Efficacy Population, Interim Analysis, Infection, Pandemic",False,True,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.pdf,Vaccine Efficacy Analysis - First COVID-19 Occurrence From 7 Days After Dose 2,2020-11-15,https://drive.google.com/file/d/13Zqiyel_NTtrhliOK0BHkg0kH3ug1JSv/view?usp=drivesdk,eua-051925,PDF,10,M5,report,,"Subgroup Analysis, Pharmaceutical, Statistical Reporting, Vaccine Efficacy, Exclusion, Regulatory Compliance, COVID-19, C4591001, M5, Phase 3, Dose 2, Data Analysis, Clinical Trial, SAS Program, Evaluable Efficacy",False,True,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.pdf,Vaccine Efficacy - First Severe COVID-19 Occurrence From 7 Days After Dose 2,2020-11-19,https://drive.google.com/file/d/13HbARCQLeMfztirMn0Smq9JxzjO5v52E/view?usp=drivesdk,eua-051925,PDF,19,M5,report,,"Pandemic Response, Severe COVID-19, Vaccine Efficacy, Safety, Public Health, Regulatory Compliance, M5, Dose 2, Adverse Events, Clinical Trial, Data Analysis, Pharmaceutical Research, Immunogenicity, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-7pd2-wo-eval-sas.pdf,Vaccine Efficacy - First Severe COVID-19 Occurrence From 7 Days After Dose 2,2020-11-19,https://drive.google.com/file/d/1PZAZoq6MglB_WmdAvt_KDrfi7iBZaR4-/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Medical Research, Severe COVID-19, Pandemic Response, Vaccine Efficacy, Statistical Reporting, Public Health, Pharmaceutical Development, Regulatory Compliance, Medical Product Evaluation, M5, Data Analysis, Clinical Trial, 7 Days After Dose 2, Evaluable Efficacy Population",False,False,False,True
27034_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-7pd2-eval-sas.pdf,Vaccine Efficacy - First Severe COVID-19 Occurrence From 7 Days After Dose 2,2020-11-19,https://drive.google.com/file/d/1_zt6weH8z2QqSCw2FAve0so97iIdUMUz/view?usp=drivesdk,eua-051925,PDF,5,M5,report,,"Medical Research, Vaccine Efficacy, Clinical Trial, Statistical Programming, Public Health, COVID-19 Pandemic, C4591001, M5, Data Analysis, Severe COVID-19, 7 Days After Dose 2, SAS, Infection Prior To 7 Days, Evaluable Efficacy Population",False,False,False,True
27034_S1_M5_c4591001-A-P-adce-s020-se-age-p3-saf-sas.pdf,adce-s020-se-age-p3-saf,2020-11-15,https://drive.google.com/file/d/1DU3iZ7Kh7uZywX1qv18uwvJbuQfpNPnB/view?usp=drivesdk,eua-051925,PDF,166,M5,program,,"Se, Safety Analysis, Data Processing, P3, M5, Saf, Age, Adce, Data Analysis, Clinical Trial, Programming, SAS, S020, Adverse Events",False,False,False,True
27034_S1_M5_c4591001-A-P-adce-s010-lr-age-p3-saf-sas.pdf,adce-s010-lr-age-p3-saf,2020-09-28,https://drive.google.com/file/d/1_Z59Qu5RhM-U5DavtOBXhG-7yph1SpAr/view?usp=drivesdk,eua-051925,PDF,66,M5,program,,"Statistical Programming, Clinical Trial, Safety, Lr, Data Processing, P3, M5, Saf, Age, Adce, Data Analysis, S010, Adverse Events, SAS",False,False,False,True
27034_S1_M5_c4591001-A-P-adcevd-sas.pdf,adcevd Dataset Creation,2020-09-21,https://drive.google.com/file/d/1bECMIvQ1eacdWy1Mohb1_kNoO2lUQR0M/view?usp=drivesdk,eua-051925,PDF,18,M5,program,,"Dataset Creation, Data Management, Data Processing, Reactogenicity Events, SAS Programming, Data Transformation, Data Pipeline, Data Quality, M5, Data Integration, Data Analysis, Clinical Trial, Data Engineering, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adds-s002-p3-rand-sas.pdf,Adds-s002-p3-rand SAS Program,2020-11-13,https://drive.google.com/file/d/1eEvgtENpcCyo2cdyo0gvn-3B1gftOM8U/view?usp=drivesdk,eua-051925,PDF,80,M5,program,,"CDISC, Data Management, Statistical Programming, Data Processing, SAS Programming, Adverse Event, Data Transformation, Randomization, M5, Protocol, Data Analysis, Clinical Trial, Data Generation, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adds-sas.pdf,ADDS Dataset Creation,2020-11-03,https://drive.google.com/file/d/19egIWqQdtlFdhfMNCu8sHpg1zHOfpdeS/view?usp=drivesdk,eua-051925,PDF,5,M5,program,,"Suppds, Dataset Creation, Data Management, Disposition Event, Data Processing, SAS Programming, SDTM, M5, Data Quality, Data Integration, Data Analysis, Clinical Trial, Data Preparation, Data Merging",False,False,False,True
27034_S1_M5_c4591001-A-P-admh-sas.pdf,ADMH Dataset Creation,2020-11-06,https://drive.google.com/file/d/1Ddw6B4ESheMym70p3DU_mgb8wKe5lHhU/view?usp=drivesdk,eua-051925,PDF,17,M5,code,,"Data Reporting, Dataset Creation, Clinical Data Management, Data Processing, SAS Programming, Medical History, M5, Data Quality, Data Standardization, Pharmaceutical Research, Data Analysis, Clinical Trial, Data Preparation, Data Merging",False,False,False,True
27034_S1_M5_c4591001-A-P-adfacevd-sas.pdf,Create adfacevd Dataset,2020-11-04,https://drive.google.com/file/d/1bx3gIO32DTdgi5BDhuLXFJIBssNeh9qH/view?usp=drivesdk,eua-051925,PDF,28,M5,program,,"Face Vs Ex, Dataset Creation, Data Management, Suppvs, Data Processing, SAS Programming, ADSL, Data Transformation, Data Quality, M5, Data Analysis, Clinical Trial, Data Preparation, Suppface",False,False,False,True
27034_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-ia-sas.pdf,Demographic Characteristics - Subjects Without Evidence of Infection Prior to 7 Days After Dose 2 - Evaluable Efficacy Population (7 Days) - Interim Analysis 1,2020-11-16,https://drive.google.com/file/d/1YDuWm8aQ22s7gAMxyQVut6V3OII5jfeC/view?usp=drivesdk,eua-051925,PDF,52,M5,report,,"Statistical Analysis, Data Management, Vaccine, Data Processing, SAS Programming, Regulatory Compliance, COVID-19, M5, Demographic Data, Dose 2, Clinical Trial, Interim Analysis, Infection Rate, Evaluable Efficacy Population",False,False,False,True
27034_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.pdf,Demographic Characteristics - Subjects Without Evidence of Infection Prior to 7 Days After Dose 2 - Evaluable Efficacy Population (7 Days),2020-11-16,https://drive.google.com/file/d/1-o_QWvfY4cvkt0ExQNQPDm5PEBEx6XbW/view?usp=drivesdk,eua-051925,PDF,52,M5,report,,"7 Days, Demographic Characteristics, Clinical Trial, Vaccine, SAS Program, ADSL, C4591001, COVID-19, M5, Dose 2, Data Analysis, Evaluable Efficacy Population, Adc19ef, Infection",False,False,False,True
27034_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.pdf,ADSL Demographic Characteristics - Subjects With or Without Evidence of Infection Prior to 7 Days After Dose 2 - Evaluable Efficacy (7 Days) Population,2020-11-19,https://drive.google.com/file/d/1Afuk6rFMrjHsD9l_h2z3OXK5OxEFlURF/view?usp=drivesdk,eua-051925,PDF,52,M5,report,,"Statistical Analysis, Demographic Characteristics, Clinical Trial, Vaccine, Data Processing, ADSL, C4591001, COVID-19, M5, Data Analysis, Subjects With Or Without Evidence Of Infection, 7 Days After Dose 2, SAS Program, Evaluable Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adsl-sas.pdf,ADSL Dataset Creation,2020-11-17,https://drive.google.com/file/d/17m_W5I6us_NPJXmV-lhse_gmI4Pa07zL/view?usp=drivesdk,eua-051925,PDF,67,M5,program,,"Dataset Creation, Data Management, Data Processing, SAS Programming, Regulatory Compliance, ADSL, M5, Data Quality, Data Integration, Pharmaceutical Research, Data Analysis, Clinical Trial, Clinical Data, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adsl-ia-sas.pdf,ADSL Dataset Creation,2020-11-16,https://drive.google.com/file/d/1F_SaeqSDkgXceJD_B0bMTeeJvpNiVAl4/view?usp=drivesdk,eua-051925,PDF,62,M5,program,,"Dataset Creation, Data Management, CDISC, Data Output, Data Processing, SAS Programming, ADSL, C4591001, M5, Phase 3, Data Integration, Data Analysis, Clinical Trial, Data Storage",False,False,False,True
27034_S1_M5_c4591001-A-P-adsympt-ia-sas.pdf,ADSYMPT Dataset Creation,2020-11-15,https://drive.google.com/file/d/1ROhiY6GSX_Tv3-YmgN2fXSbeZFuYK-IH/view?usp=drivesdk,eua-051925,PDF,15,M5,code,,"Symptom Data, CDISC Standards, Dataset Creation, Data Management, Data Processing, SAS Programming, M5, Ia Phase 3, Data Quality, Adverse Events, Data Analysis, Clinical Trial, C4591001 Study, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-A-P-adsympt-sas.pdf,adsympt SAS Program,2020-11-17,https://drive.google.com/file/d/1VqYDhJFcOYQjNDMUrqGcZx7lJpCXg-f1/view?usp=drivesdk,eua-051925,PDF,22,M5,program,,"Adsympt, Data Preparation, CDISC, Data Management, Data Processing, Data Transformation, M5, Data Quality, Clinical Data, Programming, Data Analysis, Clinical Trial, SAS, Adverse Symptoms",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s001-gm-18-b2-aai-p1-sas.pdf,ADVA S001 GM 18 B2 AAI P1 SAS Program,2020-09-23,https://drive.google.com/file/d/1zau1REab9ab3r1dSK1_Pd7da1B3BCjsB/view?usp=drivesdk,eua-051925,PDF,15,M5,program,,"B2, AAI, Pharmaceutical, Data Management, P1, Clinical Trial, Data Processing, Gm 18, M5, Biostatistics, Programming, Data Analysis, ADVA, S001, SAS",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s001-gm-p2-eval-sas.pdf,Adva S001 GM P2 Evaluation,2020-11-17,https://drive.google.com/file/d/1dPQofNhKgJe5U0cxkWNvbF_BXtArZS_6/view?usp=drivesdk,eua-051925,PDF,18,M5,program,,"P2, Pharmaceutical, Statistical Analysis, CDISC, Clinical Trial, Drug Development, Gm, M5, Programming, Data Analysis, ADVA, S001, SAS, Evaluation",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s001-gm-lt-p2-eval-sas.pdf,Adva S001 GM LT P2 Evaluation,2020-11-17,https://drive.google.com/file/d/1U6SyhiGk0fVWvLiCntTPnujBluN7N1BB/view?usp=drivesdk,eua-051925,PDF,20,M5,program,,"P2, Statistical Analysis, Pharmaceutical, Clinical Trial, Data Processing, Lt, Gm, M5, Programming, Data Analysis, ADVA, S001, SAS, Evaluation",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s001-gmfr-p2-eval-sas.pdf,adva_s001_gmfr_p2_eval,2020-11-17,https://drive.google.com/file/d/1cHVY67tipxYYCWIWIbU3F8hxTAzvFXXg/view?usp=drivesdk,eua-051925,PDF,18,M5,program,,"P2, Statistical Analysis, Pharmaceutical, GMFR, Clinical Trial, Safety, Drug Development, M5, Programming, Data Analysis, ADVA, SAS, Eval, Efficacy",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s002-gmfr-lt-p2-eval-sas.pdf,Adva s002 GMFR LT P2 Evaluation,2020-11-17,https://drive.google.com/file/d/1OIx7UNK-uMprcXZE75fMM1etAssvLdre/view?usp=drivesdk,eua-051925,PDF,20,M5,program,,"P2, Pharmaceutical, Statistical, GMFR, Clinical Trial, Data Processing, Lt, M5, Programming, Data Analysis, ADVA, SAS, Evaluation, S002",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s002-gmfr-18-b2-aai-p1-sas.pdf,ADVA S002 GMFR 18 B2 AAI P1 SAS Program,2020-09-23,https://drive.google.com/file/d/1Q1TrzLCLTAdjzzQ39kYcbLKV_kurMlVZ/view?usp=drivesdk,eua-051925,PDF,15,M5,program,,"B2, 18, AAI, Pharmaceutical, GMFR, P1, Clinical Trial, Data Processing, M5, Programming, Data Analysis, ADVA, SAS, S002, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-comp-list-clin-sites.pdf,27034 S1 M5 c4591001-comp-list-clin-sites,undated,https://drive.google.com/file/d/1f3LzvC2eO7njsNEl-RlFPGY4ZTLTTbCz/view?usp=drivesdk,eua-051925,PDF,66,M5,document,,"FDA, Clinical, Review-needed, Vaccine, Study, COVID-19, M5, Research",False,False,False,True
27034_S1_M5_c4591001-A-P-adva-s003-fr4-18-b2-aai-p1-sas.pdf,ADVA S003 FR4 18 B2 AAI P1 SAS Program,2020-09-23,https://drive.google.com/file/d/1F7hC9NPYPLk3kgHdYDryl2K-qQD8rs9m/view?usp=drivesdk,eua-051925,PDF,29,M5,program,,"CDISC, Safety, Data Processing, ADVA, Data Transformation, M5, Phase 1, Biostatistics, Adverse Events, Data Analysis, Clinical Trial, Programming, SAS, Data Preparation",False,False,False,True
27034_S1_M5_c4591001-efficacy-listing-ex-eval-eff-pop.pdf,Listing of Subjects Excluded From All-Available and Evaluable Efficacy Populations,undated,https://drive.google.com/file/d/1z5fkooeISWjyJlXOMZVoEZtpDCemxLOO/view?usp=drivesdk,eua-051925,PDF,851,M5,report,,"Age Groups, Subject Exclusion, BNT162B2, Eligibility Criteria, Vaccine Efficacy, Exclusion, All-available Population, Randomization, M5, Dose 1, Predefined Window, Dose 2, Clinical Trial, Evaluable Efficacy Population, Dose Administration",False,True,False,True
27034_S1_M5_c4591001-efficacy-figures.pdf,COVID-19 Vaccine Efficacy Figures,2020-11-19,https://drive.google.com/file/d/13-LtYnyOmL0DlT9YvremK5GyfRIxqmsy/view?usp=drivesdk,eua-051925,PDF,4,M5,report,,"Fda-cber, Incidence Curves, Pandemic Response, Vaccine, Public Health, COVID-19, M5, Infection Prior, Dose 1, Dose 2, Pharmaceutical Research, Clinical Trial, Efficacy, Evaluable Population",False,False,False,True
27034_S1_M5_c4591001-efficacy-listings.pdf,COVID-19 Vaccine Efficacy Listings,undated,https://drive.google.com/file/d/14xGJOPbusuJ8uGZ781xl9rkrVv6eXi8U/view?usp=drivesdk,eua-051925,PDF,251,M5,report,,"SARS-COV-2, Medical Research, Nasal Swab, Vaccine Efficacy, Clinical Trial, COVID-19, Cdc-defined Symptoms, M5, Dose 1, Evaluable Efficacy, Dose 2, Severe COVID-19, Naat-positive, COVID-19 Symptoms",False,False,False,True
27034_S1_M5_c4591001-efficacy-tables-ad-hoc.pdf,COVID-19 Efficacy Tables,2020-11-20,https://drive.google.com/file/d/1wz6JQHcjm25umjvGqLdZz3Zm7NlGXRn4/view?usp=drivesdk,eua-051925,PDF,4,M5,report,,"SARS-COV-2, Prior SARS-COV-2 Status, Vaccine Efficacy, Demographic Characteristics, Clinical Trial, COVID-19, M5, Nucleic Acid Amplification Test, Safety Population, 16-17 Years Of Age, Evaluable Efficacy Population, Interim Analysis, Nucleoprotein-binding, Occurrence From 7 Days After Dose 2",False,False,False,True
27034_S1_M5_c4591001-ia efficacy-A-adrg.pdf,Analysis Data Reviewer's Guide,2020-11-19,https://drive.google.com/file/d/1bEbPbddn5BWDWrWZwZ9iCjS2bZ-tdf2k/view?usp=drivesdk,eua-051925,PDF,29,M5,guide,"BioNTech SE, PFIZER INC.","FDA, Statistical Analysis, Data Review, Vaccine, Data Standards, COVID-19, Study C4591001, Protocol Design, Data Quality, M5, Data Analysis, Clinical Trial, Interim Analysis, Data Dictionary",False,False,False,True
27034_S1_M5_c4591001-efficacy-tables.pdf,Vaccine Efficacy - COVID-19 Occurrence,2021,https://drive.google.com/file/d/1p92B3MSFa1erx3Ecy90nSeK39g7g7gIs/view?usp=drivesdk,eua-051925,PDF,154,M5,report,,"7 Days, First Occurrence, Medical Research, With Or Without Prior Infection, Vaccine Efficacy, 14 Days, Public Health, COVID-19, M5, Dose 2, Data Analysis, Clinical Trial, Infection Rate, Evaluable Population",False,False,False,True
27034_S1_M5_c4591001-ia efficacy-S-acrf.pdf,Annotated Study Book for Study Design: C4591001,2020-10-12,https://drive.google.com/file/d/1XD4xUj2zOIvj6HDE-Ti5RwZ_yHyzobEx/view?usp=drivesdk,eua-051925,PDF,124,M5,study protocol,,"CBER, FDA, Annotated, Vaccine, Central Designer, Exclusion, COVID-19, M5, Protocol, Adverse Events, Study Design, Clinical Trial, Inclusion/exclusion Criteria, Pfizer, Immunogenicity",False,True,False,True
27034_S1_M5_c4591001-ia efficacy-A-supplementaldatadefinitions.pdf,C4591001 IA Phase1 Participants,2020-06,https://drive.google.com/file/d/1-WN9WWlKe1qqLzFDTc9U1_8VDqHHu4yA/view?usp=drivesdk,eua-051925,PDF,176,M5,data definitions,,"Medical Research, Sentinel Cohorts, Vaccine Efficacy, Pharmaceutical Development, Subject Numbers, Enrollment Dates, Participant Data, Data Definitions, Phase 1, Cohort Selection, M5, Data Collection, Clinical Trial, Informed Consent",False,False,False,True
27034_S1_M5_c4591001-ia-efficacy-tables-figures.pdf,COVID-19 Vaccine Efficacy Tables and Figures,2020-11-19,https://drive.google.com/file/d/1rvOl6PoURIc5NgY3sJH21GzvuXck8fon/view?usp=drivesdk,eua-051925,PDF,46,M5,report,,"Regulatory Submission, FDA, BNT162B2, SARS-COV-2, Vaccine Efficacy, COVID-19, Surveillance Time, M5, Dose 2, Vaccine Effectiveness, Clinical Trial, Interim Analysis, Infection Rate, Evaluable Population",False,False,False,True
27034_S1_M5_c4591001-safety-fa-eff-A-adrg.pdf,Analysis Data Reviewer's Guide,2020-11-20,https://drive.google.com/file/d/1IUoaOAX7U2GL0xGC_lQV1A4mL-elFfgO/view?usp=drivesdk,eua-051925,PDF,50,M5,guide,"BioNTech SE, PFIZER INC.","FDA, Data Review, November 2020, Vaccine, Safety Analysis, Needs-review, COVID-19, Study C4591001, Regulatory, M5, Clinical Trial, Efficacy Analysis, Pfizer, BioNTech",False,False,False,True
27034_S1_M5_c4591001-ia efficacy-S-csdrg.pdf,Clinical Study Data Reviewer's Guide,2020-11-18,https://drive.google.com/file/d/17iYECNuwd9GjUUMavE8BTt9Okjv6QIfO/view?usp=drivesdk,eua-051925,PDF,79,M5,report,"BioNTech SE, PFIZER INC.","Data Management, Exclusion, Data Standards, Safety, Regulatory Review, Regulatory Compliance, COVID-19, Clinical Study, Study Protocol, M5, Vaccine Development, Pharmaceutical Research, Phase 2/3, Interim Analysis, Efficacy",False,True,False,True
27034_S1_M5_c4591001-safety-fa-eff-A-supplementaldatadefinitions.pdf,c4591001-safety-fa-eff-A-supplementaldatadefinitions,2020-06,https://drive.google.com/file/d/14bkXT42oACCWkw9VXKSYeOe-DRaBXJfA/view?usp=drivesdk,eua-051925,PDF,215,M5,data definitions,,"Stage 1 Sentinel Cohorts, Medical Research, Participant Enrollment, Data Definitions, Clinical Study, M5, Cohort Selection, Patient Data, Supplemental Information, Data Collection, Clinical Trial, Safety Data, June 2020, Informed Consent",False,False,False,True
27034_S1_M5_c4591001-safety-fa-eff-S-csdrg.pdf,Clinical Study Data Reviewer's Guide,2020-11-19,https://drive.google.com/file/d/1oJFNvggQ5FNBBk6N4ZSlI4CM8Sc8b1sC/view?usp=drivesdk,eua-051925,PDF,78,M5,report,"BioNTech SE, PFIZER INC.","FDA, Pharmaceutical, Data Review, Medical Research, Safety Analysis, Vaccine, Exclusion, Needs-review, COVID-19, Clinical Study, Regulatory, M5, EUA, Clinical Trial, Efficacy",False,True,False,True
27034_S1_M5_c4591001-safety-fa-eff-S-acrf.pdf,Annotated Study Book for Study Design: C4591001,2020-10-12,https://drive.google.com/file/d/1DKbNoYmx7aqXZbL2ziYJTus9O9jFgkWY/view?usp=drivesdk,eua-051925,PDF,124,M5,study protocol,,"Efficacy Evaluation, Adverse Event Reporting, Central Lab Testing, Vaccine Study, Exclusion, Regulatory Compliance, COVID-19, M5, Visit Schedule, Study Design, Clinical Trial, Inclusion/exclusion Criteria, Safety Assessment, Pfizer, Immunogenicity Tracking",False,True,False,True
27034_S1_M5_c4591001-safety-figures.pdf,COVID-19 Vaccine Reactogenicity and Safety Figures,2020-11-19,https://drive.google.com/file/d/1SIJiKGuG_3H2mip_-7OIu0_5amnkjhBL/view?usp=drivesdk,eua-051925,PDF,6,M5,report,,"CBER, FDA, Health Statistics, Vaccine, Safety, Public Health, Reactogenicity, COVID-19, M5, Regulatory, Adverse Events, Clinical Trial, Phase 2/3, Medical Data",False,False,False,True
27034_S1_M5_c4591001-safety-listing-random-act-vac-rec.pdf,Listing of Randomization Scheme and Actual Vaccine Received - All Subjects,2020-11-19,https://drive.google.com/file/d/1SV6T3i0CfixZnr2vlCITv4jJbdPeQxeE/view?usp=drivesdk,eua-051925,PDF,4375,M5,listing,,"Pharmaceutical, Medical Research, Vaccine, Safety, Regulatory Compliance, COVID-19, Randomization, BNT162B1, Dosage, M5, Adverse Events, Clinical Trial, Placebo, Subject Data",False,False,False,True
27034_S1_M5_c4591001-safety-listing-who-rec-vac-not-rand.pdf,Safety Listing of Subjects Who Received Vaccine Not as Randomized,2020-11-19,https://drive.google.com/file/d/1POEjBnd86B6sh8_5zePilgNFjkv1wVsf/view?usp=drivesdk,eua-051925,PDF,2,M5,listing,,"Pharmaceutical, BNT162B2, Medical Research, Vaccine Safety, Regulatory Compliance, COVID-19, Randomization, BNT162B1, Dosage, M5, Adverse Events, Data Analysis, Clinical Trial, Subject Listing",False,False,False,True
27034_S1_M5_c4591001-safety-tables-ae1.pdf,c4591001 Safety Tables,undated,https://drive.google.com/file/d/11oFf2W1tY53-OImqQmbcOuufuRi1Tjb4/view?usp=drivesdk,eua-051925,PDF,204,M5,report,,"Phase 2/3 Analysis, Age Groups, Pharmaceutical, Health And Safety, Medical Research, Baseline SARS-COV-2 Status, Regulatory Compliance, COVID-19, Clinical Study, M5, Vaccine Trial, Adverse Events, Data Analysis, Safety Data",False,False,False,True
27034_S1_M5_c4591001-safety-tables-ae2.pdf,Safety Tables for COVID-19 Vaccine Phase 2/3 Analysis,2021,https://drive.google.com/file/d/1Cq_WIQFw_JmxAhtlZlDO_GHxvYndb766/view?usp=drivesdk,eua-051925,PDF,697,M5,report,,"Age Groups, Sex, SARS-COV-2, Race, Vaccine, Safety, Baseline Status, COVID-19, M5, Demographics, Adverse Events, Data Analysis, Clinical Trial, Phase 2/3",False,False,False,True
27034_S1_M5_c4591001-safety-tables-ae3.pdf,Safety Tables for COVID-19 Vaccine,2020-11-14,https://drive.google.com/file/d/11DdshbfrhshDFCBXMRkGElpIwdygR8px/view?usp=drivesdk,eua-051925,PDF,472,M5,report,,"System Organ Class, Vaccine, Preferred Term, Data Cutoff, Serious Adverse Events, COVID-19, M5, Regulatory, Adverse Events, Safety Population, Clinical Trial, Phase 2/3, Safety Data, Age Group",False,False,False,True
27034_S1_M5_c4591001-safety-tables-label.pdf,COVID-19 Vaccine Safety Tables,2020-11-19,https://drive.google.com/file/d/1jHc73UoMV7eIgYgYtTPUg3Jnb5zFbMFU/view?usp=drivesdk,eua-051925,PDF,16,M5,report,,"Age Groups, FDA, Pharmaceutical, Vaccine, Safety, COVID-19, M5, Regulatory, Demographics, Adverse Events, Clinical Trial, Systemic Events, Efficacy, Local Reactions",False,False,False,True
27034_S1_M5_c4591001-safety-tables-cos-reacto.pdf,c4591001 Safety Tables,2022-01,https://drive.google.com/file/d/10HHzx9bjfsAVvCPWOSz8NVRfZN-VSc6Z/view?usp=drivesdk,eua-051925,PDF,293,M5,report,,"Age Groups, Sex, SARS-COV-2, Race, Vaccine, Ethnicity, Phase 2/3 Clinical Trial, Baseline Status, COVID-19, Subject Disposition, M5, Pharmaceutical Research, Demographic Analysis, Safety Data",False,False,False,True
27034_S1_M5_cummings-mj-2020.pdf,27034 S1 M5 cummings-mj-2020,undated,https://drive.google.com/file/d/1NeaolfXIirHOOmeKHqoP05rR3jZf_L3G/view?usp=drivesdk,eua-051925,PDF,8,M5,document,,"Review-needed, Clinical, Study, 2020, COVID-19, M5, Data, Research",False,False,False,True
27034_S1_M5_docherty-ab-2020.pdf,27034 S1 M5 docherty-ab-2020,undated,https://drive.google.com/file/d/1XYao4f6e02gpzl5YYRpgxeULplO_1sIg/view?usp=drivesdk,eua-051925,PDF,12,M5,document,,"Review-needed, Clinical, Study, 2020, COVID-19, M5, Data, Research",False,False,False,True
27034_S1_M5_ecdc-2020.pdf,Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - eleventh update,2020-08-10,https://drive.google.com/file/d/1NJddBXNHvXmngMedJCNevZJKitzIa_oh/view?usp=drivesdk,eua-051925,PDF,37,M5,report,,"Risk Assessment, European Union, Disease Control, Pandemic Response, Public Health, United Kingdom, Healthcare System, COVID-19, M5, Disease Outbreak, European Economic Area, Data Analysis, Policy Recommendations, Epidemiology",False,False,False,True
27034_S1_M5_ecdc-2020b.pdf,COVID-19 Situation Update Worldwide,2020-07-31,https://drive.google.com/file/d/1jwFRrhYCJD__fQwWe6L6J0MUL_YZsA8t/view?usp=drivesdk,eua-051925,PDF,12,M5,report,,"SARS-COV-2, Global Health, EU/EEA, WHO, Public Health, International Health Regulations, Coronavirus, COVID-19, M5, Disease Outbreak, West Nile Virus, Infectious Disease, Epidemiology, Surveillance",False,False,False,True
27034_S1_M5_gold-jaw-2020.pdf,27034 S1 M5 gold-jaw-2020,undated,https://drive.google.com/file/d/1x3sGENC96V_1bteGl-nXzEkM1vFgFEW3/view?usp=drivesdk,eua-051925,PDF,6,M5,document,,"Review-needed, Clinical, 2020, COVID-19, M5, Data, Research",False,False,False,True
27034_S1_M5_ecdc-2020c.pdf,COVID-19 Situation Update,2020-07-31,https://drive.google.com/file/d/17SkqqIcRzfXKAqct9wcX5xGDvfy77vX6/view?usp=drivesdk,eua-051925,PDF,12,M5,report,,"Case Data, SARS-COV-2, Global Health, EU/EEA, Public Health, Coronavirus, COVID-19, Mortality, Disease Outbreak, M5, West Nile Virus, Infectious Disease, Epidemiology, Surveillance",False,False,False,True
27034_S1_M5_haynes-bf-2020.pdf,Prospects for a safe COVID-19 vaccine,2020-11-04,https://drive.google.com/file/d/1oagk1XDxHXR2Yv3WsWCr982mEjBtC9zJ/view?usp=drivesdk,eua-051925,PDF,12,M5,review,"Barton F. Haynes, Lawrence Corey, Prabhavathi Fernandes, Peter B. Gilbert, Peter J. Hotez, Srinivas Rao, Michael R. Santos, Hanneke Schuitemaker, Michael Watson, Ann Arvin","SARS-COV-2, Safety, Viral Infections, Postlicensure Surveillance, Coronavirus, Clinical Trials, COVID-19, M5, Vaccine Development, Adverse Events, Therapeutic Interventions, Immune Enhancement, ACTIV, Pandemic",False,False,False,True
27034_S1_M5_graham-bs-2020.pdf,Rapid Development of a COVID-19 Vaccine,2020,https://drive.google.com/file/d/1PsNwH8tV8dRgOJQAkL_pztwDCRSIOBVp/view?usp=drivesdk,eua-051925,PDF,2,M5,report,Barney S. Graham,"Herd Immunity, Gene-based Vaccines, SARS-COV-2, Pandemic Response, Benefit-risk Analysis, Public Health, COVID-19, Scientific Research, M5, Antiviral Vaccines, Vaccine Development, Vaccine Manufacturing, Protein-based Vaccines, Regulatory Decisions",False,False,False,True
27034_S1_M5_hur-k-2020.pdf,Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19,2020,https://drive.google.com/file/d/1Hq194uTzeStAMpRHVTWAifD6RvtmnKiv/view?usp=drivesdk,eua-051925,PDF,9,M5,research article,"Kevin Hur, Caroline P. E. Price, Elizabeth L. Gray, Reeti K. Gulati, Matthew Maksimoski, Samuel D. Racette, Alexander L. Schneider, Ashoke R. Khanwalkar","Medical Research, Critical Care, Pandemic, Clinical Characteristics, COVID-19, Otolaryngology, Risk Factors, M5, Healthcare, Respiratory Failure, Epidemiology, Intubation, Ventilation, Hospitalization",False,False,False,True
27034_S1_M5_holmes-l-2020.pdf,27034 S1 M5 holmes-l-2020,undated,https://drive.google.com/file/d/1h6pK7_At58pPjyRUNyvihgf92hf8pcIp/view?usp=drivesdk,eua-051925,PDF,18,M5,document,,"FDA, Review-needed, 2020, COVID-19, M5, Data, Research",False,False,False,True
27034_S1_M5_iaccarino-g-2020.pdf,COVID-19 Mortality and Cardiovascular Disease,2020,https://drive.google.com/file/d/1Kz4mujzA45e6zi6MYtWF6ljkXRocNE8k/view?usp=drivesdk,eua-051925,PDF,7,M5,research paper,"G. Iaccarino, G. Grassi, C. Borghi","SARS-COV-2, Medical Research, Public Health, 2020, Coronavirus, Needs-review, COVID-19, Clinical Study, M5, Epidemiology, Hypertension, Cardiovascular Disease, Mortality, Pandemic",False,False,False,True
27034_S1_M5_iavarone-c-2017.pdf,Mechanism of action of mRNA-based vaccines,2017,https://drive.google.com/file/d/1NyKcEcCpFZQ1Kdb8dm9xNGI5yV6oSSAj/view?usp=drivesdk,eua-051925,PDF,11,M5,review,"Carlo Iavarone, Derek T. O'hagan, Dong Yu, Nicolas F. Delahaye, Jeffrey B. Ulmer","Immune Response, mRNA Vaccines, Vaccine Mechanism, Vaccine Adjuvants, Vaccine Research, Vaccine Efficacy, Vaccine Safety, Vaccine Design, M5, Vaccine Development, Vaccine Optimization, Vaccine Delivery, Adaptive Immunity, Innate Immunity, Vaccine Technology",False,False,False,True
27034_S1_M5_kranz-lm-2016.pdf,27034 S1 M5 kranz-lm-2016,undated,https://drive.google.com/file/d/1rSRMISChtxOdR7q39nwC9jShnyFKB28Z/view?usp=drivesdk,eua-051925,PDF,16,M5,document,,"Review-needed, Vaccine, M5, Data, Trial",False,False,False,True
27034_S1_M5_kamphuis-e-2006.pdf,Kamphuis E. 2006 Presentation,2006,https://drive.google.com/file/d/1ikKgK8e8bEPnL5szbxmbNeDLNByiYMix/view?usp=drivesdk,eua-051925,PDF,9,M5,presentation,Kamphuis E.,"CBER, FDA, Kamphuis, Vaccine, Submission, Presentation, Safety, Clinical Trials, Biologics, M5, Regulatory, 2006, Product Development, Efficacy",False,False,False,True
27034_S1_M5_lambert-ph-2020.pdf,27034 S1 M5 lambert-ph-2020,undated,https://drive.google.com/file/d/1ne0O4uaAvJQ14Nw4tqKRqVcBKn1bAE44/view?usp=drivesdk,eua-051925,PDF,9,M5,document,,"Review-needed, Clinical, Vaccine, 2020, COVID-19, M5, Trial, Research",False,False,False,True
27034_S1_M5_mulligan-mj-2020.pdf,27034 S1 M5 mulligan-mj-2020,undated,https://drive.google.com/file/d/1_vUKgnZXBeAECLCt9X1gyeM9c6tV4UOP/view?usp=drivesdk,eua-051925,PDF,16,M5,document,,"FDA, Clinical, Review-needed, Vaccine, Study, 2020, COVID-19, M5, Data, Trial",False,False,False,True
27034_S1_M5_pallesen-j-2017.pdf,27034 S1 M5 pallesen-j-2017,undated,https://drive.google.com/file/d/1KxF5uZVCXM5gtRLX30LKhvgwsCylS-Dn/view?usp=drivesdk,eua-051925,PDF,10,M5,document,,"Review-needed, Vaccine, COVID-19, M5, Research",False,False,False,True
27034_S1_M5_openshaw-pj-2001.pdf,Immunopathogenesis of vaccine-enhanced RSV disease,2001,https://drive.google.com/file/d/1Oe_HOKYLje_TAWxruAVP-MP-6FJiub92/view?usp=drivesdk,eua-051925,PDF,5,M5,research,"Peter J.M. Openshaw, Fiona J. Culley, Wieslawa Olszewska","Th2 Cells, Immune Response, Immunopathogenesis, RSV, Vaccine, Needs-review, Respiratory Syncytial Virus, M5, Disease Enhancement, Vaccine Development, Animal Models, T Cell Priming, Eosinophilic Response, Formalin-inactivated Vaccine",False,False,False,True
27034_S1_M5_nowak-b-2020.pdf,Short-term outcomes of patients with COVID-19 in Poland,2020,https://drive.google.com/file/d/1YVxhiWRdus1n-3UYrUql4P_GD1SpyVng/view?usp=drivesdk,eua-051925,PDF,5,M5,article,"Błażej Nowak, Piotr Szymański, Igor Pańkowski, Agnieszka Szarowska, Katarzyna Życińska, Wojciech Rogowski, Robert Gil, Mariusz Furmanek, Jacek Tatur, Artur Zaczyński, Zbigniew Król, Waldemar Wierzba","Medical Research, Public Health, Poland, Designated Hospital, Clinical Characteristics, Retrospective Study, COVID-19, Healthcare System, M5, Short-term Outcomes, Patient Outcomes, Epidemiology, Disease Management, Pandemic",False,False,False,True
27034_S1_M5_petrilli-cm-2020.pdf,Factors associated with hospital admission and critical illness among people with COVID-19 in New York City,2020,https://drive.google.com/file/d/1EOPFUClpA76oTMvrjyWTUfdFwqYLl2Qu/view?usp=drivesdk,eua-051925,PDF,15,M5,research,"Christopher M Petrilli, Simon A Jones, Jie Yang, Harish Rajagopalan, Luke O'Donnell, Yelena Chernyak, Katie A Tobin, Robert J Cerfolio, Fritz Francois, Leora I Horwitz","Hospital Admission, Critical Illness, Exclusion, Public Health, Healthcare Research, Coronavirus, Clinical Characteristics, COVID-19, M5, Risk Factors, Medical Outcomes, Prospective Cohort Study, Epidemiology, Mortality, New York City",False,True,False,True
27034_S1_M5_pardi-n-2018.pdf,Nucleic Acid Therapeutics for Vaccine Development,2018,https://drive.google.com/file/d/1QAqKyOA_pNCjSiMaJ14gpP4JotH1upsf/view?usp=drivesdk,eua-051925,PDF,19,M5,report,,"Technological Innovation, Nucleic Acid Therapeutics, Infectious Diseases, Therapeutic Approaches, Vaccines, mRNA, Emerging Viruses, Adaptive Immune Response, In Vivo Delivery, M5, Vaccine Development, Research Investment, Vaccine Platforms, Immunogenicity",False,False,False,True
27034_S1_M5_sahin-u-2020.pdf,27034 S1 M5 sahin-u-2020,undated,https://drive.google.com/file/d/1KOhvEcxfVWynliYDMwJe_RJsTk7AamIe/view?usp=drivesdk,eua-051925,PDF,27,M5,document,,"FDA, Clinical, Review-needed, Vaccine, 2020, COVID-19, M5, Data, Trial, Research",False,False,False,True
27034_S1_M5_richardson-s-2020.pdf,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",2020,https://drive.google.com/file/d/1e2nGfE5DYzBDgHkgQM-iD2UCIcxcOi03/view?usp=drivesdk,eua-051925,PDF,8,M5,report,"Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, James M. Crawford, Thomas McGinn, Karina W. Davidson","Hospital Patients, Kidney Replacement Therapy, Respiratory Virus, Public Health, Healthcare System, Clinical Characteristics, COVID-19, M5, Comorbidities, Mechanical Ventilation, Mortality, Outcomes, New York City, Pandemic",False,False,False,True
27034_S1_M5_price-haywood-eg-2020.pdf,Racial Differences in COVID-19 Outcomes,2020-06-25,https://drive.google.com/file/d/1h9UMU0GOQI3oExwEqIxReiM4KMqBt5Ow/view?usp=drivesdk,eua-051925,PDF,10,M5,research article,"E.G.P.-H., J.B., D.F., L.S.","Chronic Conditions, Health Outcomes, Medical Research, Public Health, Healthcare Access, Ochsner Health, COVID-19, Retrospective Study, M5, In-hospital Mortality, Louisiana, Hospitalization, Epidemiology, Racial Disparities",False,False,False,True
27034_S1_M5_singh-dk-2020.pdf,27034 S1 M5 singh-dk-2020,undated,https://drive.google.com/file/d/1tVne7qx5c1Pu9pmeGdoXbcoQg3F1DABu/view?usp=drivesdk,eua-051925,PDF,88,M5,document,,"FDA, Clinical, Review-needed, Vaccine, 2020, COVID-19, M5, Research",False,False,False,True
27034_S1_M5_sedic-m-2020.pdf,Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA,2020,https://drive.google.com/file/d/1IsclUlRwHoYB4hIR1ROTegKtxZsY30qj/view?usp=drivesdk,eua-051925,PDF,14,M5,research article,"Maja Sedic, Joseph J. Senn, Andy Lynn, Michael Laska, Mike Smith, Stefan J. Platz, Joseph Bolen, Stephen Hoge, Alex Bulychev, Eric Jacquinet, Victoria Bartlett, Peter F. Smith","Sprague-dawley Rat, Pharmaceutical, Hematopoiesis, Complement Activation, Cynomolgus Monkey, Drug Development, Regulatory Compliance, Pharmacology, M5, Pharmacokinetics, Modified mRNA, Liver Injury, Lipid Nanoparticles, Toxicology, Preclinical Research, Drug Safety",False,False,False,True
27034_S1_M5_stokes-ek-2020.pdf,"Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020",2020-06-19,https://drive.google.com/file/d/1nccB0aWe5FLOnw9dfdzk2TXEaRNtILQc/view?usp=drivesdk,eua-051925,PDF,7,M5,report,"Erin K. Stokes, Laura D. Zambrano, Kayla N. Anderson, Ellyn P. Marder, Kala M. Raz, Suad El Burai Felix, Yunfeng Tie, Kathleen E. Fullerton","Mmwr, United States, Public Health, 2020, Disease Surveillance, Coronavirus, COVID-19, Mortality, M5, Demographics, Hospitalization, Underlying Conditions, Epidemiology, CDC",False,False,False,True
27034_S1_M5_vogel-ab-2020.pdf,27034 S1 M5 vogel-ab-2020,undated,https://drive.google.com/file/d/1IaeSsB9zCIFf6HexFMEo-Ye4Io2Zbe_X/view?usp=drivesdk,eua-051925,PDF,38,M5,document,,"FDA, Clinical, Review-needed, Vaccine, Study, 2020, COVID-19, M5, Trial, Research",False,False,False,True
27034_S1_M5_verity-r-2020.pdf,27034 S1 M5 verity-r-2020,undated,https://drive.google.com/file/d/1zyDuoEQwMFNrWL4PpTLKO5eWaA_D3CUO/view?usp=drivesdk,eua-051925,PDF,9,M5,document,,"Review-needed, Clinical, 2020, COVID-19, M5, Data, Research",False,False,False,True
27034_S1_M5_suleyman-g-2020.pdf,27034 S1 M5 suleyman-g-2020,undated,https://drive.google.com/file/d/1GEzKVKMrt7N4ZXZy9oGM-JSET_3bqPKm/view?usp=drivesdk,eua-051925,PDF,12,M5,document,,"FDA, Clinical, Review-needed, Study, 2020, COVID-19, M5, Data",False,False,False,True
27034_S1_M5_who-2005.pdf,WHO guidelines on nonclinical evaluation of vaccines,2005,https://drive.google.com/file/d/13yOFV906SUbipehzcay24QU0FmggoV4q/view?usp=drivesdk,eua-051925,PDF,33,M5,guidelines,,"WHO, Biotechnology, Public Health, Nonclinical Testing, Toxicity Assessment, Regulatory Guidance, Delivery Devices, Infectious Disease Prevention, M5, Vaccine Development, Adjuvants, Immunogenicity, Vaccine Formulation, Basic Immunology",False,False,False,True
27034_S1_M5_walsh-ee-2020.pdf,EE 2020 Walsh,2020,https://drive.google.com/file/d/11yRaP2KLbrjWVASywBDOQD0BnEE7fRBV/view?usp=drivesdk,eua-051925,PDF,13,M5,report,Walsh,"Assignment, Coursework, 2020, Technical, Ee, Walsh, M5, Project, Academic, Student, Curriculum, Electrical Engineering, University, Research",False,False,False,True
27034_S1_M5_wiersinga-wj-2020.pdf,"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)",2020,https://drive.google.com/file/d/1EXFDI1sOA1rRfOZuC7_b1rvNeupYEROc/view?usp=drivesdk,eua-051925,PDF,12,M5,review,"W. Joost Wiersinga, Andrew Rhodes, Allen C. Cheng, Sharon J. Peacock, Hallie C. Prescott","SARS-COV-2, Respiratory Disease, Public Health, Treatment, Transmission, COVID-19, M5, Pathophysiology, Medical Review, Diagnosis, Healthcare, Pneumonia, Multi-organ Disease, Pandemic",False,False,False,True
27034_S1_M5_who-2019.pdf,WHO Guidelines on Nonclinical Evaluation of Vaccines,2005,https://drive.google.com/file/d/1GNwobn8k2kIrxOsbsJo5FYf_52kvblwD/view?usp=drivesdk,eua-051925,PDF,33,M5,guidelines,,"Biotechnology, Regulatory Expectations, Alternative Administration, Nonclinical Testing, Regulatory Guidance, Toxicity Assessment, Infectious Disease Prevention, M5, Vaccine Development, WHO Recommendations, Adjuvants, Immunogenicity, Vaccine Formulation, Biological Products",False,False,False,True
27034_S1_M5_wrapp-d-2020.pdf,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,2020,https://drive.google.com/file/d/1j1yODsMzCVASiHQ1X0Wa27d9FrAVntDQ/view?usp=drivesdk,eua-051925,PDF,4,M5,research paper,"Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Jory A. Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S. Graham, Jason S. McLellan","2019-ncov, ACE2, Cryo-em, Vaccine, Exclusion, Therapeutic, Public Health, Coronavirus, Antibody, COVID-19, Diagnostic, Outbreak, M5, Prefusion Conformation, Betacoronavirus, Spike Protein, Pandemic",False,True,False,True
27034_S1_M5_zhu-n-2020.pdf,The New England Journal of Medicine,2020-02-20,https://drive.google.com/file/d/1bpiN1jY2qE7f6u4kpgvOIloLYHMOqCBP/view?usp=drivesdk,eua-051925,PDF,7,M5,report,,"SARS-COV, 2019-ncov, MERS-COV, Emerging Pathogens, Viral Infections, Public Health, China, Coronavirus, Disease Surveillance, Zoonotic Diseases, M5, Epidemiology, Pneumonia, Wuhan, Respiratory Illness",False,False,False,True
27034_S24_M1_fact-sheet-recipients-lab-1451-0-7-clean.pdf,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/12cuTX4LwvAR8vqpqwFnN7paMk0qAvgR-/view?usp=drivesdk,eua-051925,PDF,6,M1,fact sheet,,"Emergency Use Authorization, SARS-COV-2, Symptoms, M1, Two-dose Series, Vaccine, Coronavirus, Needs-review, COVID-19, Respiratory Illness, Recipients, Pfizer-biontech, Caregivers, Pandemic",False,False,False,True
27034_S20_M1_vrbpac-presentation.pdf,BNT162b2 Vaccine Candidate Against COVID-19,2020-12-10,https://drive.google.com/file/d/1OlobJCnoATHlnEMYarXl40LRp26_S3b2/view?usp=drivesdk,eua-051925,PDF,64,M1,presentation,"Kathrin Jansen, William Gruber","FDA Advisory Committee, SARS-COV-2, M1, Safety, Public Health, Clinical Trials, COVID-19, Non-clinical Data, Vaccine Development, Benefit-risk, Pfizer, Efficacy, Immunization, Pandemic",False,False,False,True
27034_S27_M1_vrbpac-presentation.pdf,CC-1BNT162b2 Vaccine Candidate Against COVID-19,2020-12-10,https://drive.google.com/file/d/1HIgNilSSOr45639KwnoYw8pB2S2s4g5Q/view?usp=drivesdk,eua-051925,PDF,64,M1,presentation,"Kathrin Jansen, William Gruber","FDA Advisory Committee, BNT162B2, Pandemic Response, M1, Safety, Public Health, Clinical Trials, COVID-19, Vaccine Development, Regulatory Affairs, Pharmaceutical Research, Pfizer, Efficacy, Immunization",False,False,False,True
27034_S24_M1_hcp-fact-1450-0-5-pi-lab-1457-0-7-clean.pdf,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers),2020-12,https://drive.google.com/file/d/1ZkbuxiiwVZYlCwHCHIYcowxPe9bnNqS0/view?usp=drivesdk,eua-051925,PDF,29,M1,fact sheet,,"Emergency Use Authorization, Multisystem Inflammatory Syndrome, Healthcare Providers, Intramuscular Injection, M1, Vaccine, Coronavirus, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Hospitalization, Pfizer-biontech, Immunization",False,False,False,True
27034_S24_M1_thermal-shipping-instructions.pdf,Pfizer-BioNTech COVID-19 Vaccine Thermal Shipping Instructions,2020-12-10,https://drive.google.com/file/d/1M6o6Oeh_n0hkD-nOukRekx8vF3_wsmmX/view?usp=drivesdk,eua-051925,PDF,5,M1,instructions,,"Emergency Use Authorization, FDA, M1, Vaccine, Safety, Storage, COVID-19, Thermal Shipping, Temperature Control, Dry Ice, BioNTech, Pfizer, Logistics, Ventilation",False,False,False,True
27034_S28_M1_hcp-fact-1450-1-0-pi-lab-1457-1-0-clean.pdf,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers),2020-12,https://drive.google.com/file/d/178CXAdAVAkkpAO4BlmBXlK89OFgBv_hK/view?usp=drivesdk,eua-051925,PDF,29,M1,fact sheet,,"Emergency Use Authorization, Healthcare Providers, M1, Vaccine, Mandatory Reporting, Coronavirus, Clinical Trials, COVID-19, Respiratory Illness, Vaccination, Adverse Events, Pfizer-biontech, Immunization, Pandemic",False,False,False,True
27034_S28_M1_fact-sheet-recipients-lab-1451-1-0-clean.pdf,Fact Sheet for Recipients and Caregivers - Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/10Jk9kaudpX09KaZUfamoQADk8Z_jMACL/view?usp=drivesdk,eua-051925,PDF,6,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, Health And Safety, M1, Public Health, Coronavirus, Disease Prevention, COVID-19, Medical Information, Vaccination, Recipients, Vaccine Information, Caregivers, Pandemic",False,False,False,True
27034_S2_M5_CRF_c4591001-1003-10031113.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-06,https://drive.google.com/file/d/1717HjjizNldHwVny6Rrq9bQVeeVrKXkm/view?usp=drivesdk,eua-051925,PDF,291,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1003-10031065.pdf,c4591001 Cohort Selection and Informed Consent,2020-06-12,https://drive.google.com/file/d/1H7_u1zmnOlQUh3odvOvzlV5dSJAaknmC/view?usp=drivesdk,eua-051925,PDF,355,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1005-10051054.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1MUUW4NnUevWBq4QSmXmwlH1EnfwtYQCL/view?usp=drivesdk,eua-051925,PDF,176,M5,form,,"Subject Id 10051054, Protocol Amendment, Audit Trail, Exclusion, eCRF, Subject Enrollment, Rochester Clinical Research, C4591001, M5, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1003-10031149.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1YURHLlNQAkQFeQXOYc3OKjPJQ0y3p-dA/view?usp=drivesdk,eua-051925,PDF,222,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1005-10051214.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1OS0j8pViUvxdXRj7vbJjoaScOTayLUNf/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"eCRF Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, Fda-regulated, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1005-10051069.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1IIQZcg87uI9_cy5Ry34sOPi-nIX1NWDo/view?usp=drivesdk,eua-051925,PDF,145,M5,form,,"Protocol Amendment, Medical Research, C4591001 Study, Exclusion, Subject Enrollment, Rochester Clinical Research, Needs-review, M5, Cohort Selection, Patient Data, Clinical Trial, Phase 2/3, FDA Compliance, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1006-10061020.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1GOQrY9nYbq-ZOV8pvvNhxGSsFWjNXDW6/view?usp=drivesdk,eua-051925,PDF,176,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1005-10051293.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-10-17,https://drive.google.com/file/d/1_wt0MeX87-3jR0ugEKtmyMeshLrf57h-/view?usp=drivesdk,eua-051925,PDF,112,M5,form,,"FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1007-10071276.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/11gjmqb5sO3iUPQzzBELJuldMGr_uodgp/view?usp=drivesdk,eua-051925,PDF,214,M5,form,,"FDA, Phase 2/3, Protocol Amendment, Vaccine, Exclusion, eCRF, COVID-19, M5, Demographics, Cohort Selection, Clinical Trial, Medical Center, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1006-10061098.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/10vf6qXBpRRcaKXR5Ly5tL79UZT2q06MG/view?usp=drivesdk,eua-051925,PDF,206,M5,form,,"Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Case Report Form, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1007-10071101.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1oFyGm1H7fDiDquvaO6DcBiOABm3Gk1jT/view?usp=drivesdk,eua-051925,PDF,186,M5,form,,"Pharmaceutical Study, FDA Regulation, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1007-10071347.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-10-15,https://drive.google.com/file/d/1UUCvNDy6U6hRr3eGtMERqzfb_Kr52GN6/view?usp=drivesdk,eua-051925,PDF,137,M5,form,,"Phase 2/3, Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Clinical Trial, Medical Center, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1009-10091135.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Pa4SxKkmoNrs98Ty5_-YsGyibvkmws6a/view?usp=drivesdk,eua-051925,PDF,251,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1008-10081184.pdf,COVID-19 Vaccine Trial Cohort Selection,2020-07-30,https://drive.google.com/file/d/1PzeoRD8KNYovjLThkgsTADwDyewKIGmo/view?usp=drivesdk,eua-051925,PDF,106,M5,form,,"Protocol Amendment, Clinical Trial Management, Medical Research, Clinical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Trial, Patient Data, Phase 2/3, FDA Compliance, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1008-10081603.pdf,Cohort Selection and Informed Consent,2020-10-14,https://drive.google.com/file/d/1vuaSrlNzwQ6g6CUzfjv1xwQAyG2xnFCC/view?usp=drivesdk,eua-051925,PDF,117,M5,form,,"Protocol Amendment, Medical Research, Clinical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1011-10111029.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/19cp3G7o-9tLRPb5dq8ovwRtBylq2jZ1a/view?usp=drivesdk,eua-051925,PDF,158,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Subject Details, Exclusion, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, FDA Compliance, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1011-10111181.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-17,https://drive.google.com/file/d/17_i27eZubH3OfalX_UVdjZ228ZcXsOrv/view?usp=drivesdk,eua-051925,PDF,122,M5,form,,"Audit Trail, Protocol Amendment, Subject Details, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Demographics, Cohort Selection, Data Verification, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1012-10121163.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1emWrvNsKkIXuilt4yIsUk67rojP7yVyX/view?usp=drivesdk,eua-051925,PDF,211,M5,form,,"Informed Consent, Protocol Amendment, Medical Research, COVID-19 Vaccine, Vaccine Efficacy, Exclusion, Subject Enrollment, M5, Cohort Selection, Hope Research Institute, Clinical Data, Adverse Events, Clinical Trial, FDA Compliance, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1013-10131084.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1yi08sdrzmCUIKSb5ZtBRoyuGKm3UhGKU/view?usp=drivesdk,eua-051925,PDF,157,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1013-10131176.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/10WcbKQTu6vQC0wcl-bGHPOHbq38Dxt1f/view?usp=drivesdk,eua-051925,PDF,483,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Clinical Neuroscience, Regulatory Compliance, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1013-10131517.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1U40ucwXzsZyaxr1UwwpenrF_yMJGIrBK/view?usp=drivesdk,eua-051925,PDF,120,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, eCRF, Subject Enrollment, Subject Demographics, M5, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Site Information, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1015-10151047.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/11eIIxmgxCe9ETyZ0aPti-I4XVuBoBuJ7/view?usp=drivesdk,eua-051925,PDF,137,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Boston Medical Center, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1015-10151134.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1lPNHTCQHBf4vQVzjjThm5YJHzPagEK4z/view?usp=drivesdk,eua-051925,PDF,151,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, Fda-regulated, M5, Cohort Selection, Demographic Data, Vaccine Development, Data Collection, Clinical Trial, Site Information, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1016-10161277.pdf,COVID-19 Vaccine Clinical Trial Subject Enrollment,2020-11-17,https://drive.google.com/file/d/1kDRdI5iYlhd0JJRoHjfZAoTuIPMIpHpq/view?usp=drivesdk,eua-051925,PDF,107,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Kentucky Pediatric Adult Research, Subject Enrollment, COVID-19, C4591001, M5, Demographics, Cohort Selection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1016-10161087.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1_ucZEKSsB12Ryf55jPuoDjtg7u5XEpU6/view?usp=drivesdk,eua-051925,PDF,214,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Kentucky, eCRF, Exclusion, COVID-19, M5, Cohort Selection, Adult, Clinical Trial, Pediatric, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1016-10161289.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-09-15,https://drive.google.com/file/d/1x6VG106m1UoAmiXnRGr1pk-XTRbMV8PH/view?usp=drivesdk,eua-051925,PDF,342,M5,form,,"FDA, Protocol Amendment, Vaccine, Exclusion, eCRF, Kentucky Pediatric Adult Research, COVID-19, M5, Demographics, Cohort Selection, Data Verification, Clinical Trial, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1018-10181132.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1qbnJK2VZZVHfOzuMl3irtxUkcrTWP2Qp/view?usp=drivesdk,eua-051925,PDF,241,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, FDA Compliance, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1019-10191010.pdf,c4591001 Clinical Research Form,2020-07-30,https://drive.google.com/file/d/1FKtVsJVENkmudUUa2Fa9FJguX5zDz_B6/view?usp=drivesdk,eua-051925,PDF,679,M5,form,---,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, Exclusion, Clinical Trial, Confidential, M5, Cohort Selection, Data Collection, Demography, Site Information, Subject Identification, Subject Data",False,True,False,True
27034_S2_M5_CRF_c4591001-1019-10191037.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1CRuCp00a3-KSHbKSqXRO_GX4t8_NQaSL/view?usp=drivesdk,eua-051925,PDF,380,M5,form,,"Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Adverse Events, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1018-10181159.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1TVaJXKybGbjHXov11h4ZzS2ngLMDCCAA/view?usp=drivesdk,eua-051925,PDF,152,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1019-10191146.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/10BXQwqA643nKsDRWahV_G2lJLyMbBoj8/view?usp=drivesdk,eua-051925,PDF,117,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Clinical Trial, Phase 2/3, Diagnostics Research Group, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1019-10191229.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1VQlTx6b3OWBbyeOY8YHQgHN-1XqMPMll/view?usp=drivesdk,eua-051925,PDF,151,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Study Protocol, Cohort Selection, Data Collection, Clinical Trial, Patient Information, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1019-10191254.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1RmpYr94qCwnNeAv2rsxxrq0AS7Fv29Ri/view?usp=drivesdk,eua-051925,PDF,153,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1021-10211190.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1DtVbA0i3t3SOuxEBM05Mim3huDEDIRT0/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"Protocol Amendment, Medical Research, Subject Details, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1027-10271105.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1LRkWLaq4e4CswPhH7IB1yAAidIzIv139/view?usp=drivesdk,eua-051925,PDF,264,M5,form,,"Exclusion, Subject Enrollment, COVID-19, M5, Study Protocol, Cohort Selection, Demographic Data, Vaccine Development, Pharmaceutical Research, Clinical Trial, Phase 2/3, Site Information, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1027-10271054.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ABrflpt13Q1vofYcU1rklTRu1PFb5vqA/view?usp=drivesdk,eua-051925,PDF,158,M5,form,,"Protocol Amendment, Medical Research, Subject Details, Exclusion, Pharmaceutical Development, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1028-10281060.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1M7hLapxkMzQnJyWkCPdNDnwtJlkg9AJy/view?usp=drivesdk,eua-051925,PDF,252,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Clinical Trial, Subject Enrollment, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1028-10281059.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/18l6C_R3zctc_bJ37gyaSKo7_jJQKue-p/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"FDA, Lillestol Research Llc, Subject Id 10281059, Medical Research, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Clinical Trial, Pfizer, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1037-10371252.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-15,https://drive.google.com/file/d/1_WE1PXob85DDaIf4nJ0O7X1A6m4IkAJX/view?usp=drivesdk,eua-051925,PDF,128,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1038-10381101.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/126_85GA5DfnulGHVRZ61WxYO8E5eLOyS/view?usp=drivesdk,eua-051925,PDF,160,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1042-10421166.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1W_4p6UuZr3YEAsP8CA2QOL8T22pODdZz/view?usp=drivesdk,eua-051925,PDF,183,M5,form,,"Audit Trail, Protocol Amendment, Medical Group, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Healthcare, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1044-10441093.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1eU0lAIma6WB7iyQtiw1dY5Zy-YSqvdRC/view?usp=drivesdk,eua-051925,PDF,161,M5,form,,"Medical Research, Exclusion, Clinical Data Collection, Subject Enrollment, COVID-19, FDA Regulatory, M5, Cohort Selection, Demographic Data, Vaccine Development, Phase 3 Trial, Clinical Trial, Site Information, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1047-10471252.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/12VgQiBvPMuSM54fnnQCunQYyJOW1_Bw_/view?usp=drivesdk,eua-051925,PDF,494,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Medical Affiliated Research Center, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1047-10471114.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/15DLjMEejtfDtxiliF7tTdF51RE-HpGDB/view?usp=drivesdk,eua-051925,PDF,173,M5,form,,"Safety Monitoring, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Phase 3, Cohort Selection, Medical Affiliated Research Center, Adverse Events, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1054-10541173.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-09-15,https://drive.google.com/file/d/1vGj2cD3GnlIjLzYZw1biTJup8cRwT10d/view?usp=drivesdk,eua-051925,PDF,353,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Collaborative Neuroscience Network, Site Information, Clinical Trial, Data Collection, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1054-10541186.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-23,https://drive.google.com/file/d/1qK8Ox_TSCcpOxR57YS9lhiqsgaBNF3vT/view?usp=drivesdk,eua-051925,PDF,158,M5,form,,"Subject Details, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Study Protocol, Collaborative Neuroscience Network, Cohort Selection, Demographic Data, Phase 3 Trial, Vaccine Development, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1055-10551145.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1Zb1hB9ra_fhwqt8vKj81KV-TBkBC0u1X/view?usp=drivesdk,eua-051925,PDF,137,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1055-10551153.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1t8w4AbPuYrFEAZiHqBh2CxEfbToK2lPD/view?usp=drivesdk,eua-051925,PDF,134,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Data Verification, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1055-10551176.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1El2YMdPGIEtnVVAgQ1MdnA5ShhjAFIQI/view?usp=drivesdk,eua-051925,PDF,147,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Diablo Clinical Research, Subject Enrollment, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1057-10571137.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1X4VS03tQRC2y0o0BFGXQYihZCy0KXcYH/view?usp=drivesdk,eua-051925,PDF,153,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1057-10571052.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1gZv61vyxWqN7io6s3XetdFXL_uyL1q04/view?usp=drivesdk,eua-051925,PDF,391,M5,form,,"Pharmaceutical, FDA, Protocol Amendment, Medical Research, COVID-19 Vaccine, Exclusion, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Site Information, Healthcare, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1057-10571327.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-10-16,https://drive.google.com/file/d/1Ehz7h8VCKrfLU-3-6PssNhsGcvPNB5Fk/view?usp=drivesdk,eua-051925,PDF,411,M5,form,,"Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Phase 3, Cohort Selection, Protocol, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1066-10661350.pdf,c4591001 Cohort Selection and Informed Consent,2020-10-19,https://drive.google.com/file/d/1dvx1MsHSNd0zSifc1NYJJQZoKXBfGthc/view?usp=drivesdk,eua-051925,PDF,116,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1071-10711169.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-15,https://drive.google.com/file/d/1nnDJoOlU4F2IHw-BL3JFwb-mlD9zNzC7/view?usp=drivesdk,eua-051925,PDF,160,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Quality Clinical Research, Subject Enrollment, Regulatory Compliance, M5, Study Documentation, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1071-10711023.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1SgF9Ddqt-K7eRkUblmxqkzGsLv-KaktZ/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Quality Clinical Research, Subject Enrollment, Adverse Event Monitoring, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1079-10791004.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-06,https://drive.google.com/file/d/1JQZZRU6OYYIgMttFDN_Td4cNJnPsDkXz/view?usp=drivesdk,eua-051925,PDF,205,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1072-10721007.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1s5Fqzc3FUFBVCPGCxNBune8sAuyj9azS/view?usp=drivesdk,eua-051925,PDF,163,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1079-10791228.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/16EWG3i0wR5tHZDhZDw-f3b2QS0G3xO3a/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Data Collection, Clinical Trial, Site Information, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1079-10791246.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/171ay9M_8YX9kU1vxhYyaXYq2x216UpQd/view?usp=drivesdk,eua-051925,PDF,137,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1080-10801013.pdf,COVID-19 Vaccine Clinical Trial,2020-07-30,https://drive.google.com/file/d/1m-Yz3_wGC0hcKR6COWVcfcOBJAxKPGJh/view?usp=drivesdk,eua-051925,PDF,282,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, Clinical Study, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1080-10801152.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1tPb-aBVC4jA4rAxVj-sqYq6WFSeH2Hpq/view?usp=drivesdk,eua-051925,PDF,163,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Confidential, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811026.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1oAs0alLARXVoxEDptKU6dqcj5__dbm4a/view?usp=drivesdk,eua-051925,PDF,446,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Patient Privacy, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811046.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/10zxi6_yKuVKZkhgJ1HVGUiY-KKxtnVSD/view?usp=drivesdk,eua-051925,PDF,209,M5,form,,"Medical Research, Exclusion, Subject Enrollment, COVID-19, M5, Study Protocol, Cohort Selection, Demographic Data, Phase 3 Trial, Vaccine Development, Clinical Trial, Site Information, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811036.pdf,Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1qaOnZPJgw8Q_8ContvTQtUdJjPklBzwc/view?usp=drivesdk,eua-051925,PDF,252,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811110.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1x5ULfqwD5GvbsalRBlUqtd2Fa8oi1JmU/view?usp=drivesdk,eua-051925,PDF,439,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Data Collection, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811194.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1HhqyC2WzKKM7u6s8Xyz-a2_aKB4IDbYT/view?usp=drivesdk,eua-051925,PDF,347,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1081-10811135.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1zh7H69ikPMsCqqV76SFWZLaqRelma1xg/view?usp=drivesdk,eua-051925,PDF,229,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1082-10821076.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1EpSyAfqScBMV5Y6VEcfnxIKEd4nGEixL/view?usp=drivesdk,eua-051925,PDF,173,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Fda-regulated, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Data Collection, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1082-10821094.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1tsfcXZjumM-UkOCDAiCLvnKCpRiiyIlO/view?usp=drivesdk,eua-051925,PDF,141,M5,form,,"Pharmaceutical Study, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, FDA Compliance, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1083-10831029.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/16ePq9uOZ9f2OXSFgp6hPZDqBCthhOYBC/view?usp=drivesdk,eua-051925,PDF,482,M5,form,,"Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Benchmark Research, COVID-19, Clinical Study, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1083-10831060.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1JVoQqL1uKePNzUBAVCZvEZIDgRacRv2g/view?usp=drivesdk,eua-051925,PDF,327,M5,form,,"FDA, Medical Research, Vaccine, Exclusion, Benchmark Research, 2020, COVID-19, M5, Cohort Selection, Protocol, Clinical Trial, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1084-10841219.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1nZ9Obq4nVgMc-Gjz_KCAhaQsjD5Oe23U/view?usp=drivesdk,eua-051925,PDF,191,M5,form,,"FDA, Audit Trail, Protocol Amendment, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1083-10831194.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/12tWsfOvxgAUNcIs41qimdG9jS3N3jZ4a/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Benchmark Research, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1084-10841317.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1kACpsDkdNsG9FeudOWwVuRrCN3di8Mse/view?usp=drivesdk,eua-051925,PDF,141,M5,form,,"Protocol Amendment, Medical Research, Subject Details, Exclusion, Subject Enrollment, Regulatory Compliance, Medical History, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1085-10851216.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1vHxfZHiDXBBBfjPlpUAP_leLcnq20oCh/view?usp=drivesdk,eua-051925,PDF,138,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, Ventavia Research Group, C4591001, COVID-19, M5, Cohort Selection, Vaccine Development, Clinical Trial, FDA Compliance, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1084-10841480.pdf,c4591001 Cohort Selection and Informed Consent,2020-10-14,https://drive.google.com/file/d/1OR3jad5-bY6cLEE9P1P8LxfLj_1V0tHA/view?usp=drivesdk,eua-051925,PDF,191,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871070.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1tV7J3NawQAvkoaFea-_3YujkVaZuvg1s/view?usp=drivesdk,eua-051925,PDF,239,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871029.pdf,COVID-19 Vaccine Clinical Trial,2020-07-30,https://drive.google.com/file/d/1MoYFW-UReAoNmZtcJiOMpHyUKXVcnxXY/view?usp=drivesdk,eua-051925,PDF,308,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Pmg Research, COVID-19 Vaccine, Exclusion, Wilmington, M5, Cohort Selection, Protocol, Clinical Trial, Phase 2/3, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871121.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1VMWiBadXJoPxVQ2uMzQL5U0p3nahf0F8/view?usp=drivesdk,eua-051925,PDF,156,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871150.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1A15C8s-SJ4FsER_lZVXRKqOlCsm1STmP/view?usp=drivesdk,eua-051925,PDF,195,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Study Documentation, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871557.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-10-14,https://drive.google.com/file/d/10pfyE6iS6wo4i6bESv0oVIYiLUJcuHgB/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1087-10871228.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/18aU6YZggsQSvlBH4m1L_rRnijPfpaDyC/view?usp=drivesdk,eua-051925,PDF,321,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1089-10891150.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/12Z9SUVkBxW5ykc2STwxF5-ieTjmh7qFW/view?usp=drivesdk,eua-051925,PDF,152,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Phase 3, Cohort Selection, Protocol, Adverse Events, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1088-10881220.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1r_HfhdOcAW341xFPi692Lpj3LW5JA0YX/view?usp=drivesdk,eua-051925,PDF,127,M5,form,,"Pharmaceutical, Pmg Research, Medical Research, Vaccine, Exclusion, COVID-19, M5, Phase 3, Cohort Selection, Protocol, Hickory, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1089-10891182.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1g54w4UNq2AdPxHL4YOxI6HxLig8ujoVF/view?usp=drivesdk,eua-051925,PDF,521,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Clinical Trial, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Phase 2/3, Site Information",False,True,False,True
27034_S2_M5_CRF_c4591001-1090-10901300.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1SUi2dwxY5IYXwoV7qnqdbwuXGwl56bLh/view?usp=drivesdk,eua-051925,PDF,195,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Wake Research Associates, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1090-10901507.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1LNeCpzfd-huMA9YejJ1Ek4ppgGQZ5hWq/view?usp=drivesdk,eua-051925,PDF,105,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1090-10901415.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-09-15,https://drive.google.com/file/d/1O1T1PoWD8enCDw1Grlliv8u2ZFrZAQhG/view?usp=drivesdk,eua-051925,PDF,202,M5,form,,"Pharmaceutical, FDA, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1091-10911197.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ws_ds_bfhu8Swv0YW6MNvEXyqyR4FG7n/view?usp=drivesdk,eua-051925,PDF,501,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1091-10911300.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1ML7_gS9hlDQLViM8aj71qCbunDpZv58d/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"Protocol Amendment, Medical Research, Aventiv Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1092-10921015.pdf,Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1CAhzff9HncM8I0Z-Pq7GmpqX3HOil8Qe/view?usp=drivesdk,eua-051925,PDF,156,M5,form,,"eCRF Audit Trail, Protocol Amendment, Medical Research, Exclusion, Medical Study, Subject Enrollment, M5, Confidential Information, Cohort Selection, Demographic Data, Data Verification, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1092-10921123.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1SvLhnaDawki3xMbQQ85G9tcwE0wAgPs1/view?usp=drivesdk,eua-051925,PDF,159,M5,form,,"Protocol Amendment, FDA Submission, Clinical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Pharmaceutical Research, Clinical Trial, Site Information, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1092-10921187.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/12_jF7GqhxOGjXkUmgkfLI5-Yfcz5C5b_/view?usp=drivesdk,eua-051925,PDF,169,M5,form,,"Vaccine, Exclusion, eCRF, Subject Enrollment, Regulatory Compliance, COVID-19, Needs-review, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1094-10941155.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1wqx-eaHdWWngsXxVTy20gk3NoIPF7EFz/view?usp=drivesdk,eua-051925,PDF,112,M5,form,,"Pharmaceutical, Medical Research, Patient Enrollment, Vaccine, Clinical Research, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951101.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1XB6xG9WZmKgn_bkg0uJg2o6AtGm75Q3O/view?usp=drivesdk,eua-051925,PDF,376,M5,form,,"Protocol Amendment, Medical Research, Subject Details, Exclusion, Clinical Trial, Pharmaceutical Development, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Site Information, Phase 2/3, Data Collection, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1093-10931058.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/15EXOThl7tXaVDQ_8ak0Hh5P--j0aFF4H/view?usp=drivesdk,eua-051925,PDF,133,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951107.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1VrCXDMmloGvacpfGktEbwQaFCh2zcc9r/view?usp=drivesdk,eua-051925,PDF,208,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Tekton Research, eCRF, C4591001, M5, Cohort Selection, Clinical Trial, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951141.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Ap5MFVtm1-hzmfz4qNiO1lITH5HCL3Bf/view?usp=drivesdk,eua-051925,PDF,151,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Tekton Research, Subject Enrollment, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951173.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/193XUCN6KWbPxajrt4BN3PhxAC0sz6akC/view?usp=drivesdk,eua-051925,PDF,141,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951180.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1Or0eM29pNLVYriOtzYWcsBebxbsYB302/view?usp=drivesdk,eua-051925,PDF,140,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Phase 2/3 Study, Clinical Trial, Site Information, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951204.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1amE4PXerCJThFhoJWr9d7QOADEtQvPuI/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1095-10951228.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1c9855DglGWO5JfXOecNAJrcCuhZ0XbwI/view?usp=drivesdk,eua-051925,PDF,116,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Tekton Research, eCRF, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Trial, Data Collection, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1096-10961031.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/12fEQHlSSbv8-v7FUF-ncRra3NVw2e5yw/view?usp=drivesdk,eua-051925,PDF,430,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Ventavia Research Group, M5, Demographics, Cohort Selection, Adverse Events, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1096-10961044.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1CINul9hQwSfsaucqi50PQHMFm4Mr0Viv/view?usp=drivesdk,eua-051925,PDF,147,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Ventavia Research Group, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1096-10961062.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1kDBF_wYEXLDY9qODiu8QJXZXGTJuG5C7/view?usp=drivesdk,eua-051925,PDF,149,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Ventavia Research Group, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1097-10971011.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/16SoNMtj2BHVACgY_VeaDM0ExDPYHfE83/view?usp=drivesdk,eua-051925,PDF,342,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Patient Privacy, Subject Enrollment, Regulatory Compliance, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Healthcare, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1097-10971025.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1MAq7879AQhO5S6kZrOSEfI3xb80ZZGxb/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Phase 3, Cohort Selection, Protocol, Adverse Events, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1097-10971017.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1uSR_BVGw6JAwZ5NaolYMUGAFw7RbxM6s/view?usp=drivesdk,eua-051925,PDF,139,M5,form,,"FDA, Pharmaceutical, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1097-10971061.pdf,COVID-19 Vaccine Clinical Trial Subject Enrollment,2020-07-30,https://drive.google.com/file/d/1wRgxjuTkaWOsyP2DFcLjX-sJh4GLUQI6/view?usp=drivesdk,eua-051925,PDF,162,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Patient Data, Clinical Trial, Healthcare, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1098-10981024.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1PFemNV12ZGDlBko2uu2-qWN2XHyW-KvI/view?usp=drivesdk,eua-051925,PDF,585,M5,form,,"Protocol Amendment, Race, Exclusion, Medical Study, Ethnicity, Patient Demographics, Subject Enrollment, M5, Gender, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1097-10971084.pdf,COVID-19 Vaccine Trial Cohort Selection,2020-07-30,https://drive.google.com/file/d/1s8aweckYpYZKbHkdyqjdSHzEbdramwAM/view?usp=drivesdk,eua-051925,PDF,209,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, COVID-19, Clinical Study, M5, Cohort Selection, Demographic Data, Vaccine Trial, Clinical Trial, Phase 2/3, Healthcare, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1107-11071044.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1XQ8A3Mpb7SyUICWqCnuzZqw6CqQ_ROto/view?usp=drivesdk,eua-051925,PDF,146,M5,form,,"Pharmaceutical, FDA, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091111.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1qqq-tuK725DgsDdY05_KWllnXS5ibI_R/view?usp=drivesdk,eua-051925,PDF,254,M5,form,,"Audit Trail, Protocol Amendment, Accel Research Sites, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1107-11071065.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/186F7NPWLUKRZSe6_01d-AYre_-JH4WWP/view?usp=drivesdk,eua-051925,PDF,156,M5,form,,"FDA, Coastal Clinical Research, Protocol Amendment, Medical Research, Race, Exclusion, Ethnicity, Subject Enrollment, Subject Demographics, M5, Gender, Cohort Selection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091204.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/18225meZ_P7pfvmGmvaBqxSxkNDYKAhX-/view?usp=drivesdk,eua-051925,PDF,204,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Accel Research Sites, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Research Study, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091164.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1iJlW1EhTNMz5U9ZYQYJU0QzKpNFwF0M3/view?usp=drivesdk,eua-051925,PDF,147,M5,form,,"Pharmaceutical, FDA, Safety Monitoring, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Adverse Events, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091276.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1S9P0TLdv4EkMGuQYlJfdetiieLlASTHt/view?usp=drivesdk,eua-051925,PDF,118,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Accel Research Sites, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091387.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ij4UgJIArWnr7tw9oKT2cvs_ORv_79Zs/view?usp=drivesdk,eua-051925,PDF,143,M5,form,,"eCRF Audit Trail, Protocol Amendment, Medical Research, Accel Research Sites, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091448.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/18BHh22qPLmiAA-EzisUgCgLKRqvgpQMH/view?usp=drivesdk,eua-051925,PDF,314,M5,form,,"FDA, Pharmaceutical, Safety Monitoring, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Adverse Events, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091503.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1M0HnzvmDo8fS_7xPJ_EzDAdYdFMx3oxM/view?usp=drivesdk,eua-051925,PDF,138,M5,form,,"Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Data Collection, Clinical Trial, Site Information, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1109-11091558.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/13rwxc-qc_v4cxjFnUT8ttdosxzUi2CNH/view?usp=drivesdk,eua-051925,PDF,119,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1110-11101031.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/12CyOqaLB7drdmXL7Ns5r9XZ_wvxg1DFS/view?usp=drivesdk,eua-051925,PDF,144,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1111-11111095.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1JJDH-LJgIGr1LYTHcb66N8P0ur2QXXl6/view?usp=drivesdk,eua-051925,PDF,172,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Clinical Trial, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1111-11111109.pdf,Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1OJWecen5FRDrWV9f2nnlmzhnJagj3ywA/view?usp=drivesdk,eua-051925,PDF,208,M5,form,,"Audit Trail, Protocol Amendment, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1111-11111130.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1Vd0eoWimV2qq-bBNQz1kiH1eETjIDjYR/view?usp=drivesdk,eua-051925,PDF,152,M5,form,,"eCRF Audit Trail, Protocol Amendment, Exclusion, Confidential, Subject Enrollment, Fda-regulated, M5, Cohort Selection, Demographic Data, Data Verification, Site Information, Clinical Trial, Pharmaceutical Research, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1112-11121118.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1DVExGLVEMRPDVAfJIRr0cOVNJ7gx5rkt/view?usp=drivesdk,eua-051925,PDF,166,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1111-11111193.pdf,Cohort Selection and Informed Consent,2020-10-15,https://drive.google.com/file/d/19HAN7Whvir1f54AQWRr1_Z7t04qLvEd2/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1112-11121337.pdf,c4591001 Cohort Selection and Informed Consent,2020-10-21,https://drive.google.com/file/d/1J4VCW3jr5aBOq0mBS7JjPEanMYoHl5DN/view?usp=drivesdk,eua-051925,PDF,170,M5,form,,"Protocol Amendment, Medical Research, Subject Details, Clinical Research, Exclusion, Subject Enrollment, M5, Demographics, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1112-11121255.pdf,c4591001 Cohort Selection,2020-11-17,https://drive.google.com/file/d/1cvBh8zpxy9Dea3jVrFQ645ZCAPHCa4UF/view?usp=drivesdk,eua-051925,PDF,177,M5,form,,"eCRF Audit Trail, Protocol Amendment, Subject Details, Exclusion, Subject Enrollment, C4591001, Fda-regulated, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1116-11161045.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1AyJHP-jFeJMB3gh95W6vWMAldB2PyoCR/view?usp=drivesdk,eua-051925,PDF,225,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1114-11141080.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/14S80S8HwEpzVhnex3fDBbyog74I7k8xs/view?usp=drivesdk,eua-051925,PDF,185,M5,form,,"FDA, Protocol Amendment, Exclusion, Multispecialty Research, 2020, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Vaccine Development, Clinical Trial, July, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1116-11161253.pdf,c4591001 Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1CqbnGNBu-4xB0KrdvAwyQmiam97V0HWz/view?usp=drivesdk,eua-051925,PDF,554,M5,form,,"Pharmaceutical Study, Informed Consent, Medical Research, Protocol Amendment, Exclusion, Clinical Trial, Subject Enrollment, FDA Regulated, Medical History, M5, Cohort Selection, Data Collection, Demography, Site Information, Subject Data",False,True,False,True
27034_S2_M5_CRF_c4591001-1116-11161059.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/10_Wpx6AKJkDrcgLDc7KqJP8rQ_BVydG-/view?usp=drivesdk,eua-051925,PDF,140,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, COVID-19 Vaccine, Exclusion, Regulatory Compliance, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1117-11171186.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-17,https://drive.google.com/file/d/1M9qI3yC7xGpqG2uytKxoXEVCf2Hgbo-Y/view?usp=drivesdk,eua-051925,PDF,152,M5,form,,"Protocol Amendment, Medical Research, Sundance Clinical Research, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Fda-regulated, M5, Cohort Selection, Demographic Data, Vaccine Development, Data Collection, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1117-11171036.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1J1CmMVtL0ozD6HEoyj9gShCjDo8ByTQs/view?usp=drivesdk,eua-051925,PDF,233,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, M5, Cohort Selection, Demographic Data, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1118-11181057.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1ygOfO9QzLH_D0dlvVnkjtr2sRGLGMFQK/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"Pharmaceutical, FDA, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1118-11181044.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1UUXBcLJamq_WYe4y7Bz-labTD2J7JJuM/view?usp=drivesdk,eua-051925,PDF,331,M5,form,,"Pharmaceutical, Protocol Amendment, Clinical Research, Medical Study, Exclusion, COVID-19, Fda-regulated, M5, Demographics, Cohort Selection, Vaccine Trial, Data Collection, Healthcare, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1120-11201127.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1fcLs1dUklKfPPQNRLek4LuPt7G2tWqxv/view?usp=drivesdk,eua-051925,PDF,121,M5,form,,"FDA, Meridian Clinical Research, Protocol Amendment, Medical Research, Audit Trail, Exclusion, eCRF, Subject Enrollment, COVID-19, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1118-11181074.pdf,COVID-19 Vaccine Clinical Trial Subject Enrollment,2020-11-17,https://drive.google.com/file/d/1Fj4_HwMDeoBxKaz6bQFvoYgp1H3nlsj_/view?usp=drivesdk,eua-051925,PDF,117,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Vaccine Trial, Site Information, Clinical Trial, Data Collection, FDA Compliance, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1122-11221026.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ncFYaGO-6g4U9S3Z-eV0dM9WRNl2ODxF/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1120-11201408.pdf,c4591001 Cohort Selection,2020-11-17,https://drive.google.com/file/d/1DUkrhtkauZMUMcbXoEcdjHOmVj2NWfH6/view?usp=drivesdk,eua-051925,PDF,106,M5,form,,"FDA, Audit Trail, Informed Consent, Protocol Amendment, Subject Details, Medical Research, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1124-11241106.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1D4GRZfw_sBWn-_etlfHZA38AEhO3sez0/view?usp=drivesdk,eua-051925,PDF,110,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Demography, Informed Consent, Omega Medical Research",False,True,False,True
27034_S2_M5_CRF_c4591001-1127-11271022.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/16_vUzP2wEhBFkRouk55MvY--GLj9_F5l/view?usp=drivesdk,eua-051925,PDF,247,M5,form,,"FDA, Protocol Amendment, Heartland Research Associates, Medical Research, Vaccine, CRF, Exclusion, COVID-19, Clinical Study, M5, Cohort Selection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1127-11271023.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/18nlhheulWZHLF-tj-_TDRB3utc_PhlIz/view?usp=drivesdk,eua-051925,PDF,252,M5,form,,"Protocol Amendment, Heartland Research Associates, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1128-11281014.pdf,COVID-19 Vaccine Clinical Trial,2020-07-30,https://drive.google.com/file/d/1Zkh1TaYQALfFPXPq3sgOklilcm5Gu2OE/view?usp=drivesdk,eua-051925,PDF,195,M5,form,,"Informed Consent, Protocol Amendment, Medical Research, COVID-19 Vaccine, Exclusion, Pharmaceutical Development, Subject Enrollment, Ventavia Research Group, M5, Cohort Selection, Clinical Data, Vaccine Trial, Clinical Trial, FDA Compliance, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1128-11281103.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1-5lYRs0M0Bt4LsmZxdfzlNC6LZ7nxWIS/view?usp=drivesdk,eua-051925,PDF,466,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Ventavia Research Group, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1129-11291074.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1TOI5MkIIJPaUEXYjUDGzAbz1AsoAAX-T/view?usp=drivesdk,eua-051925,PDF,189,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Site Information, Clinical Trial, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1129-11291138.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1su7pXvG3YPzlfEUrb-fWkfimiRN-8a8O/view?usp=drivesdk,eua-051925,PDF,234,M5,form,,"CBER, FDA, Pharmaceutical, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1131-11311145.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1vSgJGW6zhde34qWN-RrgydOgAoEmRnSa/view?usp=drivesdk,eua-051925,PDF,188,M5,form,,"Audit Trail, Informed Consent, Medical Research, Protocol Amendment, Subject Details, Exclusion, Subject Enrollment, M5, Race And Ethnicity, Gender, Cohort Selection, Date Of Birth, Site Information, Clinical Trial, Phase 2/3, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1131-11311222.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-25,https://drive.google.com/file/d/1H3kbHy5EcSbPu8K4ODdz92osXc-NcMF8/view?usp=drivesdk,eua-051925,PDF,111,M5,form,,"Phase 2/3, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1133-11331006.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1BU62Vv6l_o4tVKTWQOzcdHSQJ-ujXtPm/view?usp=drivesdk,eua-051925,PDF,215,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1134-11341058.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1ftI9NrJech1IMUthCk9Py5Tq1fOqLESE/view?usp=drivesdk,eua-051925,PDF,160,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1133-11331170.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1DEdEOi-EuQHLgCrRLkNgcknyK4wZ7Clf/view?usp=drivesdk,eua-051925,PDF,142,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1134-11341153.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1GLrTjbOrrpOhMh3zOjMxQuv__JpiLyj7/view?usp=drivesdk,eua-051925,PDF,224,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1134-11341174.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/10WfDAOYcbvaqxPgn5mIDSrOHDh-h7BLR/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Patient Information, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1134-11341250.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1DVPMM5WIP-R3rVHXW70BXHee8JFNEkfo/view?usp=drivesdk,eua-051925,PDF,149,M5,form,,"Pharmaceutical, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Study Protocol, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1135-11351143.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/13-d0uBpjOQkMSW1TO3ovgBd1qtD2F69F/view?usp=drivesdk,eua-051925,PDF,197,M5,form,,"Audit Trail, Protocol Amendment, Exclusion, eCRF, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Anaheim Clinical Trials, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401009.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1sBgGoxIR-ugr3hPGmXwX4rPkDfLfVPRR/view?usp=drivesdk,eua-051925,PDF,486,M5,form,,"Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, Clinical Study, M5, Cohort Selection, SUNY Upstate Medical University, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401002.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-06,https://drive.google.com/file/d/19mQVoBTpsUxbjY54bUV0fuL4AEQRGhRC/view?usp=drivesdk,eua-051925,PDF,239,M5,form,,"Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, SUNY Upstate Medical University, Data Collection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401078.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1sIcCOnTgKfeKrdXa4utAZhF-qRHOcTAK/view?usp=drivesdk,eua-051925,PDF,228,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Vaccine Development, SUNY Upstate Medical University, Demographic Data, Clinical Trial, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401035.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1lbCq-cL7Zt9Y9RhagQpuxbWVNCky0lPn/view?usp=drivesdk,eua-051925,PDF,277,M5,form,,"Protocol Amendment, Exclusion, Medical Study, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401306.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-17,https://drive.google.com/file/d/1Ehi9NPYp8LBk1iBwMNVQR--pdJK3107b/view?usp=drivesdk,eua-051925,PDF,144,M5,form,,"Protocol Amendment, Exclusion, Medical Study, Subject Enrollment, Subject Demographics, COVID-19, Regulatory Compliance, Needs-review, M5, Cohort Selection, Vaccine Development, SUNY Upstate Medical University, Data Collection, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1140-11401244.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1mexwJzNGuJn03yL7ZzX0OytdNXdDSNgL/view?usp=drivesdk,eua-051925,PDF,198,M5,form,,"Medical University, Pharmaceutical, Medical Research, SUNY Upstate, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1142-11421032.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1XWmQOLTW69dm2a-wC--sqQ7UzADn7u4v/view?usp=drivesdk,eua-051925,PDF,156,M5,form,,"FDA, Pharmaceutical, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1142-11421044.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1fsMbJIm3TMm4nF7oK_l8xDpfCtzP3Wtw/view?usp=drivesdk,eua-051925,PDF,382,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Study Protocol, Cohort Selection, Patient Data, Clinical Trial, Healthcare, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1142-11421111.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1MtQH3BJSwJNKoGLyy5uuouw4yvOOaenc/view?usp=drivesdk,eua-051925,PDF,133,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Galveston, Regulatory Compliance, COVID-19, University Of Texas, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1142-11421084.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1DwXFrj1ZOAIAqrrrWySBsz8HWBe8oI1V/view?usp=drivesdk,eua-051925,PDF,140,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Galveston, COVID-19, University Of Texas, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1145-11451056.pdf,COVID-19 Vaccine Clinical Trial Subject Enrollment,2020-07-30,https://drive.google.com/file/d/1kqDZOV_LZ50fxXGDvfJDaLGY3qExs-oC/view?usp=drivesdk,eua-051925,PDF,219,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Healthcare, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1142-11421247.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-21,https://drive.google.com/file/d/1tK0TgA2Aesy-qSdZC8izRyD_NkITkKuU/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1145-11451076.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1J9VlyuIjcyDq67gWi354fp-XcHOInuRu/view?usp=drivesdk,eua-051925,PDF,119,M5,form,,"CBER, Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Clinical Trial, Johns Hopkins, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1145-11451063.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1-tgFqxH9vicMV9Db_A3PSoCCm9y2vYrv/view?usp=drivesdk,eua-051925,PDF,443,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1146-11461200.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ZwodK_aVfUUolhGddTBueiIF9U-C1qG6/view?usp=drivesdk,eua-051925,PDF,135,M5,form,,"Protocol Amendment, Amici Clinical Research, Race, Birth Date, Exclusion, Ethnicity, Subject Enrollment, Subject Demographics, Needs-review, M5, Gender, Cohort Selection, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1146-11461161.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1YeMaNgX9eBrirPoMPg0aNfeFeyQWdHG4/view?usp=drivesdk,eua-051925,PDF,146,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1147-11471239.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Iuc12lKWtG7MAviRxG8-99Ni4DLclKvr/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Protocol, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1146-11461264.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1kzShU_Em9AMmLZestpwodLdQWjdTtVIv/view?usp=drivesdk,eua-051925,PDF,128,M5,form,,"Protocol Amendment, Amici Clinical Research, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1149-11491313.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-09-15,https://drive.google.com/file/d/1bGrf_JKxlktjn5UxLLuEpO6rNt67D_Ku/view?usp=drivesdk,eua-051925,PDF,187,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Collaborative Neuroscience Network, Cohort Selection, Patient Data, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521085.pdf,COVID-19 Vaccine Clinical Trial,2020-07-30,https://drive.google.com/file/d/1KXEhoHCjp5VqEcG7xRtruL8B8lbM8bF4/view?usp=drivesdk,eua-051925,PDF,110,M5,form,,"Pharmaceutical, FDA, Medical Research, Vaccine, Exclusion, Needs-review, COVID-19, M5, Regulatory, Demographics, Cohort Selection, Phase 3, Clinical Trial, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1150-11501001.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/17Ab6uFvjZ6Z1bjk2XYFIkjPGfWsBipDb/view?usp=drivesdk,eua-051925,PDF,112,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521260.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1reDY11HNYBC1xWJGJcrr1zRGGpVtkUA_/view?usp=drivesdk,eua-051925,PDF,140,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Demographics, Cohort Selection, Research Study, Data Collection, Clinical Trial, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521095.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1fNwq3cNbKEUp2en9y1GQ5hn5HdS3FxC3/view?usp=drivesdk,eua-051925,PDF,248,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, 2020, COVID-19, M5, Regulatory, Cohort Selection, Protocol, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521359.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1QESqazQ8aASZhosGEsEvBttM52ugTo_x/view?usp=drivesdk,eua-051925,PDF,197,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521476.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-25,https://drive.google.com/file/d/1lTnkp2yShxlOTE6c7xadJwfQ70_gGLSN/view?usp=drivesdk,eua-051925,PDF,175,M5,form,,"Protocol Amendment, Exclusion, Subject Enrollment, COVID-19, Fda-regulated, M5, Cohort Selection, Demographic Data, Pharmaceutical Research, Vaccine Development, Clinical Trial, Site Information, Data Verification, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1152-11521497.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-17,https://drive.google.com/file/d/1de8NhTPjNwQ1NqxnWJ9gQaZ2aCsetK7n/view?usp=drivesdk,eua-051925,PDF,117,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Patient Privacy, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Case Report Form, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1156-11561006.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1zp0Jk5LsusfUgubEZnrc5gwtelFY2jyd/view?usp=drivesdk,eua-051925,PDF,372,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1156-11561001.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1WyKX1bmNB8p4eJzC7Ij3yqLhptbZzxRz/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"FDA, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1156-11561015.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ZFnzRPRUjGaXRTiodeMT37KSP8WUbqE1/view?usp=drivesdk,eua-051925,PDF,155,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Phase 2/3, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1156-11561007.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1ztpM-Iv1eIY9TbEhaClb9iLHpNVBZEvv/view?usp=drivesdk,eua-051925,PDF,144,M5,form,,"Audit Trail, Protocol Amendment, Exclusion, Confidential, Subject Enrollment, Fda-regulated, M5, Cohort Selection, Demographic Data, Data Verification, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1157-11571134.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1HiU_Hq3Yk8_wgodGgIy1eTOsQ9KujA7j/view?usp=drivesdk,eua-051925,PDF,115,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Paradigm Research, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1156-11561044.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/17Qd6OjxkvxcrKt2-9NimFsKUE0IBu7zV/view?usp=drivesdk,eua-051925,PDF,341,M5,form,,"FDA, Pharmaceutical, SARS-COV-2, Medical Research, Vaccine, Exclusion, COVID-19, M5, Regulatory, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent, Pandemic",False,True,False,True
27034_S2_M5_CRF_c4591001-1162-11621059.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1kJcFzcN2Atj_3jG6bnQ2DWmdmIE1yOhx/view?usp=drivesdk,eua-051925,PDF,180,M5,form,,"Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Protocol, Site Information, Clinical Trial, Data Collection, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1161-11611029.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1i2gIAFfvQsPbYOHBwOs5rS6gsU66gB4q/view?usp=drivesdk,eua-051925,PDF,251,M5,form,,"Audit Trail, Protocol Amendment, San Angelo, Vaccine, Exclusion, eCRF, Benchmark Research, COVID-19, M5, Demographics, Cohort Selection, Clinical Trial, Phase 2/3, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1162-11621327.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1hfA3yPiS5pjSmsSXfTQRNypfdTvrT2mk/view?usp=drivesdk,eua-051925,PDF,114,M5,form,,"Subject Tracking, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1163-11631059.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1yBGnwUAnT0glAqxoNUA6TcofW2ylJwlX/view?usp=drivesdk,eua-051925,PDF,192,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Patient Data, Protocol, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1166-11661047.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1L88R6KU8OeEYc27L9TZMW3mkTdJYOnVD/view?usp=drivesdk,eua-051925,PDF,236,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1167-11671085.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1ruwCmdwtEwUYKilydHrriccTQaF47I_h/view?usp=drivesdk,eua-051925,PDF,148,M5,form,,"Audit Trail, Protocol Amendment, Subject Data, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Medical Group, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1167-11671009.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1g416gc_f1IMxbeCY1FxiOFcH7cq6HguQ/view?usp=drivesdk,eua-051925,PDF,145,M5,form,,"Protocol Amendment, Subject Details, Exclusion, Medical Study, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1167-11671175.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/13ozYr5bKp1lTmHvmaNn2r66Aaj7WHLcs/view?usp=drivesdk,eua-051925,PDF,108,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Patient Data, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1170-11701217.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1BgRuWj1pnCv2tn294aEn54gqU-kjYezV/view?usp=drivesdk,eua-051925,PDF,431,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Protocol, Adverse Events, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1174-11741042.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1rA0dXG1M9CcVlZ5bD-rkdhrRDwo-dLvG/view?usp=drivesdk,eua-051925,PDF,158,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Care-id, Cohort Selection, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781025.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1us0dtdwkQZXz6usC7FbQcxh956Fdujlj/view?usp=drivesdk,eua-051925,PDF,168,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, Fda-regulated, M5, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Site Information, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781048.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1WLjlRIk8HUUL6sB_VXNuPuLPZyUsI1kP/view?usp=drivesdk,eua-051925,PDF,123,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781015.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/121qZn_-F9EXjOyPYWXzlgYj-9Xw0cvUR/view?usp=drivesdk,eua-051925,PDF,149,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Data Verification, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781107.pdf,c4591001 Cohort Selection,2020-11-17,https://drive.google.com/file/d/18oYj0M7QqgDBVGOfA8ZSa0G45lXTzutm/view?usp=drivesdk,eua-051925,PDF,207,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Clinical Trial, Subject Enrollment, M5, Cohort Selection, Site Information, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781138.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/12-8t1LtC7vHX92RCyNvMNmAV2Xr9fGTH/view?usp=drivesdk,eua-051925,PDF,117,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, M5, Subject Identification, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1195-11951023.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1T1-Ece1jVWuCofTyK-A6zzBldtPxDPo2/view?usp=drivesdk,eua-051925,PDF,348,M5,form,,"Essen Borbeck, Phase 2/3, Protocol Amendment, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Clinical Trial, Medical Center, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1178-11781167.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1mX4r3lZ87vloF4Wa1hfggTAC7hVajQa3/view?usp=drivesdk,eua-051925,PDF,135,M5,form,,"FDA, Safety Monitoring, Pharmaceutical, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Protocol, Adverse Events, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1221-12211002.pdf,c4591001 Cohort Selection,2020-11-18,https://drive.google.com/file/d/18UlIgSRDRVxfXGilaz2ak-Zb5CHHtGyH/view?usp=drivesdk,eua-051925,PDF,328,M5,form,,"CBER, FDA, Protocol Amendment, Exclusion, Gallup, Subject Enrollment, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Clinical Trial, Phase 2/3, American Indian, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1205-12051028.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/124qKev_1wTFw87ypTnzR_27evU3m3Hka/view?usp=drivesdk,eua-051925,PDF,115,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1223-12231097.pdf,Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1IwDGlGNKyQLteEEJhCNqeIIa-n3e9vdF/view?usp=drivesdk,eua-051925,PDF,107,M5,form,,"Phase 2/3, Subject Tracking, Protocol Amendment, Data Management, Clinical Research, Exclusion, Subject Enrollment, M5, Cohort Selection, Demographic Data, Vaccine Development, Clinical Trial, Medical Center, FDA Compliance, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1221-12211007.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/176gKafFpjy64NqYMNSGw0BHpzDq_ArIV/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1223-12231166.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1FcDSj1Jy8FN3CxshfLl1TDzqbAkSi00h/view?usp=drivesdk,eua-051925,PDF,119,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, COVID-19, M5, Subject 12231166, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Yale New Haven Medical Center, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1223-12231159.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1ik4Zh52mrlEFZwa6mxmyDLVx_QQCMAWQ/view?usp=drivesdk,eua-051925,PDF,126,M5,form,,"Protocol Amendment, Vaccine, Clinical Research, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Patient Data, Clinical Trial, Medical Center, FDA Compliance, Healthcare, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1223-12231182.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1I7O0a81XGH7l_Wi-U7KF_Zmu3DBBgYOl/view?usp=drivesdk,eua-051925,PDF,125,M5,form,,"Protocol Amendment, Exclusion, Patient Privacy, Subject Enrollment, Regulatory Compliance, Medical History, M5, Cohort Selection, Demographic Data, Data Collection, Clinical Trial, Medical Center, Study Procedures, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1224-12241012.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/19jhAVUuIWfbyMWQlbvt4QvFPkuuh6XRt/view?usp=drivesdk,eua-051925,PDF,160,M5,form,,"FDA, Audit Trail, Vaccine, Clinical Research, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Phase 3, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261067.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/190G2NpT_XnDuKbz5BrCSOXA5neFnbVII/view?usp=drivesdk,eua-051925,PDF,181,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1224-12241065.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1IWAIwIBqMpEjFvYWR2dAGk45YdOkc8lx/view?usp=drivesdk,eua-051925,PDF,152,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261072.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1AwI4MB-MaxpQB4JMRpiwHWw4BRopzKEt/view?usp=drivesdk,eua-051925,PDF,167,M5,form,,"Protocol Amendment, Cepic, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, Clinical Study, M5, Cohort Selection, Clinical Trial, Case Report Form, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261282.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1QoUyzos_neQv97kpJrBxg9xX0JZfV0qk/view?usp=drivesdk,eua-051925,PDF,120,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, Clinical Study, M5, Cohort Selection, Patient Data, Clinical Trial, Case Report Form, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261137.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1rIW21Dx5raL_X78deBB5tGAF7gfiGsPU/view?usp=drivesdk,eua-051925,PDF,221,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261571.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1bjjXL5i_N6jJJRV8rGXffOeawpECuqIG/view?usp=drivesdk,eua-051925,PDF,184,M5,form,,"Pharmaceutical Study, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, Regulatory Compliance, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Data Collection, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261300.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1IvXSmhbyci-VNrGTVsteL44WlW2RwkJA/view?usp=drivesdk,eua-051925,PDF,141,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Pharmaceutical Development, Subject Enrollment, Subject Demographics, Regulatory Compliance, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261624.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1iX-br15DAUINZ_A5uDSOVXt1sSsjg9tc/view?usp=drivesdk,eua-051925,PDF,384,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261599.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Lm3dpLnjxiI1OX41QgEeCE51uBeFCRL8/view?usp=drivesdk,eua-051925,PDF,329,M5,form,,"FDA, Protocol Amendment, Cepic, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261769.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-17,https://drive.google.com/file/d/1CDLmzxM6HNAT6ndl5Y4vuenbGaXCUWz_/view?usp=drivesdk,eua-051925,PDF,186,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12261745.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-16,https://drive.google.com/file/d/1IXzquzSA3N7fzKoDQVetiSoBdukv5ou-/view?usp=drivesdk,eua-051925,PDF,166,M5,form,,"Subject Tracking, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, Clinical Study, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12262240.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/12-SPz5KgHkC321MqImXvIgXSC83B3ntg/view?usp=drivesdk,eua-051925,PDF,120,M5,form,,"Pharmaceutical, Protocol Amendment, Cepic, Exclusion, Subject Enrollment, Centro Paulista De Investigacao Clinica E Servicos Medicos Ltda, COVID-19, Fda-regulated, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1226-12262089.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1RiRPdFcvZLjfFfCL4UgChdyIofEZS0S0/view?usp=drivesdk,eua-051925,PDF,315,M5,form,,"Pharmaceutical, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, Clinical Study, M5, Cohort Selection, Data Collection, Clinical Trial, Case Report Form, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1230-12301025.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1K4R9l4toykZII0963u3wHaA-Spy9Dy8t/view?usp=drivesdk,eua-051925,PDF,134,M5,form,,"Protocol Amendment, Exclusion, Subject Enrollment, Regulatory Compliance, Medical History, M5, Demographics, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Medical Center, Data Verification, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1230-12301045.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-28,https://drive.google.com/file/d/1fIQBeADbe5kyGHGX1Aow-p5BM96-IMs6/view?usp=drivesdk,eua-051925,PDF,145,M5,form,,"Audit Trail, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Needs-review, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Medical Center, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311281.pdf,c4591001 Clinical Research Form,2020-07-30,https://drive.google.com/file/d/1S82wjciEwmKx9Zlk6RWl-kkBiCMHbU-Q/view?usp=drivesdk,eua-051925,PDF,183,M5,form,,"Pharmaceutical, Informed Consent, Medical Research, Protocol Amendment, Vaccine, Clinical Trial, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Site Information, Demography, Data Collection, Subject Data",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311205.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/15vvF71bVEGStNZRC8D6Az6fkezAglkM-/view?usp=drivesdk,eua-051925,PDF,191,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, eCRF, M5, Cohort Selection, Data Collection, Clinical Trial, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311352.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/11TgAylA-clPNFwXxJhDEABislO_yYT2q/view?usp=drivesdk,eua-051925,PDF,338,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311315.pdf,COVID-19 Vaccine Clinical Trial Form,2020-07-30,https://drive.google.com/file/d/1po1JYf0Msfjwbu7W8_9Q-FnHKXKUtr9K/view?usp=drivesdk,eua-051925,PDF,209,M5,form,Cosme Argerich,"Vaccine, Exclusion, Military, COVID-19, Needs-review, Hospital, Demographics, Cohort Selection, M5, Clinical Trial, Argentina, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311579.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1oLvVvvXGlDk8njdFp0sQJ9rF21MClPLd/view?usp=drivesdk,eua-051925,PDF,175,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311409.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1fICtLt2HnrDWeLy-IlF0cEAh3Fzz3i1O/view?usp=drivesdk,eua-051925,PDF,177,M5,form,,"Pharmaceutical, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Regulatory Compliance, M5, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Phase 2/3, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311711.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1mz6r5ILIMByc_JBr1hyTxJDKYJViVZtZ/view?usp=drivesdk,eua-051925,PDF,179,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311766.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1dp4VBLipvI-5yvTVZBhoblsuEEnlySJw/view?usp=drivesdk,eua-051925,PDF,179,M5,form,,"FDA, eCRF Audit Trail, Vaccine, Stage 3 Cohorts, Exclusion, Subject 12311766, COVID-19, M5, Protocol Amendment 5, Cohort Selection, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Clinical Trial, Demography, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311844.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1xW_GX-Xt4qcpNzAmf_vww2z1no2mthwk/view?usp=drivesdk,eua-051925,PDF,181,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, eCRF, Subject Enrollment, COVID-19, M5, Regulatory, Cohort Selection, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Clinical Trial, Demography, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311834.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/15z53fh8kSiqwp0m9pDcUP2p5QorBwwM9/view?usp=drivesdk,eua-051925,PDF,136,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Confidential, Pharmaceutical Development, Subject Enrollment, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311946.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Ixt7rxeNryVpQcKC6JC_2osnR1SIzclH/view?usp=drivesdk,eua-051925,PDF,162,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, Clinical Study, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12311926.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1TIYsLzA3BzLhNjrxe6cDCuZPq1orjB-k/view?usp=drivesdk,eua-051925,PDF,160,M5,form,,"Adverse Event Reporting, Protocol Amendment, Medical Research, Data Management, Exclusion, Patient Privacy, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312390.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1DmRwNPqgGhWrkks_mi1ZUc4k_0uE0-wG/view?usp=drivesdk,eua-051925,PDF,184,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Subject Details, Exclusion, Subject Enrollment, C4591001, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312576.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1oF1KkuUOoZFhBECfygFGSHuxxWPXNa5n/view?usp=drivesdk,eua-051925,PDF,166,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Patient Privacy, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312593.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1kZaPNUQLBX077gdMLOtXtTiMuW8C6EPP/view?usp=drivesdk,eua-051925,PDF,178,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312577.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1M3mG5hXU45dnQ8xwevGtgXGtyHHo-6Gx/view?usp=drivesdk,eua-051925,PDF,146,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Patient Privacy, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312868.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1kUieUHt9YmvHtqjdC92BfaypbE7rTgXA/view?usp=drivesdk,eua-051925,PDF,302,M5,form,,"eCRF Audit Trail, Protocol Amendment, Medical Research, Subject Details, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Healthcare, Demography, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312854.pdf,c4591001 Cohort Selection,2020-07-30,https://drive.google.com/file/d/1uaFCI0DEm3vZJ0THNj_MNfE87_VsOhnl/view?usp=drivesdk,eua-051925,PDF,186,M5,form,,"Protocol Amendment, Exclusion, Clinical Trial, Subject Enrollment, Needs-review, M5, Cohort Selection, Demographic Data, Site Information, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312982.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1zXUkosGaF0R8bUnzz8UjTqPFB8ZufYFe/view?usp=drivesdk,eua-051925,PDF,323,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, M5, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12312914.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1FuNoUygRRRe3nVsm4eJOR-FgRvdZ0BcE/view?usp=drivesdk,eua-051925,PDF,358,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313193.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1EK3uU7VbYfegSKQXHAfrE1ldy5_Pzuy3/view?usp=drivesdk,eua-051925,PDF,208,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Patient Data, Clinical Trial, Healthcare, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313422.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1lo7v7p0emcDXr2PFq0uYCj36aOUeG3NG/view?usp=drivesdk,eua-051925,PDF,367,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Data Collection, Clinical Trial, Site Information, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313653.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1FwdVxdqSwFfFK4oWsvWa3OCOyzgNEnzi/view?usp=drivesdk,eua-051925,PDF,279,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, M5, Hospital Militar Central, Cohort Selection, Subject 12313653, Data Collection, Clinical Trial, July 2020, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313621.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1rERuxFTR3fNC1tDy9drxzk5NDrD8z2OM/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, M5, Cohort Selection, Data Collection, Clinical Trial, Patient Information, Healthcare, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313674.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1RWj8SfvMe_UaFXEiM_sd7Tiwlkh6V1e5/view?usp=drivesdk,eua-051925,PDF,315,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313783.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Jy9UasNnGO1UN2onDml6PcTglFMQRaVt/view?usp=drivesdk,eua-051925,PDF,146,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, Audit Trail, COVID-19 Vaccine, Exclusion, M5, Cohort Selection, Data Collection, Clinical Trial, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314001.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1PUumLzufmqjZvN6a19fhnjEWeN0cDIh9/view?usp=drivesdk,eua-051925,PDF,215,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12313972.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Dvnp2-C0dGpr7NKvFfgvMSteyThDNpe-/view?usp=drivesdk,eua-051925,PDF,147,M5,form,,"Pharmaceutical, FDA, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Clinical Data, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314216.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1oi6r8TrRUYBghlVtBXju-_Lq8U4prNqf/view?usp=drivesdk,eua-051925,PDF,131,M5,form,,"Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, Subject Enrollment, COVID-19, M5, Hospital Militar Central, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314035.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Byeo01htlFsDtnFbny56NuFqccZCs4M4/view?usp=drivesdk,eua-051925,PDF,140,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Adverse Events, Data Collection, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314407.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/13eWx6eW_dJWUnOfkxJEzSBK7CYo8kYPD/view?usp=drivesdk,eua-051925,PDF,129,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Hospital Militar Central, Cohort Selection, Clinical Data, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314833.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1zfbn_4ksKLiHkFkEBYNxhtw_NaPUJEu_/view?usp=drivesdk,eua-051925,PDF,129,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Hospital Military Central, Exclusion, Subject Enrollment, M5, Cohort Selection, Demographic Data, Vaccine Development, Data Verification, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315429.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Ay7ag1oTmYUC4v5oCAWB-R6-62tqa6FF/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Hospital Militar Central, Cohort Selection, Data Collection, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315291.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/15UsFvhpmnM6Yv9_rgN2nuOPXWeS5J0Ax/view?usp=drivesdk,eua-051925,PDF,130,M5,form,,"Protocol Amendment, Medical Research, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Data Collection, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12314898.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1tM7_sqgOEt7-AOenEymeh3vo0JR_Pb5p/view?usp=drivesdk,eua-051925,PDF,218,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, Patient Enrollment, COVID-19 Vaccine, Exclusion, eCRF, M5, Cohort Selection, Data Collection, Clinical Trial, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315473.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1VZeYiRlFfqg6DtkNVYp4LD9bu0pTfPS-/view?usp=drivesdk,eua-051925,PDF,126,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Data Collection, Clinical Trial, Site Information, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315441.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1mRvLwEMm91fMR9euoM7Rj61HHtAH2jP4/view?usp=drivesdk,eua-051925,PDF,143,M5,form,,"Protocol Amendment, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Medical History, M5, Cohort Selection, Adverse Events, Site Information, Clinical Trial, Phase 2/3, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315653.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1-n1VCiUNbFIszENFsCL5euQW65C99YoP/view?usp=drivesdk,eua-051925,PDF,142,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1231-12315632.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1Imcz7O73P2jNyjvw2Kh4p2Y5i5rg9WtY/view?usp=drivesdk,eua-051925,PDF,186,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1232-12321293.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1olcfUmCQiiB9eZMAZWj8G88d58-ysnCJ/view?usp=drivesdk,eua-051925,PDF,149,M5,form,,"FDA, Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, CRF, Exclusion, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1232-12321213.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1w83nxnbQBoWZ25wAna_cTXIwZn5MDc-_/view?usp=drivesdk,eua-051925,PDF,163,M5,form,,"Pharmaceutical, FDA, Protocol Amendment, Medical Research, Vaccine, Exclusion, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1235-12351071.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1TLax5aaM_t4dIdnZL66B6kiyab--4pCl/view?usp=drivesdk,eua-051925,PDF,572,M5,form,,"eCRF Audit Trail, Informed Consent, Protocol Amendment, Lsu Health Shreveport, Exclusion, Subject Enrollment, Subject 12351071, Fda-regulated, M5, Cohort Selection, Vaccine Development, Clinical Trial, Phase 2/3, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12411206.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1khDnRbi83ydlKAl3p1zzUaaYDFZ397eX/view?usp=drivesdk,eua-051925,PDF,168,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12411279.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1yEWAebTyUy7Q7le85EL79fK8YmUxAE8b/view?usp=drivesdk,eua-051925,PDF,177,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, Subject Enrollment, M5, Cohort Selection, Site Information, Clinical Trial, Subject Data, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12411643.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/14q9RuK07r3OSI9a4RWfwoDwO4XoGNdtJ/view?usp=drivesdk,eua-051925,PDF,154,M5,form,,"eCRF Audit Trail, Informed Consent, Protocol Amendment, Subject Details, Exclusion, Subject Enrollment, COVID-19, M5, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Confidential, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12411766.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1l-iLHP0P9XZsMyQ3GAJoGkfeYEwChafI/view?usp=drivesdk,eua-051925,PDF,157,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Clinical Research, Exclusion, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Demography",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12412191.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1K5bY58J6iGHTE8wbEXo_PsYlOoLIWoxF/view?usp=drivesdk,eua-051925,PDF,150,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1241-12411825.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1tzY1bh7D5GeoUv4c9a3MIyFubKmugTCT/view?usp=drivesdk,eua-051925,PDF,138,M5,form,,"Hospital Irma Dulce, Protocol Amendment, Vaccine, Exclusion, COVID-19, M5, Subject 12411825, Cohort Selection, Site 1241, Clinical Trial, Phase 2/3, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1246-12461025.pdf,c4591001 Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1ML8MnQ90TXrgzLhhPF5EijMwxIhhZb5g/view?usp=drivesdk,eua-051925,PDF,243,M5,form,,"Informed Consent, Protocol Amendment, Medical Research, Exclusion, Clinical Trial, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Vaccine Development, Site Information, Demography, Phase 2/3, Data Collection, Subject Data",False,True,False,True
27034_S2_M5_CRF_c4591001-1246-12461035.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1RqW5ks0M3f55TelB-8AMbOGfdg38F4w_/view?usp=drivesdk,eua-051925,PDF,124,M5,form,,"Protocol Amendment, Clinical Research, Exclusion, Subject Enrollment, Regulatory Compliance, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Phase 2/3, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1247-12471121.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1ej6WfVSrNRlNd4Y9gq87X681fvj_TivY/view?usp=drivesdk,eua-051925,PDF,437,M5,form,,"Clinical Trial Form, Pharmaceutical, Protocol Amendment, Medical Research, FDA, Clinical Research, Exclusion, COVID-19, M5, Cohort Selection, Vaccine Trial, Demography, Healthcare, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1247-12471135.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1JTh-pl1Y-mz2-7sP1-5c1ahPo5I72aLm/view?usp=drivesdk,eua-051925,PDF,170,M5,form,,"Audit Trail, Protocol Amendment, Exclusion, Subject Enrollment, Subject Demographics, Needs-review, M5, Cohort Selection, Site Information, Clinical Trial, Phase 2/3, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1248-12481120.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1F4jLBZ6gDczOYYKVL2YFeTj5YFTW772c/view?usp=drivesdk,eua-051925,PDF,162,M5,form,,"eCRF Audit Trail, Protocol Amendment, Exclusion, Snbl Clinical Pharmacology Center, Subject Enrollment, Needs-review, M5, Cohort Selection, Demographic Data, Data Verification, Clinical Trial, FDA Compliance, Clinical Pharmacology, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1248-12481163.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1JvPDG61kwQzI4gP1zCrKLGkWMN2gfkA7/view?usp=drivesdk,eua-051925,PDF,123,M5,form,,"Pharmaceutical, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Study Protocol, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1248-12481218.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-18,https://drive.google.com/file/d/11CSY8yqy4uePh90MP_RRq5nTeJcOiK0m/view?usp=drivesdk,eua-051925,PDF,116,M5,form,,"Protocol Amendment, Exclusion, Snbl Clinical Pharmacology Center, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Vaccine Development, Data Verification, Clinical Trial, Phase 2/3, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1251-12511050.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1xlRZwYpy5K3Y0aBiN05LmnNWxVir9lL6/view?usp=drivesdk,eua-051925,PDF,399,M5,form,,"Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, M5, Cohort Selection, Demographic Data, Confidential Data, Data Collection, Clinical Trial, Site Information, FDA Compliance, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1254-12541142.pdf,c4591001 Cohort Selection and Informed Consent,2020-11-18,https://drive.google.com/file/d/1xY8fl6ZKm0PJC3LPRNQMx7IPIxjOnDAN/view?usp=drivesdk,eua-051925,PDF,203,M5,form,,"FDA, Audit Trail, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Needs-review, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1260-12601037.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/1qQzXTFKyBQJdRs_gDh091xozASpCKtZY/view?usp=drivesdk,eua-051925,PDF,120,M5,form,,"Phase 2/3, Audit Trail, Protocol Amendment, Vaccine, Exclusion, eCRF, COVID-19, M5, Cohort Selection, Clinical Trial, Medical Center, Demography, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1261-12611006.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1OtVsEgt0Lg_Qe7qMRJQdzmoPxxfB3Z3w/view?usp=drivesdk,eua-051925,PDF,171,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1260-12601069.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,https://drive.google.com/file/d/15UinwDVulY8dCBML8BjrMXgqN4XHFw0h/view?usp=drivesdk,eua-051925,PDF,133,M5,form,,"FDA, Protocol Amendment, Medical Research, Vaccine, Exclusion, Pharmaceutical Development, Subject Enrollment, COVID-19, M5, Umass Memorial Medical Center, Cohort Selection, Data Collection, Clinical Trial, Demography, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1270-12701057.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1vKuvhtmI7IHPWgHruh-OFx0tMd9Fktfq/view?usp=drivesdk,eua-051925,PDF,689,M5,form,,"Audit Trail, Protocol Amendment, Data Management, Vaccine, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, Needs-review, M5, Cohort Selection, Demographic Data, Site Information, Clinical Trial, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1265-12651101.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1gf6euRqaFGC_q9IwWnWZinH8yYle_y1E/view?usp=drivesdk,eua-051925,PDF,202,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Demographics, Cohort Selection, Vaccine Development, Site Information, Clinical Trial, Data Collection, Subject Identification, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-1270-12701069.pdf,c4591001 Cohort Selection and Informed Consent,2020-07-30,https://drive.google.com/file/d/1WYBalrVGVHR7VjAWlmtX7vtpsHLFExQl/view?usp=drivesdk,eua-051925,PDF,156,M5,form,,"FDA, Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Regulatory Compliance, COVID-19, M5, Cohort Selection, Demographic Data, Vaccine Development, Site Information, Clinical Trial, Data Collection, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-4444-44441007.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1yXBvgSQ9Jeg_cy4Q_nFGjCk1WSU4Wi6E/view?usp=drivesdk,eua-051925,PDF,127,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Vaccine, Exclusion, Military, COVID-19, M5, Hospital, Cohort Selection, Clinical Trial, Phase 2/3, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-4444-44441748.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1UD67ruermKY9xx_gN5WojhKkiYTRO8uu/view?usp=drivesdk,eua-051925,PDF,126,M5,form,,"Pharmaceutical, Protocol Amendment, Medical Research, Patient Enrollment, Vaccine, Exclusion, Regulatory Compliance, COVID-19, M5, Cohort Selection, Data Collection, Clinical Trial, Demography, Subject Data, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-4444-44441249.pdf,COVID-19 Vaccine Trial CRF,2020-11-18,https://drive.google.com/file/d/1HTf-RAgy12QXrlEyaBPeqa6bK4OESObW/view?usp=drivesdk,eua-051925,PDF,111,M5,form,,"Audit Trail, Protocol Amendment, Clinical Research, Exclusion, COVID-19, M5, Demographics, Cohort Selection, Vaccine Trial, Cosme Argerich, Hospital Militar Central, Phase 2/3, Subject Data, Confidential, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-4444-44441979.pdf,c4591001 Cohort Selection and Informed Consent,2020-09-15,https://drive.google.com/file/d/1tISI1ZVghGittEdxcJNsh8_tyuqkgrGD/view?usp=drivesdk,eua-051925,PDF,162,M5,form,,"Protocol Amendment, Medical Research, Exclusion, Subject Enrollment, Subject Demographics, COVID-19, Needs-review, M5, Cohort Selection, Vaccine Development, Data Collection, Clinical Trial, Site Information, Informed Consent",False,True,False,True
27034_S2_M5_CRF_c4591001-4444-44442304.pdf,COVID-19 Vaccine Clinical Trial CRF,2020-11-18,https://drive.google.com/file/d/1HmG4CCuDxawXrRRGoorQsO_UsfU8Xc5h/view?usp=drivesdk,eua-051925,PDF,169,M5,form,,"Pharmaceutical, FDA, Informed Consent, Medical Research, Protocol Amendment, COVID-19 Vaccine, Exclusion, eCRF, M5, Cohort Selection, Site Information, Clinical Trial, Data Collection, Subject Data, Demography",False,True,False,True
27034_S4_M1_vrbpac-bd.pdf,Pfizer-BioNTech COVID-19 Vaccine VRBPAC Briefing Document,2020-12-10,https://drive.google.com/file/d/1bsAymKxHaR7EU5vwXZAKK8KNmFHMA4W5/view?usp=drivesdk,eua-051925,PDF,91,M1,briefing,,"FDA, Pandemic Response, M1, Vaccine, Safety, Public Health, Medical Countermeasures, Clinical Trials, COVID-19, Regulatory, BioNTech, Pfizer, Efficacy, VRBPAC",False,False,False,True
27034_S4_M1_pi-lab-1457-0-4.pdf,PFIZER-BIONTECH COVID-19 VACCINE FULL PRESCRIBING INFORMATION,2021,https://drive.google.com/file/d/1AQs8ex8lp6UstFGojKWuOoMFTt4Yg4WE/view?usp=drivesdk,eua-051925,PDF,24,M1,prescribing information,,"Emergency Use Authorization, Pharmaceutical, Pandemic Response, M1, Vaccine, Clinical Trial Results, Patient Counseling, Public Health, Medical Guidance, COVID-19, Safety Information, Adverse Events, Storage And Handling, Dosage And Administration",False,False,False,True
27034_S4_M5_baum-a-2020.pdf,A promising approach to combat the COVID-19 pandemic,2020-06-15,https://drive.google.com/file/d/1NFyIO-X7NEbDaCeXjvNq3yntWce5zkSU/view?usp=drivesdk,eua-051925,PDF,7,M5,report,A. Baum,"SARS-COV-2, Resistance, Therapeutic, Treatment, Antibody, Neutralizing, COVID-19, M5, Convalescent, RBD, Humanized Mice, Mutation, Spike Protein, Pandemic",False,False,False,True
27034_S4_M5_Ssui-j-2004.pdf,27034 S4 M5 Ssui-j-2004,undated,https://drive.google.com/file/d/1jt2MOvU82aOkDlsMejgUuhcCE_LAAkob/view?usp=drivesdk,eua-051925,PDF,6,M5,document,,"Review-needed, Clinical, Vaccine, COVID-19, M5, Data, Research",False,False,False,True
27034_S4_M5_maruggi-g-2019.pdf,mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases,2019,https://drive.google.com/file/d/1TsL0EBbqJC5qjKXs-N17P962W-OSSPQ3/view?usp=drivesdk,eua-051925,PDF,16,M5,review,"Giulietta Maruggi, Cuiling Zhang, Junwei Li, Jeffrey B. Ulmer, Dong Yu","Infectious Diseases, Medical Research, Vaccine Discovery, Biotechnology, Vaccine Efficacy, Public Health, RNA Biology, Vaccine Safety, M5, Vaccine Development, Immunology, Vaccine Delivery, Emerging Diseases, Vaccine Manufacturing, mRNA Technology",False,False,False,True
27034_S4_M5_jiang-l-2014.pdf,Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein,2014,https://drive.google.com/file/d/1fF-_Abnckd1718uBy7RuUz4N0b2xgVs0/view?usp=drivesdk,eua-051925,PDF,9,M5,research paper,"Liwei Jiang, Nianshuang Wang, Teng Zuo, Xuanling Shi, Kwok-Man Vincent Poon, Yongkang Wu, Fei Gao, Danyang Li, Ruoke Wang, Jianwei Guo, Lili Fu, Kwok-Yung Yuen, Bo-Jian Zheng, Xinquan Wang, Linqi Zhang","Neutralizing Antibodies, Receptor Binding Domain, MERS-COV, Therapeutic Intervention, Monoclonal Antibodies, DPP4, Coronavirus, M5, Viral Entry, Prophylaxis, Infectious Disease, Neutralization, Synergistic Effect, Spike Glycoprotein",False,False,False,True
27034_S4_M5_zhang-l-2020.pdf,The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity,2020,https://drive.google.com/file/d/15g5Rgh6uJTSso61m9jYi_AKT72DyjOhg/view?usp=drivesdk,eua-051925,PDF,25,M5,research paper,"Lizhou Zhang, Cody B Jackson, Huihui Mou, Amrita Ojha, Erumbi S Rangarajan, Tina Izard, Michael Farzan, Hyeryun Choe","SARS-COV-2, Molecular Biology, S1 Shedding, ACE2, D614g Mutation, Structural Biology, Coronavirus, Pandemic, Virology, M5, Immunology, Neutralization, Spike Protein, Infectivity, Viral Transmission",False,False,False,True
27034_S6_M1_vrbpac-bd.pdf,Pfizer-BioNTech COVID-19 Vaccine VRBPAC Briefing Document,2020-12-10,https://drive.google.com/file/d/196nik5_AQXPQ2b55PUHqfKig5Z_VMDdo/view?usp=drivesdk,eua-051925,PDF,92,M1,briefing,,"FDA, Emergency Use Authorization, M1, Spike Glycoprotein, Vaccine, Coronavirus, Clinical Trials, COVID-19, Regulatory, BioNTech, Nonclinical Data, Pfizer, VRBPAC, Rna-lipid Nanoparticle",False,False,False,True
27034_S9_M5_c4591001-safety-fa-eff-S-csdrg.pdf,Clinical Study Data Reviewer's Guide,2020-12-02,https://drive.google.com/file/d/13vRcbe3XqPXx1hClIxYuqOZGwJ3-Ya09/view?usp=drivesdk,eua-051925,PDF,78,M5,report,"BioNTech SE, PFIZER INC.","FDA, Pharmaceutical, Data Review, Medical Research, Vaccine, Safety Analysis, Exclusion, Data Guide, Clinical Study, COVID-19, Regulatory, M5, EUA, Clinical Trial, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1200875–1203435_Slipsheet.pdf,FDA FOIA Request 2021-5683 Slipsheet,2021,https://drive.google.com/file/d/1G9oZAJJp1Cb5oewe_wyMrjOp2IZi8zfe/view?usp=drivesdk,eua-051925,PDF,1,,slipsheet,,"FDA, Exemptions, Data Redaction, FOIA, Public Records, Request, Government Transparency, Regulatory Compliance, Exemption, Confidential Information, Document Withholding, Bates Numbers, 2021-5683, Information Disclosure",True,False,False,True
FDA-CBER-2021-5683-1203436-1203447_27034_S1_M5_bnt162-01-A-adae.xpt,BNT162 Adverse Event Analysis,2020-10-14,https://drive.google.com/file/d/1QJh4IlaF_HSFCOquU0ElXt3LmVFo4Ft7/view?usp=drivesdk,eua-051925,XPT,144,M5,data,,"CBER, FDA, Cohorts, Safety Analysis, Medical Events, Regulatory Compliance, Treatment Groups, BNT162, M5, Adverse Events, Pharmaceutical Research, Clinical Trial, Subject Identifiers, Study Data",False,False,False,True
FDA-CBER-2021-5683-1203448-1203540_27034_S1_M5_bnt162-01-A-adcevd.xpt,BNT162 Vaccine Study Data,2020-10-15,https://drive.google.com/file/d/1xpANNfoEP-orMGZzXmldhiOokfWOqDhI/view?usp=drivesdk,eua-051925,XPT,751,M5,dataset,,"CBER, FDA, Pharmaceutical, Medical Research, Vaccine, Public Health, COVID-19, BNT162, ADCEVD, Treatment Groups, Regulatory, M5, Adverse Events, Clinical Trial, Subject Identifiers, Study Data",False,False,False,True
FDA-CBER-2021-5683-1203541-1204338_27034_S1_M5_bnt162-01-A-adfacevd.xpt,BNT162 Vaccine Study Data,2020-10-14,https://drive.google.com/file/d/14MAiFR8yFkfQ3zYXuQBCgHoh4GUL0LI7/view?usp=drivesdk,eua-051925,XPT,6290,M5,data,,"CBER, FDA, Cohorts, Medical Research, Vaccine, Analysis Dates, Treatment Groups, BNT162, Regulatory, M5, Clinical Trial, Subject Identifiers, Study Data, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1204339-1205274_27034_S1_M5_bnt162-01-A-adlb.xpt,BNT162 Study ADLB Data,2020-10-14,https://drive.google.com/file/d/1vB59bDcr-xofJ6GMIzYJAeFlUWwgiZ4R/view?usp=drivesdk,eua-051925,XPT,7306,M5,data,,"Pharmaceutical, FDA Submission, Adlb, Medical Research, Regulatory Compliance, Clinical Study, BNT162, Laboratory Data, COVID-19, M5, Vaccine Development, Data Analysis, Biostatistics, Pfizer",False,False,False,True
FDA-CBER-2021-5683-1205306-1205308_27034_S1_M5_bnt162-01-A-adsl.xpt,Subject-Level Analysis Dataset,2025-03-27,https://drive.google.com/file/d/1teC9H4fYeKkIk4dCeHJNIA83bQoplgSI/view?usp=drivesdk,eua-051925,XPT,35,M5,dataset,,"CBER, Sex, Race, FDA Submission, Vaccine, Study Identifier, Subject Identifier, Investigator, Exclusion, BNT162, Analysis Dataset, Demographics, Site Identifier, Age, M5, Clinical Trial, Subject Data",False,True,False,True
FDA-CBER-2021-5683-1205401-1205682_27034_S1_M5_bnt162-01-A-advs.xpt,BNT162 Adverse Events Analysis,2020-10-14,https://drive.google.com/file/d/1mDMItlD7Ip4f_cfJADjXQHn7-dcsIgHs/view?usp=drivesdk,eua-051925,XPT,2331,M5,data,,"CBER, FDA, Vaccine, Medical Analysis, Study Parameters, Treatment Groups, BNT162, M5, Cohort Data, Adverse Events, Clinical Trial, Subject Identifiers, Planned Vs. Actual Treatment, Safety Data",False,False,False,True
FDA-CBER-2021-5683-1205309-1205400_27034_S1_M5_bnt162-01-A-adva.xpt,BNT162 Vaccine Study Data,2020-10-14,https://drive.google.com/file/d/1duh71JJif3DBIppfNNsuAy5L8S3mymlL/view?usp=drivesdk,eua-051925,XPT,467,M5,data,,"CBER, FDA Submission, Treatment Outcomes, Medical Research, Vaccine, Exclusion, Regulatory Compliance, BNT162, M5, Adverse Events, Clinical Trial, Subject Identifiers, Study Data, SAS Data, Analysis Variables",False,True,False,True
FDA-CBER-2021-5683-1205683-1205788_27034_S1_M5_bnt162-01-A-define.xml,"BNT162-01 A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2021,https://drive.google.com/file/d/195vFIz62UwNiun9qlw8b0OzCXHd0p4xN/view?usp=drivesdk,eua-051925,XML,24,M5,report,,"Healthy Adults, SARS-COV-2, Prophylactic Vaccines, Exclusion, Dose-escalation Trial, Safety, RNA Vaccines, Phase I/ii, Dosing Regimens, COVID-19, Multi-site, M5, Clinical Trial, Immunogenicity, Bnt162-01",False,True,False,True
FDA-CBER-2021-5683-1205789-1205883_27034_S1_M5_bnt162-01-A-define2-0-0.xsl,BNT162 Clinical Study Definition,2021,https://drive.google.com/file/d/1LjUpzN_yDJhBHHuL9NDJKL9xkxxu30dD/view?usp=drivesdk,eua-051925,XSL,4,M5,study definition,,"CBER, FDA, Vaccine, Datasets, Controlled Terminology, Methods, Clinical Study, BNT162, COVID-19, M5, Protocol, External Dictionaries, Metadata, Comments, Analysis Results",False,False,False,True
FDA-CBER-2021-5683-1205925-1205936_27034_S1_M5_bnt162-01-S-ae.xpt,Adverse Event Data,2022-09-22,https://drive.google.com/file/d/1ADI4ShiNSwKh3N4vi3A4CHeYIyIATSea/view?usp=drivesdk,eua-051925,XPT,51,M5,data,,"CBER, Pharmaceutical, FDA, Dictionary-derived Term, Medical Research, Vaccine, Study Identifier, Subject Identifier, Reported Term, BNT162, M5, Adverse Events, Clinical Trial, Safety Data",False,False,False,True
FDA-CBER-2021-5683-1206030-1206035_27034_S1_M5_bnt162-01-S-cm.xpt,BNT162 Vaccine Study Metadata,2022-09-22,https://drive.google.com/file/d/10xgCt5KVLN5BaU2EcImYSEn8vrExTGNC/view?usp=drivesdk,eua-051925,XPT,18,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Vaccine, Drug Development, Clinical Study, BNT162, COVID-19, Regulatory, M5, Data File, SAS, Metadata",False,False,False,True
FDA-CBER-2021-5683-1205937-1206029_27034_S1_M5_bnt162-01-S-ce.xpt,BNT162 Clinical Event Data,2020-10-15,https://drive.google.com/file/d/12lK0TJPv6gzTfKTj2Qjj-KFo8DvRxp4U/view?usp=drivesdk,eua-051925,XPT,582,M5,data,,"Regulatory Submission, FDA, Medical Coding, Medical Terminology, Study Identifier, Subject Information, BNT162, M5, Vaccine Development, Adverse Events, Pharmaceutical Research, Clinical Trial, Data Analysis, Safety Data",False,False,False,True
FDA-CBER-2021-5683-1206036-1206040_27034_S1_M5_bnt162-01-S-co.xpt,BNT162-01 Study Data,2022-09-22,https://drive.google.com/file/d/1nw8T5xTQX2iNZ2TYYiy0-eu-i2KEdL2D/view?usp=drivesdk,eua-051925,XPT,10,M5,data,,"FDA Submission, Study Identifier, Subject Identifier, Comment Data, Sasdata, Module 5, M5, Regulatory, Vaccine Development, Clinical Trial, Data File, Study Data, SAS Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1206227-1206321_27034_S1_M5_bnt162-01-S-define2-0-0.xsl,BNT162 Study Definition,2021,https://drive.google.com/file/d/15vXlQr8QCdpTJSncSA1P6n29BBGiFEQn/view?usp=drivesdk,eua-051925,XSL,4,M5,study definition,,"CBER, FDA, Vaccine, Controlled Terminology, Data Standards, Datasets, Programming Statements, Clinical Study, BNT162, Study Protocol, M5, Data Analysis, Study Metadata, Data References",False,False,False,True
FDA-CBER-2021-5683-1206106-1206226_27034_S1_M5_bnt162-01-S-define.xml,BNT162-01 Phase I/II Dose-Escalation Trial for SARS-CoV-2 RNA Vaccines,2021,https://drive.google.com/file/d/1CrJWxscc4sB6JGNuYhSWyQ7hfmHBGEeL/view?usp=drivesdk,eua-051925,XML,20,M5,protocol,,"CBER, FDA, Healthy Adults, SARS-COV-2, Exclusion, Phase I/ii, Safety, RNA Vaccines, COVID-19, BNT162, M5, Dose Escalation, Vaccine Development, Clinical Trial, Immunogenicity",False,True,False,True
FDA-CBER-2021-5683-1206340-1206342_27034_S1_M5_bnt162-01-S-dv.xpt,BNT162-01 Protocol Deviations,2020-04,https://drive.google.com/file/d/1_ldlgQeEX6sd6tljm4fhdTd86CPkV8MW/view?usp=drivesdk,eua-051925,XPT,8,M5,data,,"Data Extract, Pregnancy Data, Regulatory Submission, FDA, ECG Data, M5, Laboratory Data, Screening, Study Identifiers, Clinical Trial, Subject Identifiers, Safety Data, Protocol Deviations, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1206325-1206339_27034_S1_M5_bnt162-01-S-ds.xpt,BNT162-01 Disposition Summary,2020-09-22,https://drive.google.com/file/d/1CS3OJhb7xOHkmjlavAyVlRo3IVhLg3Sn/view?usp=drivesdk,eua-051925,XPT,27,M5,data,,"Informed Consent, Event Category, Event Subcategory, Disposition Event, Study Identifier, Subject Information, Protocol Milestone, Study Epoch, Standardized Term, M5, Unique Subject Id, Clinical Trial, Study Data, Disposition, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1206322-1206324_27034_S1_M5_bnt162-01-S-dm.xpt,BNT162 Study Data,2020-09-22,https://drive.google.com/file/d/17gNO-RncelIOkg0QuQKXviQe4zQF9Mbc/view?usp=drivesdk,eua-051925,XPT,12,M5,data,,"Efficacy Evaluation, Safety Monitoring, FDA Submission, Medical Trial, Regulatory Compliance, Clinical Study, BNT162, COVID-19, M5, Vaccine Development, Pharmaceutical Research, Data Analysis, Patient Information, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1206364-1206369_27034_S1_M5_bnt162-01-S-ex.xpt,BNT162 Study Data Submission,2022-09-22,https://drive.google.com/file/d/1NzwnA-eh55x6cd2Y5TRi1QQgWWqwZyEN/view?usp=drivesdk,eua-051925,XPT,15,M5,data,,"CBER, Treatment Details, Route Of Administration, FDA Submission, Visit Data, Regulatory Compliance, Clinical Study, BNT162, M5, Vaccine Data, Dose Information, Pharmaceutical Research, SAS Data, Usubjid",False,False,False,True
FDA-CBER-2021-5683-1206349-1206363_27034_S1_M5_bnt162-01-S-eg.xpt,BNT162 Study Data,2020-09-22,https://drive.google.com/file/d/1_ooEdZ9YsG1--OttdJup9yMNpLP-DMLG/view?usp=drivesdk,eua-051925,XPT,27,M5,data,,"CBER, Data Structure, Data Format, FDA Submission, Medical Research, ECG Data, Regulatory Compliance, Clinical Study, BNT162, M5, Vaccine Development, Subject Identifiers, Study Metadata, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1206343-1206348_27034_S1_M5_bnt162-01-S-ec.xpt,BNT162 Study Data,2020-09-22,https://drive.google.com/file/d/1nI1r9w_xk1wWKLh16m-rvg22k-1Od57l/view?usp=drivesdk,eua-051925,XPT,16,M5,data,,"CBER, FDA, Unique Subject, Dose, Vaccine, Route, Treatment, Visit, Clinical Study, BNT162, M5, Study Identifier, SAS Data, Location",False,False,False,True
FDA-CBER-2021-5683-1206370-1208269_27034_S1_M5_bnt162-01-S-face.xpt,BNT162 Vaccine Study Face Data,2020-09-22,https://drive.google.com/file/d/11GrY22zOqs0l1WHC9CTe_fNNYfxKz5Bk/view?usp=drivesdk,eua-051925,XPT,8319,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Face Data, Vaccine, Safety Analysis, Sasdata, Clinical Study, BNT162, COVID-19, Regulatory, M5, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1208270-1208320_27034_S1_M5_bnt162-01-S-is.xpt,BNT162 Immunogenicity Study,2020-09-22,https://drive.google.com/file/d/1h85qyDeKbiaF3z00CKYnrBoeApl5-heQ/view?usp=drivesdk,eua-051925,XPT,105,M5,dataset,,"CBER, Pharmaceutical, SARS-COV-2, FDA Submission, Medical Research, Vaccine, COVID-19, BNT162, Clinical Study, M5, Biostatistics, Study Data, SAS Data, Immunogenicity",False,False,False,True
FDA-CBER-2021-5683-1208321-1209251_27034_S1_M5_bnt162-01-S-lb.xpt,BNT162 Study Data,2020-09-23,https://drive.google.com/file/d/1tnud5iMdJvQeW_0EXeYdKyqFLVuPSQqB/view?usp=drivesdk,eua-051925,XPT,2221,M5,dataset,,"CBER, FDA, Pharmaceutical, Data Repository, Medical Research, Vaccine, Safety Analysis, COVID-19, BNT162, Clinical Study, Laboratory Data, M5, Clinical Trial, Pfizer",False,False,False,True
FDA-CBER-2021-5683-1209276_27034_S1_M5_bnt162-01-S-mh.xpt,BNT162 Clinical Study Data,2022-09-22,https://drive.google.com/file/d/1eheiEA1sce9COEsSQdU9AWvba_-6nqoV/view?usp=drivesdk,eua-051925,XPT,5,M5,data,,"FDA Submission, Medical Terminology, Regulatory Compliance, Medical History, BNT162, Clinical Study, COVID-19, M5, Vaccine Development, Adverse Events, Pharmaceutical Research, Data Analysis, Pfizer, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1209252-1209275_27034_S1_M5_bnt162-01-S-mb.xpt,BNT162 Microbiology Study Data,2020-09-22,https://drive.google.com/file/d/1Xwhy5LdJ2rR8nFmfXOHUUYN7RdQLWjSy/view?usp=drivesdk,eua-051925,XPT,76,M5,data,,"CBER, Pharmaceutical, FDA Submission, Medical Research, COVID-19, BNT162, Regulatory, M5, Vaccine Development, Biostatistics, Data Analysis, Clinical Trial, Study Data, Microbiology",False,False,False,True
FDA-CBER-2021-5683-1209277-1209349_27034_S1_M5_bnt162-01-S-pe.xpt,BNT162 Study Data,2020-09-22,https://drive.google.com/file/d/1lSqHnrV5-HSBtpTNGsUCvQVvjfpgkTkg/view?usp=drivesdk,eua-051925,XPT,146,M5,data,,"CBER, FDA Submission, Vaccine Study, Medical Research, Safety Analysis, Regulatory Compliance, COVID-19, BNT162, M5, Biostatistics, Efficacy Data, Clinical Trial, SAS Data, Pharmaceutical Data",False,False,False,True
FDA-CBER-2021-5683-1209350_27034_S1_M5_bnt162-01-S-relrec.xpt,BNT162-01 Relationship Records,2020-09-22,https://drive.google.com/file/d/19P8UCtXkHM3BYQ1DmR3oEj-iBqfCqtXE/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Link Groups, Regulatory Submission, FDA, Medical Research, Data Management, Related Domains, M5, Vaccine Development, Data Analysis, Clinical Trial, Subject Identifiers, SAS Data, Bnt162-01, Relationship Data",False,False,False,True
FDA-CBER-2021-5683-1209351-1209352_27034_S1_M5_bnt162-01-S-rp.xpt,BNT162 Study Report,2020-09-22,https://drive.google.com/file/d/147N-Tuu1TsrTe16w603-vtoGNgOHcs5m/view?usp=drivesdk,eua-051925,XPT,6,M5,report,,"Pharmaceutical, FDA Submission, Vaccine, Subject Information, Reproductive System, Clinical Study, BNT162, Regulatory Compliance, M5, Data Analysis, Study Identifier, Visit Details, SAS Data, Test Results",False,False,False,True
FDA-CBER-2021-5683-1209368-1209404_27034_S1_M5_bnt162-01-S-suppae.xpt,BNT162-01 Adverse Event Supplementary Data,2022-09-22,https://drive.google.com/file/d/1j8mEci8_UarsMMrUGWL2aB52HYrI94V6/view?usp=drivesdk,eua-051925,XPT,39,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Safety, Study Data, Regulatory Compliance, BNT162, M5, Vaccine Development, Adverse Events, Data Analysis, Clinical Trial, Supplementary Data",False,False,False,True
FDA-CBER-2021-5683-1209353-1209367_27034_S1_M5_bnt162-01-S-se.xpt,BNT162-01 Study Data,2020-09-22,https://drive.google.com/file/d/1gV5nLDP3teVQEfmJU8RWynSbXziZDmFF/view?usp=drivesdk,eua-051925,XPT,26,M5,dataset,,"CBER, Seendy, Taetord, Screening, Epoch, Etcd, Study Data, Seseq, Sestdy, COVID-19, Usubjid, Seendtc, Sestdtc, Pfizer, Bnt162-01, Element, FDA, Vaccine, Clinical Study, M5",False,False,False,True
FDA-CBER-2021-5683-1209405-1209462_27034_S1_M5_bnt162-01-S-suppcm.xpt,BNT162-01 Supplementary Clinical Module,2020-09-22,https://drive.google.com/file/d/1cgcCsB98pg4gFiouS11hE-QL5OcM0NBQ/view?usp=drivesdk,eua-051925,XPT,76,M5,data,,"CBER, Medical Coding, SAS Data, FDA Submission, Unique Subject Identifier, Atc Classification, BNT162, M5, Adverse Events, Data Analysis, Clinical Trial, Supplementary Data, Related Domain, Safety Data",False,False,False,True
FDA-CBER-2021-5683-1209463-1209465_27034_S1_M5_bnt162-01-S-suppdm.xpt,BNT162-01 Supplemental Data Module,2025-03-24,https://drive.google.com/file/d/1W0kErrF6OeRW0Uf_2rGKCGFGC_Zof7Gs/view?usp=drivesdk,eua-051925,XPT,4,M5,data,(b)(6),"CBER, FDA, Pharmaceutical, Evaluator, Vaccine, Subject Identifier, COVID-19, M5, Data Value, Age, Clinical Trial, Related Domain, Supplemental Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1209486-1209504_27034_S1_M5_bnt162-01-S-suppec.xpt,BNT162-01 Clinical Study Supplementary Data,2020-09-22,https://drive.google.com/file/d/1I9NNKk0T2S8fH6zT0rUJsbejhH4ajuu8/view?usp=drivesdk,eua-051925,XPT,20,M5,data,,"CBER, FDA Submission, Administration Protocol, Vaccine, Subject Identifier, Clinical Study, BNT162, Medication Details, M5, Dose Information, Study Identifier, Data File, Supplementary Data, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1209483-1209485_27034_S1_M5_bnt162-01-S-suppdv.xpt,BNT162-01 Supplementary Data,2020-09-22,https://drive.google.com/file/d/18nFXAQCZ2koBoveQiqJJFXOstG8M7Vfj/view?usp=drivesdk,eua-051925,XPT,5,M5,data,,"CBER, Pharmaceutical, FDA, SAS, Subject Identifier, Clinical Trial, BNT162, Regulatory, M5, Study Identifier, Data File, Supplementary Data, Data Deviation, Reason For Deviation",False,False,False,True
FDA-CBER-2021-5683-1209466-1209482_27034_S1_M5_bnt162-01-S-suppds.xpt,BNT162-01 Clinical Study Supplementary Data,2020-09-22,https://drive.google.com/file/d/1tsIpl0dXvGH2gz_nFVPmwRXu2LcZtmih/view?usp=drivesdk,eua-051925,XPT,20,M5,dataset,,"Regulatory Submission, Protocol Version, Unique Subject Identifier, Vaccine, CRF, Qualifier Variables, Subject Allocation, Clinical Study, BNT162, M5, Data Evaluation, Cohort, Supplementary Data, Related Domain",False,False,False,True
FDA-CBER-2021-5683-1209507-1209524_27034_S1_M5_bnt162-01-S-suppex.xpt,BNT162-01 Supplementary Appendix,2020-09-22,https://drive.google.com/file/d/1ONs9_UtslbK4mYSo7f9qaEDOHaJRDOQq/view?usp=drivesdk,eua-051925,XPT,20,M5,data,,"CBER, FDA Submission, Administration Protocol, Dosage Information, Appendix, Medication Details, M5, Drug Study, Vaccine Development, Clinical Trial, Supplementary Data, SAS Data, Subject Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1209505-1209506_27034_S1_M5_bnt162-01-S-suppeg.xpt,BNT162-01 Study Supplemental Data,2020-09-22,https://drive.google.com/file/d/1d9w2VW8QlHO5lNlAUZCy4JH86Py2njCp/view?usp=drivesdk,eua-051925,XPT,3,M5,data,CRFINVESTIGATOR,"Qorig, Qnam, Qval, Rdomain, Qeval, Egseq, Clinical Study, M5, ECG Findings, Qlabel, Egclsig, Usubjid, Supplemental Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1211425-1211497_27034_S1_M5_bnt162-01-S-supplb.xpt,BNT162-01 Supplementary Data,2020-09-22,https://drive.google.com/file/d/1ZLrXRwYYaxsHpCgz9e1BZrChYOmxw77c/view?usp=drivesdk,eua-051925,XPT,87,M5,data,INVESTIGATOR,"Regulatory Submission, FDA, CBER, Needs-review, Clinical Study, COVID-19, Laboratory Data, Data Quality, M5, Vaccine Development, Subject Identifiers, Supplementary Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1209525-1211424_27034_S1_M5_bnt162-01-S-suppface.xpt,BNT162-01 Supplemental Face Data,2022-09-22,https://drive.google.com/file/d/1lDwCJsoYT9VXjKC7yxeIPQDfHESvZ9ve/view?usp=drivesdk,eua-051925,XPT,2482,M5,data,,"Pharmaceutical, FDA Submission, Face Data, CRF Data, Study Day, CBER Submission, Study Subject, M5, Regulatory, Clinical Trial, Reported Data, SAS Data, Supplemental Data, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1211499_27034_S1_M5_bnt162-01-S-supprp.xpt,BNT162-01 Supplementary Report,2020-09-22,https://drive.google.com/file/d/1V-9MUsb956m2c6eS-6fqJXeCIOAph11N/view?usp=drivesdk,eua-051925,XPT,1,M5,report,,"Supplementary Report, Qorig, Studyid, Qnam, Qval, Rdomain, Qeval, M5, Idvar, Qlabel, Clinical Trial, SAS Data, Usubjid, Bnt162-01",False,False,False,True
FDA-CBER-2021-5683-1211500-1211786_27034_S1_M5_bnt162-01-S-suppvs.xpt,BNT162-01 Study Data,2020-09-22,https://drive.google.com/file/d/1ynpZn9ikckVUTEg8l7aV-MSaiF6vM556/view?usp=drivesdk,eua-051925,XPT,377,M5,data,,"CBER, Pharmaceutical, FDA Submission, Vaccine Study, Medical Research, Reported Study Day, COVID-19, BNT162, M5, Clinical Trial, Data File, Supplementary Data, SAS Data, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1211498_27034_S1_M5_bnt162-01-S-supppe.xpt,BNT162-01 Study Data,2022-09-22,https://drive.google.com/file/d/1i9nvPocobMCRFRjvMzRH4O2pzZ20y7px/view?usp=drivesdk,eua-051925,XPT,1,M5,data,INVESTIGATOR,"Qorig, Regulatory Submission, Qnam, Qval, Rdomain, Qeval, Clinical Study, M5, Vaccine Development, Adverse Events, Bnt162-01, Qlabel, Pharmaceutical Research, Usubjid, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1211788-1211817_27034_S1_M5_bnt162-01-S-sv.xpt,BNT162-01 Study Visit Data,2020-04,https://drive.google.com/file/d/1zrCu-4Lm3GJOBq9GoS6TpJbN6Vl8xqGG/view?usp=drivesdk,eua-051925,XPT,43,M5,data,,"Svstdtc, Visitnum, Visit Data, Vaccine Study, Study Day, Svupdes, Svstdy, BNT162, M5, Screening, Svendy, Baseline, Clinical Trial, Svendtc, Usubjid",False,False,False,True
FDA-CBER-2021-5683-1211787_27034_S1_M5_bnt162-01-S-suppxa.xpt,BNT162-01 Blood Sampling for Research Purposes,2020-08-05,https://drive.google.com/file/d/1njFEqSwxlTNfaqaXq4QubsKIHWEh0kDn/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Vaccine Research, Data Management, Medical Study, Pharmaceutical Development, Data Processing, Blood Sampling, Regulatory Compliance, BNT162, Data Quality, M5, Data Analysis, Clinical Trial, Subject Identifiers, Research Data",False,False,False,True
FDA-CBER-2021-5683-1211818_27034_S1_M5_bnt162-01-S-ta.xpt,BNT162b1 Vaccine Study Data,2020-09-22,https://drive.google.com/file/d/1PQI7y89Pta28xomVLP58S8XexQyUUmWC/view?usp=drivesdk,eua-051925,XPT,2,M5,data,,"CBER, FDA, Pharmaceutical, Vaccine, Epoch, Treatment, COVID-19, Dosage, BNT162B1, Screening, M5, Arm, Baseline, Clinical Trial, Study Data, Transition, Element",False,False,False,True
FDA-CBER-2021-5683-1211819_27034_S1_M5_bnt162-01-S-te.xpt,BNT162b1 Vaccine Trial Data,2020-09-22,https://drive.google.com/file/d/1Vm3ro4Z-bhWTmSiZB87kXIFd0od-kgA3/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Cohort 1, Planned Duration, Boost Vaccine, Cohort 2, Element Code, COVID-19, M5, BNT162B1, Screening, Clinical Data, Vaccine Trial, Prime Vaccine, Pfizer, Element Description",False,False,False,True
FDA-CBER-2021-5683-1211820-1211827_27034_S1_M5_bnt162-01-S-ti.xpt,BNT162 Clinical Trial Inclusion/Exclusion Criteria,2020-09-22,https://drive.google.com/file/d/1Q1OInpskcZRHgfPeMu_xKaUunuNi7mbQ/view?usp=drivesdk,eua-051925,XPT,17,M5,data,,"Study Compliance, Vaccination History, Participant Eligibility, Exclusion, Medical History, BNT162, Study Protocol, Inclusion Criteria, Regulatory, Vaccine Development, Pharmaceutical Research, M5, Clinical Trial, Exclusion Criteria, Informed Consent",False,True,False,True
FDA-CBER-2021-5683-1211828_27034_S1_M5_bnt162-01-S-ts.xpt,BNT162-01 Trial Summary,2020-09-22,https://drive.google.com/file/d/1Zuw9-uMASLPnf1I90Gwn_4Ggfuv7Kj6t/view?usp=drivesdk,eua-051925,XPT,3,M5,data,,"FDA, Tsparm, CDISC, Tsvalcd, Vaccine, Tsvcdf, BNT162, M5, Tsgrpid, Clinical Trial, Study Data, Tsval, Tsvcdver, Tsseq",False,False,False,True
FDA-CBER-2021-5683-1211829_27034_S1_M5_bnt162-01-S-tv.xpt,BNT162 Clinical Trial Visit Schedule,2020-09-22,https://drive.google.com/file/d/1M25xX2BcaN-W9qGouvhajTIqwvr6-rNS/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Follow-up, Data Format, FDA Submission, Vaccine, Dosing Regimen, BNT162, Study Protocol, Visit Schedule, Screening, M5, Baseline, Study Design, Clinical Trial, SAS",False,False,False,True
FDA-CBER-2021-5683-1211830-1212111_27034_S1_M5_bnt162-01-S-vs.xpt,BNT162 Vaccine Study Data,2020-09-22,https://drive.google.com/file/d/168WpVxY9U24bS_PkW96llocyfG_ibNCg/view?usp=drivesdk,eua-051925,XPT,772,M5,data,,"CBER, FDA, Data Format, SAS, Medical Research, Vaccine, BNT162, M5, Linux, Data Analysis, Clinical Trial, Subject Identifiers, Study Data, Vital Signs",False,False,False,True
FDA-CBER-2021-5683-1212112-1212123_27034_S1_M5_bnt162-01-S-xa.xpt,BNT162 Study Data,2020-09-22,https://drive.google.com/file/d/1Ho_OzQ9AHdeq4u6_TtGDFCSRecZLYPOn/view?usp=drivesdk,eua-051925,XPT,31,M5,dataset,,"FDA Submission, Medical Research, Regulatory Compliance, COVID-19, BNT162, M5, Vaccine Development, Pharmaceutical Research, Biostatistics, Clinical Trial, Data Analysis, Study Data, SAS Data, Health Sciences",False,False,False,True
FDA-CBER-2021-5683-1213371-1226594_27034_S1_M5_c4591001-ia efficacy-A-adc19ef.xpt,c4591001 Efficacy Analysis,2021,https://drive.google.com/file/d/1uhRcadgJ52EMyvdR92T4rDDx21X943s-/view?usp=drivesdk,eua-051925,XPT,73619,M5,data,,"Pharmaceutical, SARS-COV-2, FDA Submission, Medical Research, Data File, Regulatory Compliance, COVID-19, C4591001, M5, Vaccine Development, Biostatistics, Data Analysis, Clinical Trial, Efficacy Analysis",False,False,False,True
FDA-CBER-2021-5683-1226624-1227706_27034_S1_M5_c4591001-ia efficacy-A-adsl.xpt,Subject-Level Analysis Dataset,2025-03-27,https://drive.google.com/file/d/1_dDsRC0OHUuba_fb541UIvs1w4uVFUZq/view?usp=drivesdk,eua-051925,XPT,15161,M5,dataset,,"CBER, FDA Submission, Study Identifier, Subject Identifier, Randomized Population, M5, Site Identifier, Demographic Data, Safety Population, Clinical Trial, Efficacy Analysis, SAS Data, Data Dictionary, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1227707-1231490_27034_S1_M5_c4591001-ia efficacy-A-adsympt.xpt,c4591001 Vaccine Efficacy Analysis,2021,https://drive.google.com/file/d/1_DPxS6y7JkWjDMWEwNk-uWK5TR3keqH_/view?usp=drivesdk,eua-051925,XPT,18756,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Vaccine, COVID-19, C4591001, M5, Biostatistics, Data Analysis, Clinical Trial, SAS, Adverse Symptoms, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1231491-1231586_27034_S1_M5_c4591001-ia efficacy-A-define.xml,"C4591001 Pfizer, Inc A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,https://drive.google.com/file/d/1BOKXOTy_l5wMWDMZDaaOzZtPVG83DrBs/view?usp=drivesdk,eua-051925,XML,19,M5,clinical protocol,,"Healthy Adults, Pandemic Response, Exclusion, Clinical Trial, Safety, Tolerability, RNA Vaccine, COVID-19, M5, Vaccine Development, C4591001, Phase 1/2/3 Study, Pfizer, Immunogenicity, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1231587-1231681_27034_S1_M5_c4591001-ia efficacy-A-define2-0-0.xsl,c4591001 Efficacy Analysis Definition,2021,https://drive.google.com/file/d/1-23-ur52L9t42spb4Rl3O2T3uSpcJ03u/view?usp=drivesdk,eua-051925,XSL,4,M5,analysis,,"CBER, FDA, Statistical Analysis, Vaccine, Data Standards, Regulatory Compliance, COVID-19, C4591001, M5, Data Analysis, Clinical Trial, Efficacy Analysis, Study Design, Metadata",False,False,False,True
FDA-CBER-2021-5683-1231982-1232400_27034_S1_M5_c4591001-ia efficacy-S-ae.xpt,Adverse Events Report,2020-11-18,https://drive.google.com/file/d/1NKspeEkxGnvRYAcR15HRKoUITHWcKUBV/view?usp=drivesdk,eua-051925,XPT,1507,M5,report,,"CBER, Adverse Event Terms, FDA Submission, Unique Subject Identifier, Study Identifier, Clinical Trial, Data Extraction, High Level Terms, M5, Medical Review, Adverse Events, Drug Efficacy, Pharmaceutical Research, Adverse Event Coding, Data Analysis, Safety Data, Preferred Terms",False,False,False,True
FDA-CBER-2021-5683-1232401-1239490_27034_S1_M5_c4591001-ia efficacy-S-ce.xpt,c4591001 Efficacy Study,2020-11-18,https://drive.google.com/file/d/1A_vBzMuvsD4IYbbf8bb4uN90mDvwgFtB/view?usp=drivesdk,eua-051925,XPT,25209,M5,data,,"CBER, Efficacy Study, FDA Submission, Cehlt, Ceterm, Cehltcd, Cedecod, Cehlgt, Ceseq, Regulatory Compliance, Clinical Events, M5, C4591001, Medical Data, SAS Data, Usubjid",False,False,False,True
FDA-CBER-2021-5683-1239491-1239580_27034_S1_M5_c4591001-ia efficacy-S-cm.xpt,c4591001 Concomitant Medications,2020-11-18,https://drive.google.com/file/d/101wbOZKRvMnOhWggWQHotcpTeaTCzc3U/view?usp=drivesdk,eua-051925,XPT,174,M5,data,,"Pharmaceutical, FDA Submission, Safety, Regulatory Compliance, Concomitant Medications, C4591001, M5, Drug Study, Healthcare, Data Analysis, Clinical Trial, Medical Data, SAS Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1239581-1241516_27034_S1_M5_c4591001-ia efficacy-S-co.jmp,c4591001 Vaccine Efficacy Analysis,2024-04-28,https://drive.google.com/file/d/1kIab1FuBg6neCfyPO_BTYeSLKC45coAG/view?usp=drivesdk,eua-051925,JMP,8790,M5,report,,"CBER, FDA, Pharmaceutical, Vaccine, Safety, COVID-19, C4591001, Regulatory, M5, Data Analysis, Clinical Trial, April 2024, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1241596_27034_S1_M5_c4591001-ia efficacy-S-dd.xpt,c4591001 Efficacy Study Data,2020-11-18,https://drive.google.com/file/d/1U2ipSbH-gMFjo7DhR3Of-zAttjVHtlLr/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"CBER, Efficacy Study, FDA Submission, Dddtc, Ddcat, Ddtest, C4591001, M5, Death Details, Clinical Trial, Study Data, SAS Data, Usubjid, Ddeval",False,False,False,True
FDA-CBER-2021-5683-1241597-1241714_27034_S1_M5_c4591001-ia efficacy-S-define.xml,"C4591001 A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,https://drive.google.com/file/d/1uptjXoRwYCOfC53CEL-AX7W6UmT9sHjS/view?usp=drivesdk,eua-051925,XML,23,M5,study protocol,,"Healthy Adults, SARS-COV-2, Vaccine, Exclusion, Safety, Tolerability, Public Health, RNA Vaccine, COVID-19, M5, Phase 1/2/3, Clinical Trial, Immunogenicity, Efficacy, Pandemic",False,True,False,True
FDA-CBER-2021-5683-1241715-1241809_27034_S1_M5_c4591001-ia efficacy-S-define2-0-0.xsl,c4591001 Vaccine Efficacy Analysis,2021,https://drive.google.com/file/d/1cDckaKKS5yPaxkFCI0OLHoli5gcT7Xbd/view?usp=drivesdk,eua-051925,XSL,4,M5,analysis,,"CBER, FDA, Statistical Analysis, Pharmaceutical, Vaccine, Safety, COVID-19, C4591001, Regulatory, M5, Data Analysis, Clinical Trial, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1241811-1242893_27034_S1_M5_c4591001-ia efficacy-S-dm.xpt,c4591001 Efficacy Data Monitoring,2025-03-28,https://drive.google.com/file/d/1KgrpCX5Qxu4WLL7XkJLdO_DybGlr7Z1K/view?usp=drivesdk,eua-051925,XPT,3013,M5,data,,"Sex, FDA, CBER, Race, Subject Information, Reference Dates, C4591001, M5, Demographics, Age, Study Identifiers, Clinical Trial, Data Monitoring, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1241810_27034_S1_M5_c4591001-ia efficacy-S-di.xpt,c4591001 Device Identifiers,2020-11-18,https://drive.google.com/file/d/1TVfzUby8Y55_cbCnqVP3oEiEO71No7MX/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Trade Names, SARS-COV-2, Medical Devices, Diagnostic Tests, Sequence Numbers, Device Identifiers, Device Identifier Elements, COVID-19, M5, Element Values, Device Types, C4591001, Sponsor Device Identifiers, Element Names",False,False,False,True
FDA-CBER-2021-5683-1242894-1246886_27034_S1_M5_c4591001-ia efficacy-S-ds.xpt,c4591001 Disposition Data,2020-03-24,https://drive.google.com/file/d/1PAphbSOzjnT5L0V8-eVF9OWjHAnP4riS/view?usp=drivesdk,eua-051925,XPT,4879,M5,data,,"CBER, FDA, SAS, Vaccine, Safety, COVID-19, C4591001, Regulatory, M5, Adverse Events, Clinical Trial, Study Data, Disposition, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1246887-1247165_27034_S1_M5_c4591001-ia efficacy-S-dv.xpt,Protocol Deviations,2020-11-18,https://drive.google.com/file/d/1g2gIbsYc2Um7U06Thspjz9RyKUcJ9ku-/view?usp=drivesdk,eua-051925,XPT,407,M5,data,,"FDA Submission, Medical Research, Protocol Adherence, Study Data, Pharmaceutical Development, Regulatory Compliance, C4591001, Data Quality, Deviations, Vaccination, M5, Data Analysis, Clinical Trial, Investigational Product",False,False,False,True
FDA-CBER-2021-5683-1247166-1249190_27034_S1_M5_c4591001-ia efficacy-S-ec.xpt,c4591001 Efficacy Study,2020-11-18,https://drive.google.com/file/d/1rIB3nWKKkururErCNa2ukW2cZZFFy0MK/view?usp=drivesdk,eua-051925,XPT,5597,M5,data,,"CBER, Treatment Details, Efficacy Study, FDA Submission, Route Of Administration, Exposure Data, Dosage Information, C4591001, M5, Clinical Trial, Subject Identifiers, Linux, SAS Data, Data Dictionary",False,False,False,True
FDA-CBER-2021-5683-1249191-1251215_27034_S1_M5_c4591001-ia efficacy-S-ex.xpt,c4591001 Exposure Data,2020-11-18,https://drive.google.com/file/d/1WPJVM7dmoEuhu64sQTOuP8Vc2uwm51_U/view?usp=drivesdk,eua-051925,XPT,5232,M5,data,,"CBER, Pharmaceutical, FDA, Treatment Details, Route Of Administration, Study Identifier, Exposure Data, Regulatory Compliance, C4591001, M5, Dose Information, Data Analysis, Clinical Trial, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1251216-1287395_27034_S1_M5_c4591001-ia efficacy-S-face.xpt,c4591001 Vaccine Efficacy Study,2020-11-18,https://drive.google.com/file/d/1PfMBBGGM6ORQBDgzp_H-EtQ6uQj_wolW/view?usp=drivesdk,eua-051925,XPT,160175,M5,data,,"CBER, FDA, SAS, Vaccine, Interventions, C4591001, M5, Linux, Events, Findings, Clinical Trial, Data Analysis, Medical Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1287396-1287425_27034_S1_M5_c4591001-ia efficacy-S-faho.xpt,c4591001 Efficacy Analysis,2021,https://drive.google.com/file/d/1fs9JeZTXtEK8cD8mptcWe98pCeW12-9i/view?usp=drivesdk,eua-051925,XPT,88,M5,data,,"CBER, FDA Submission, Findings About Events, Subject Identifiers, Study Metadata, C4591001, M5, Faho, Clinical Trial, Efficacy Analysis, Study Data, SAS Data, Visit Information, Test Results",False,False,False,True
FDA-CBER-2021-5683-1287426-1287906_27034_S1_M5_c4591001-ia efficacy-S-ho.xpt,c4591001 Immunogenicity and Efficacy Study,2025-03-24,https://drive.google.com/file/d/1U1dD64a3r4MM8qHwWxZGwGQIWyBu6Iig/view?usp=drivesdk,eua-051925,XPT,1084,M5,data,,"CBER, Healthcare Encounters, FDA Submission, Medical Research, Clinical Trial, Regulatory Compliance, Clinical Study, M5, Vaccine Development, Data Analysis, C4591001, SAS Data, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1287907_27034_S1_M5_c4591001-ia efficacy-S-ie.xpt,Inclusion/Exclusion Criteria Not Met,2020-11-18,https://drive.google.com/file/d/1zdGH-EIscWEAyHw76TMqQVG9cLp3zEyf/view?usp=drivesdk,eua-051925,XPT,3,M5,data,,"Medical Research, FDA Submission, Data Management, Subject Eligibility, Exclusion, Data Integrity, Data Processing, Regulatory Compliance, M5, Data Quality, Inclusion Criteria, Data Analysis, Clinical Trial, Study Data, Exclusion Criteria",False,True,False,True
FDA-CBER-2021-5683-1287908-1288803_27034_S1_M5_c4591001-ia efficacy-S-is.xpt,Immunogenicity Specimen Assessment,2020-11-18,https://drive.google.com/file/d/14VzA2-wPke2zj0p-0OPS01rA-sN3woJE/view?usp=drivesdk,eua-051925,XPT,2426,M5,data,,"Medical Research, FDA Submission, Specimen Assessment, Regulatory Compliance, M5, Vaccine Development, Biostatistics, Data Analysis, Clinical Trial, Study Data, Pharmaceutical Industry, Immunogenicity, Biological Products, Laboratory Testing",False,False,False,True
FDA-CBER-2021-5683-1288804-1289605_27034_S1_M5_c4591001-ia efficacy-S-lb.xpt,Laboratory Test Results,2025-03-28,https://drive.google.com/file/d/1B2byYfZ0CCio25FAUWiI9sciLdPx5oOo/view?usp=drivesdk,eua-051925,XPT,1794,M5,data,,"Sponsor-defined Identifier, Lab Test Or Examination, Unique Subject Identifier, Lab Test Category, Numeric Results, Standard Units, Reference Range, Lab Test Results, Lab Test Subcategory, M5, Sponsor Device Identifier, Study Identifier, Original Units, Domain Abbreviation, Specimen Id",False,False,False,True
FDA-CBER-2021-5683-1289606-1291764_27034_S1_M5_c4591001-ia efficacy-S-mb.xpt,c4591001 Immunogenicity and Efficacy Study,2020-11-18,https://drive.google.com/file/d/1F-QBNUlgttSP4za_Nhgzm4Qjp3grmBQ5/view?usp=drivesdk,eua-051925,XPT,3819,M5,data,,"CBER, FDA, Specimen, Vaccine, Clinical Trial, Immunogenicity, M5, Linux, Laboratory, C4591001, Study Data, SAS Data, Microbiology, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1291766_27034_S1_M5_c4591001-ia efficacy-S-pr.xpt,c4591001 Immunogenicity Analysis,2020-11-18,https://drive.google.com/file/d/1tgtEjaDf9t-uKSSJg4a6KTyeXXWn2xV4/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"CBER, FDA, Study, C4591001, Data, Domain, Subject, M5, Analysis, Clinical Trial, Procedures, SAS, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1291765_27034_S1_M5_c4591001-ia efficacy-S-mo.xpt,c4591001 Immunogenicity Analysis,2020-11-18,https://drive.google.com/file/d/1b2gfJBbs-vdMgYvkGHD6MJ7qdtaB-v8S/view?usp=drivesdk,eua-051925,XPT,4,M5,data,,"CBER, FDA, Measurement, Unique Subject Identifier, Study Identifier, Visit Number, C4591001, M5, Linux, Baseline, Data Analysis, Clinical Trial, SAS, Immunogenicity, Efficacy, Test Results",False,False,False,True
FDA-CBER-2021-5683-1291767-1291828_27034_S1_M5_c4591001-ia efficacy-S-relrec.xpt,c4591001 Efficacy Related Records,2020-11-18,https://drive.google.com/file/d/1djSvBiU0mAuGTuRueJcJpQkZQGPj7tET/view?usp=drivesdk,eua-051925,XPT,58,M5,data,,"CBER, Related Records, FDA, Vaccine, COVID-19, C4591001, Regulatory, Relrec, 2021, M5, Clinical Trial, Study Data, SAS Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1291829-1295646_27034_S1_M5_c4591001-ia efficacy-S-se.xpt,c4591001 Efficacy Study,2020-11-15,https://drive.google.com/file/d/172hQllcLk4IRqwDIFVU4WvOaAlbblxwY/view?usp=drivesdk,eua-051925,XPT,4519,M5,data,,"Pharmaceutical, Efficacy Study, Medical Research, FDA Submission, Unique Subject Identifier, Study Identifier, Study Day, Subject Elements, C4591001, M5, Screening, Data Analysis, Clinical Trial, Element Description",False,False,False,True
FDA-CBER-2021-5683-1295647-1297710_27034_S1_M5_c4591001-ia efficacy-S-suppae.xpt,Supplemental Qualifiers for AE,2020-11-18,https://drive.google.com/file/d/1al1FXGrVgVuZCM9VDQItZxCESCRi0zQH/view?usp=drivesdk,eua-051925,XPT,2544,M5,data,,"Pharmaceutical, Medical Research, Unique Subject Identifier, Study Identifier, Safety, Needs-review, M5, Regulatory, Adverse Events, Data Analysis, Clinical Trial, Variable Labels, Study Data",False,False,False,True
FDA-CBER-2021-5683-1297711-1302742_27034_S1_M5_c4591001-ia efficacy-S-suppce.xpt,c4591001 Supplemental Qualifiers for CE,2020-11-18,https://drive.google.com/file/d/1xg1vyc027VC-KTZQRMeDoEmfwSoEqDQo/view?usp=drivesdk,eua-051925,XPT,8451,M5,data,,"Evaluator, Unique Subject Identifier, Study Identifier, Qualifier Variable, Supplemental Qualifiers, Clinical Study, M5, Identifying Variable, Data Value, Ce, C4591001, Dictionary, Related Domain, Meddra",False,False,False,True
FDA-CBER-2021-5683-1302742-1302920_27034_S1_M5_c4591001-ia efficacy-S-suppcm.xpt,c4591001 Supplemental Qualifiers for CM,2020-11-18,https://drive.google.com/file/d/19wRMSwDnvOZCrUt86TE8S6BMx7P62UyL/view?usp=drivesdk,eua-051925,XPT,280,M5,data,,"Clinical Study Sponsor, Evaluator, Dictionary Version, Unique Subject Identifier, Supplemental Qualifiers, WHO Dde, Clinical Study, C4591001, M5, Medication, Data Value, Cm, Related Domain, Standardized Medication Code",False,False,False,True
FDA-CBER-2021-5683-1304059-1305876_27034_S1_M5_c4591001-ia efficacy-S-suppds.xpt,c4591001 Supplemental Qualifiers for DS,2020-11-18,https://drive.google.com/file/d/1pdFcdQ80N50xZprAIci7cWm5xcniChpR/view?usp=drivesdk,eua-051925,XPT,1853,M5,data,,"Data Structure, Vaccine, Study Identifier, Subject Identifier, Qualifier Variable, Qualifiers, C4591001, M5, Identifying Variable, Data Value, Origin, Clinical Trial, Related Domain, Supplemental Data",False,False,False,True
FDA-CBER-2021-5683-1302921-1304058_27034_S1_M5_c4591001-ia efficacy-S-suppdm.xpt,Supplemental Qualifiers for DM,2020-11-18,https://drive.google.com/file/d/1SzEGAR7tCs4OPZhcTng1lr0AYySTvqE0/view?usp=drivesdk,eua-051925,XPT,1580,M5,data,,"Study Identifier, Subject Identifier, Qualifier Variable, Qualifiers, Dm, Clinical Study, M5, Data, Identifying Variable, Data Value, Origin, C4591001, Supplemental, Related Domain",False,False,False,True
FDA-CBER-2021-5683-1305877-1306994_27034_S1_M5_c4591001-ia efficacy-S-suppdv.xpt,c4591001 Supplemental Qualifiers for DV,2020-11-18,https://drive.google.com/file/d/1d-WayYBpPFwa2NRNpe8wpkoRj9m6nkq5/view?usp=drivesdk,eua-051925,XPT,1340,M5,data,,"Data Variables, Deviation Data, Data Sources, Exclusion, Data Processing, Qualifiers, Analysis Population, Regulatory Compliance, C4591001, M5, Study Identifiers, Clinical Trial, Subject Identifiers, Visit Designators, Supplemental Data",False,True,False,True
FDA-CBER-2021-5683-1306995-1317130_27034_S1_M5_c4591001-ia efficacy-S-suppec.xpt,c4591001 Supplemental Qualifiers for EC,2020-11-18,https://drive.google.com/file/d/1h3gMksgzR5UpPBkVr_DHDSs3P21dSZQV/view?usp=drivesdk,eua-051925,XPT,14187,M5,data,,"Pharmaceutical, Medical Coding, FDA Submission, Data Management, Clinical Trial, Safety, Supplemental Qualifiers, Regulatory Compliance, Clinical Study, M5, Adverse Events, Data Analysis, C4591001, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1317131-1327266_27034_S1_M5_c4591001-ia efficacy-S-suppex.xpt,c4591001 Supplemental Qualifiers for EX,2020-11-18,https://drive.google.com/file/d/1pqf6p94LkVOOi8alAKu6SsYCWyypa399/view?usp=drivesdk,eua-051925,XPT,14187,M5,data,,"Evaluator, Unique Subject Identifier, Standardized Codes, Observed Post Dose, Blinded Therapy, Qualifiers, Clinical Study, M5, Medication, Data Values, Origin, C4591001, Linux, Related Domain",False,False,False,True
FDA-CBER-2021-5683-1327267-1389075_27034_S1_M5_c4591001-ia efficacy-S-suppface.xpt,Supplemental Qualifiers for FACE,2020-11-18,https://drive.google.com/file/d/1DEFCNpRfpVS3yxmZL5f87-DWZkNuSF82/view?usp=drivesdk,eua-051925,XPT,92931,M5,data,,"Evaluator, Unique Subject Identifier, Study Identifier, Qualifier Variable, Collection Type, Clinical Study, M5, Identifying Variable, Data Value, C4591001, Language Version, Related Domain, Diary Card, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1389635_27034_S1_M5_c4591001-ia efficacy-S-suppie.xpt,Supplemental Qualifiers for IE,2025-03-27,https://drive.google.com/file/d/14EYv9WYTkZir9gxdSsMQWSwBrCt2DRNL/view?usp=drivesdk,eua-051925,XPT,1,M5,data,(b)(6),"CBER, FDA, Pharmaceutical, Medical Research, Subject Details, Vaccine, Exclusion, C4591001, Regulatory, M5, Adverse Events, Data Analysis, Clinical Trial, Compliance, Supplemental Data, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1389076-1389634_27034_S1_M5_c4591001-ia efficacy-S-suppho.xpt,c4591001 Supplemental Qualifiers for HO,2020-11-18,https://drive.google.com/file/d/1YN9P80YapdzZG3b7g_4t1haTkhV8Ayx4/view?usp=drivesdk,eua-051925,XPT,687,M5,data,,"Variable Value, Disease Name, Evaluator, Unique Subject Identifier, CRF, Study Identifier, Qualifiers, Host Origin, C4591001, M5, Identifying Variable, Data Value, Origin, Clinical Trial, Related Domain, Supplemental Data, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1390532-1391342_27034_S1_M5_c4591001-ia efficacy-S-supplb.xpt,c4591001 Supplemental Qualifiers for LB,2020-11-18,https://drive.google.com/file/d/1sLQbEeaQwKrRtQPQ6-k5bRgOy8exea_D/view?usp=drivesdk,eua-051925,XPT,1039,M5,data,,"Pharmaceutical, Medical Research, FDA Submission, Data Management, Data Processing, Supplemental Qualifiers, Clinical Study, M5, Laboratory Data, Data Quality, Data Standardization, Sponsor, Data Analysis, C4591001",False,False,False,True
FDA-CBER-2021-5683-1389636-1390531_27034_S1_M5_c4591001-ia efficacy-S-suppis.xpt,c4591001 Supplemental Qualifiers for IS,2020-11-18,https://drive.google.com/file/d/1yew_4yREb9TxNdA39iaWT1GzUypF0ZXr/view?usp=drivesdk,eua-051925,XPT,896,M5,data,,"SAS Data, Evaluator, Unique Subject Identifier, Clinical Trial, Qualifier Variable, Supplemental Qualifiers, C4591001, M5, Identifying Variable, Study Identifier, Data Origin, Linux, Related Domain, Is",False,False,False,True
FDA-CBER-2021-5683-1391343-1393475_27034_S1_M5_c4591001-ia efficacy-S-suppmb.xpt,c4591001 Supplemental Qualifiers for MB,2020-11-18,https://drive.google.com/file/d/1-FjRbD7a9CyNjA2FCdhmQ4Mu_eqbXKCt/view?usp=drivesdk,eua-051925,XPT,2223,M5,data,,"Evaluator, Study Identifier, Subject Identifier, Qualifiers, C4591001, M5, Identifying Variable, Site CRF, Data Analysis, Clinical Trial, Data Origin, Related Domain, Mb, Supplemental Data",False,False,False,True
FDA-CBER-2021-5683-1393476-1398129_27034_S1_M5_c4591001-ia efficacy-S-suppmh.xpt,Supplemental Qualifiers for MH,2020-11-18,https://drive.google.com/file/d/13ym3_h6aFUSEJy1WBB-k5xWuqepSHTD2/view?usp=drivesdk,eua-051925,XPT,7137,M5,data,,"CBER, Data Dictionary, FDA Submission, Safety Analysis, Qualifiers, Clinical Study, Medical History, M5, Linux, Adverse Events, C4591001, Medical Data, Supplemental Data, Meddra",False,False,False,True
FDA-CBER-2021-5683-1398130_27034_S1_M5_c4591001-ia efficacy-S-suppmo.xpt,c4591001 Supplemental Qualifiers for MO,2020-11-18,https://drive.google.com/file/d/1l-EMXOeZvJfjCg5PxO97kK2sgsu6omNG/view?usp=drivesdk,eua-051925,XPT,2,M5,data,,"Medical Observations, Evaluator, SAS, Unique Subject Identifier, Study Identifier, Qualifiers, C4591001, M5, Identifying Variable, Data Value, Origin, Clinical Trial, Linux, Supplemental Data",False,False,False,True
FDA-CBER-2021-5683-1398131-1398132_27034_S1_M5_c4591001-ia efficacy-S-supppr.xpt,c4591001 Supplemental Qualifiers for PR,2020-11-18,https://drive.google.com/file/d/1nblicsC9_0wZa4SGbhwAf7dMxxBR5ea3/view?usp=drivesdk,eua-051925,XPT,3,M5,data,,"Evaluator, Pr, Unique Subject Identifier, Qualifier Variable, Supplemental Qualifiers, Body System, Clinical Study, M5, Identifying Variable, Data Value, Sponsor, C4591001, Meddra, Organ Class",False,False,False,True
FDA-CBER-2021-5683-1398133-1403883_27034_S1_M5_c4591001-ia efficacy-S-suppvs.xpt,c4591001 Vaccine Efficacy Supplemental Data,2020-11-18,https://drive.google.com/file/d/1AfqAN3iNSDTaRpIKUxbkWvFHgXTHjIJT/view?usp=drivesdk,eua-051925,XPT,7978,M5,data,,"CBER, FDA, Vsseq, Cltyp, Vaccine, Rdomain, Clinical Study, M5, Vscolsrt, C4591001, SAS Data, Usubjid, Supplemental Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1403884-1406792_27034_S1_M5_c4591001-ia efficacy-S-sv.xpt,c4591001 Subject Visits,2020-11-18,https://drive.google.com/file/d/1AxoxLtOiK2PVzXyRxdDnAioSJn1YfTuU/view?usp=drivesdk,eua-051925,XPT,2836,M5,data,,"Visit Name, Unique Subject Identifier, Epoch, Study Day, Subject Visits, Visit Number, Start Date, C4591001, M5, Vaccination, End Date, Clinical Trial, Study Data, SAS Data, Domain Abbreviation",False,False,False,True
FDA-CBER-2021-5683-1406793_27034_S1_M5_c4591001-ia efficacy-S-ta.xpt,c4591001 Trial Arms,2020-11-15,https://drive.google.com/file/d/1STubrNB5LB68pqEupQOR2OK1-b-0eMYh/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Follow-up, Planned Order, Vaccine, Study Identifier, Epoch, Element Code, M5, Randomization, BNT162B1, Phase 1, Arm Description, Screening, Vaccination, Study Design, Clinical Trial, Domain, Transition Rule",False,False,False,True
FDA-CBER-2021-5683-1406794_27034_S1_M5_c4591001-ia efficacy-S-te.xpt,c4591001 Trial Elements,2020-11-15,https://drive.google.com/file/d/1ypJNky4v3AADIN6-sRNySwyvwHL6FSGj/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"BNT162B2, Dose, Vaccine, Study Identifier, Treatment, Element Code, M5, BNT162B1, Screening, Domain, Trial Elements, C4591001, Informed Consent, Element Description",False,False,False,True
FDA-CBER-2021-5683-1406798-1406799_27034_S1_M5_c4591001-ia efficacy-S-ts.xpt,Trial Summary,2020-11-15,https://drive.google.com/file/d/1uyMSguC9mDffU6rsxi1NYlif6wQ2wiHW/view?usp=drivesdk,eua-051925,XPT,5,M5,data,,"Pharmaceutical, FDA, Medical Research, Statistical, Vaccine, COVID-19, C4591001, Regulatory, M5, Data Analysis, Clinical Trial, Study Data, Tsval, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1406795-1406797_27034_S1_M5_c4591001-ia efficacy-S-ti.xpt,Trial Inclusion/Exclusion Criteria,2020-11-15,https://drive.google.com/file/d/1RyUvSn-nNQ1ofiXBoEW7Jd4nMhsjc5zu/view?usp=drivesdk,eua-051925,XPT,8,M5,data,,"Pharmaceutical, Participant Eligibility, Vaccine, Exclusion, Safety, Medical History, COVID-19, Regulatory, Inclusion Criteria, Protocol, M5, Adverse Events, Study Design, Clinical Trial, Exclusion Criteria",False,True,False,True
FDA-CBER-2021-5683-1406800_27034_S1_M5_c4591001-ia efficacy-S-tv.xpt,c4591001 Trial Visits,2020-11-15,https://drive.google.com/file/d/13JVJ8z2s3gglH3V-0fe_Ser90nmunYt_/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Planned Study Day, Data Extract, Visit Data, Visit Name, Study Identifier, Planned Arm Code, C4591001, M5, Data Analysis, Clinical Trial, Visit End Rule, SAS Data, Visit Start Rule, Visit Number",False,False,False,True
FDA-CBER-2021-5683-1406801-1415201_27034_S1_M5_c4591001-ia efficacy-S-vs.xpt,c4591001 Efficacy Analysis,2025-03-27,https://drive.google.com/file/d/1liK1KaZTZxz3M8J34joa5LZptRJPRwTB/view?usp=drivesdk,eua-051925,XPT,23581,M5,data,,"CBER, SAS Data, FDA Submission, Medical Research, Pharmaceutical Development, Data Processing, Regulatory Compliance, C4591001, M5, Biostatistics, Data Analysis, Clinical Trial, Efficacy Analysis, Vital Signs",False,False,False,True
FDA-CBER-2021-5683-1415202-1415674_27034_S1_M5_c4591001-safety-fa-eff-A-adae.xpt,c4591001 Safety Analysis,2020-11-19,https://drive.google.com/file/d/1CFjuBhBiz2UVXWKm1nInNihi4-A2DmtL/view?usp=drivesdk,eua-051925,XPT,6128,M5,data,,"CBER, FDA, Age Groups, Safety Analysis, Subject Identifiers, Study Site, C4591001, Planned Arms, M5, Adverse Events, Clinical Trial, Data File, SAS Data, Actual Arms, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1415675-1440646_27034_S1_M5_c4591001-safety-fa-eff-A-adc19ef.xpt,c4591001 Safety and Efficacy Analysis,2021-03-18,https://drive.google.com/file/d/1yRDZjLoogq7qaV_8WejeaDkrSPLFIRRF/view?usp=drivesdk,eua-051925,XPT,135835,M5,data file,,"CBER, FDA, Pharmaceutical, Medical Research, Vaccine, Safety Analysis, Data Processing, Regulatory Compliance, C4591001, M5, Biostatistics, Clinical Trial, Efficacy Analysis, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1440647-1445780_27034_S1_M5_c4591001-safety-fa-eff-A-adcevd.xpt,c4591001 Safety Analysis,2020-11-18,https://drive.google.com/file/d/19hCjvCzEyQKZh-3TG8ZvfgLo72CO-Q9Q/view?usp=drivesdk,eua-051925,XPT,44966,M5,data,,"CBER, Pharmaceutical, FDA Submission, Medical Research, Safety Analysis, Regulatory Compliance, C4591001, M5, Healthcare, Adverse Events, Data Analysis, Clinical Trial, SAS Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1445781-1447758_27034_S1_M5_c4591001-safety-fa-eff-A-adds.xpt,c4591001 Safety Analysis Addendum,2021,https://drive.google.com/file/d/1sJq5HwlLptDSTcIuoOm1W0LE9m_dd9p_/view?usp=drivesdk,eua-051925,XPT,12905,M5,report,,"CBER, FDA, Regulatory Submission, Pharmaceutical, Medical Research, Safety Analysis, Clinical Trial, Vaccine, Statistical Report, Addendum, COVID-19, M5, Data Analysis, C4591001",False,False,False,True
FDA-CBER-2021-5683-1447759-1490221_27034_S1_M5_c4591001-safety-fa-eff-A-adfacevd.xpt,c4591001 Safety Analysis,2020-11-18,https://drive.google.com/file/d/1n7uikJ233CAye9yVtK9VaMJW9sgcsCVN/view?usp=drivesdk,eua-051925,XPT,444819,M5,data,,"CBER, FDA Submission, Safety Analysis, Subject Information, Regulatory Compliance, Medical History, C4591001, M5, Demographic Data, Adverse Events, Pharmaceutical Research, Clinical Trial, Study Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1490272-1491367_27034_S1_M5_c4591001-safety-fa-eff-A-adsl.xpt,c4591001 Safety Analysis Dataset,2025-03-27,https://drive.google.com/file/d/1PDSL-lCG8N7BfcO-UEbHFbQzRXbwcaWY/view?usp=drivesdk,eua-051925,XPT,14086,M5,dataset,,"Regulatory Submission, FDA, CBER, Statistical Analysis, Data Management, Safety Analysis, Medical History, C4591001, M5, Demographic Data, Adverse Events, Subject-level Data, Clinical Trial, Pharmaceutical Research",False,False,False,True
FDA-CBER-2021-5683-1491368-1495706_27034_S1_M5_c4591001-safety-fa-eff-A-adsympt.xpt,c4591001 Safety and Efficacy Analysis,2021,https://drive.google.com/file/d/14O6PCEhTkohufmB0icMo7BUPv2R04Mzx/view?usp=drivesdk,eua-051925,XPT,21606,M5,data,,"CBER, FDA Submission, Medical Research, Safety Analysis, Regulatory Compliance, COVID-19, C4591001, M5, Vaccine Development, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1495707-1496004_27034_S1_M5_c4591001-safety-fa-eff-A-adva.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1GUNMMqMq_OseDwOc_QhjMu_GO1uZ3lmB/view?usp=drivesdk,eua-051925,XPT,2962,M5,data,,"CBER, FDA Submission, Safety Analysis, Treatment Data, Regulatory Compliance, C4591001, Analysis Dataset, M5, Data Collection, Clinical Trial, Efficacy Analysis, Study Data, SAS Data, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1496005-1496178_27034_S1_M5_c4591001-safety-fa-eff-A-define.xml,"C4591001 Pfizer, Inc A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,https://drive.google.com/file/d/13iCWzGdepRtNvD4JTMNQ7rA6fw3hiNYY/view?usp=drivesdk,eua-051925,XML,42,M5,clinical protocol,,"Healthy Adults, Vaccine, Safety, Tolerability, RNA Vaccine, COVID-19, M5, Regulatory, Phase 1/2/3, Study Design, Clinical Trial, Pfizer, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1496179-1496273_27034_S1_M5_c4591001-safety-fa-eff-A-define2-0-0.xsl,c4591001 Safety and Efficacy Analysis Definition,2021,https://drive.google.com/file/d/1RH1TzXgUCyyVCr4Cv-HqptuX3Lm7yBSt/view?usp=drivesdk,eua-051925,XSL,4,M5,analysis,,"CBER, FDA, Data Definition, Analysis Plan, Statistical Analysis, Safety Analysis, Clinical Trial, Vaccine, COVID-19, M5, Regulatory, C4591001, Efficacy Analysis, Metadata",False,False,False,True
FDA-CBER-2021-5683-1496613-1497119_27034_S1_M5_c4591001-safety-fa-eff-S-ae.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1q--4igCNtOW32GkKT8-CSThmceAb8I3Y/view?usp=drivesdk,eua-051925,XPT,2148,M5,data,,"CBER, Pharmaceutical, FDA Submission, Medical Research, Safety Analysis, Regulatory Compliance, C4591001, M5, Biostatistics, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1497120-1504541_27034_S1_M5_c4591001-safety-fa-eff-S-ce.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1DaKJPT_ngXK_QzABdCaeDZTDD4xb8HGF/view?usp=drivesdk,eua-051925,XPT,27301,M5,data,,"CBER, FDA Submission, Medical Terminology, Safety Analysis, Study Identifier, Regulatory Compliance, Clinical Events, C4591001, M5, Adverse Events, Pharmaceutical Research, Clinical Trial, Efficacy Analysis, SAS Data",False,False,False,True
FDA-CBER-2021-5683-1504542-1504669_27034_S1_M5_c4591001-safety-fa-eff-S-cm.xpt,Concomitant Medications,2020-11-19,https://drive.google.com/file/d/1VDycQHo4TQRB6IRJbCH8kGcGym7yTwOw/view?usp=drivesdk,eua-051925,XPT,182,M5,data,,"Patient Records, FDA Submission, Concomitant Therapies, Regulatory Compliance, Medical History, Drug Interactions, M5, Medication Usage, Adverse Events, Pharmaceutical Research, Clinical Trial, Data Analysis, Healthcare, Safety Data",False,False,False,True
FDA-CBER-2021-5683-1504670-1506840_27034_S1_M5_c4591001-safety-fa-eff-S-co.jmp,c4591001 Safety and Efficacy Data,2024-04-28,https://drive.google.com/file/d/1YLLqpiBSr0WjH0ANoM8F9ThV9m3Q8U6s/view?usp=drivesdk,eua-051925,JMP,10044,M5,report,,"FDA Submission, Drug Approval, Biomedical Engineering, Regulatory Compliance, C4591001, M5, Vaccine Development, Pharmaceutical Research, Health Care, Clinical Trial, Medical Data, Product Development, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1506919_27034_S1_M5_c4591001-safety-fa-eff-S-dd.xpt,Safety and Efficacy Analysis of c4591001 Study,2020-11-19,https://drive.google.com/file/d/11pfuCttICt56up1t98ue1wNEbVNKA7Ik/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"CBER, FDA Submission, Safety Analysis, Regulatory Compliance, M5, Medical Data, Healthcare, Adverse Events, Death Details, Clinical Trial, Efficacy Analysis, C4591001 Study, Pharmaceutical Research, Data Analysis",False,False,False,True
FDA-CBER-2021-5683-1507034-1507128_27034_S1_M5_c4591001-safety-fa-eff-S-define2-0-0.xsl,c4591001 Safety and Efficacy Analysis,2021,https://drive.google.com/file/d/1YXDqNM7yT4VhXsC-6HsUrAVH5Vn-C8i4/view?usp=drivesdk,eua-051925,XSL,4,M5,analysis,,"CBER, FDA, Statistical Analysis, Safety Analysis, Vaccine, Clinical Outcomes, COVID-19, C4591001, Regulatory, M5, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis",False,False,False,True
FDA-CBER-2021-5683-1506920-1507033_27034_S1_M5_c4591001-safety-fa-eff-S-define.xml,"C4591001 A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,https://drive.google.com/file/d/1TyoVa1R1wWZO8wivTSA53rnDHE7Pv-I5/view?usp=drivesdk,eua-051925,XML,24,M5,report,,"Healthy Adults, SARS-COV-2, Vaccine, Exclusion, Safety, Tolerability, Reactogenicity, RNA Vaccine, COVID-19, M5, Phase 1/2/3, Study Design, Clinical Trial, Immunogenicity, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1507130-1508225_27034_S1_M5_c4591001-safety-fa-eff-S-dm.xpt,c4591001 Safety and Efficacy Data,2021,https://drive.google.com/file/d/1Hlpbb41NeiGaybXiO_DgttpNEyxxs-Wp/view?usp=drivesdk,eua-051925,XPT,3046,M5,dataset,,"CBER, FDA, Pharmaceutical, Vaccine, Clinical Trial, Safety, COVID-19, M5, Regulatory, Demographics, C4591001, Study Data, Efficacy, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1507129_27034_S1_M5_c4591001-safety-fa-eff-S-di.xpt,Device Identifiers,2020-11-19,https://drive.google.com/file/d/1oo7mk5Mq9mues1nLs9r_JxSyct1dp2-q/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Panel, Identifier, SARS-COV-2, FDA, Assay, Medical Device, Diagnostic Test, COVID-19, Sequence, M5, Device Type, Sponsor, Clinical Trial, Element, Trade Name",False,False,False,True
FDA-CBER-2021-5683-1508226-1512402_27034_S1_M5_c4591001-safety-fa-eff-S-ds.xpt,c4591001 Safety and Efficacy Data,2021,https://drive.google.com/file/d/1xyVc7RXluL-XVw9J_Ye6Cpo5Taci3EnE/view?usp=drivesdk,eua-051925,XPT,4667,M5,dataset,,"CBER, FDA Submission, Medical Research, Vaccine, Disposition Events, Regulatory Compliance, COVID-19, C4591001, M5, Adverse Events, Clinical Trial, Study Data, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1512403-1512784_27034_S1_M5_c4591001-safety-fa-eff-S-dv.xpt,Protocol Deviations,2020-05-01,https://drive.google.com/file/d/1KWmEzRWNGWZAxqXQqYqQAMrz25KYBLR6/view?usp=drivesdk,eua-051925,XPT,636,M5,data,,"Medical Research, Data Management, Clinical Trial, Safety, Pharmaceutical Development, Regulatory Compliance, M5, Deviations, Screening, Procedures, C4591001, Subject Identifiers, Study Data, Quality Assurance",False,False,False,True
FDA-CBER-2021-5683-1512785-1514910_27034_S1_M5_c4591001-safety-fa-eff-S-ec.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/14oVfbi2CiN1PkJaDf2e1vbTn1WJPW5PI/view?usp=drivesdk,eua-051925,XPT,5836,M5,data,,"CBER, Treatment Details, FDA Submission, Safety Analysis, Exposure Data, Regulatory Compliance, C4591001, M5, Biostatistics, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis, Pharmaceutical Research",False,False,False,True
FDA-CBER-2021-5683-1514911-1517036_27034_S1_M5_c4591001-safety-fa-eff-S-ex.xpt,c4591001 Safety and Efficacy Data,2020-11-19,https://drive.google.com/file/d/1odhcCmsm3mMMiecI_8MN7kUnNebpc3rO/view?usp=drivesdk,eua-051925,XPT,5455,M5,data,,"CBER, Pharmaceutical, FDA, Treatment Details, Medical Research, Exposure Data, Needs-review, C4591001, M5, Dose Information, Adverse Events, Clinical Trial, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1517037-1555973_27034_S1_M5_c4591001-safety-fa-eff-S-face.xpt,c4591001 Safety and Efficacy Data,2020-11-19,https://drive.google.com/file/d/1RPptlvRrKIx_xGksVevDV4wfcr8_954s/view?usp=drivesdk,eua-051925,XPT,171854,M5,dataset,,"CBER, Pharmaceutical, FDA Submission, Medical Research, Regulatory Compliance, C4591001, M5, Vaccine Development, Adverse Events, Data Analysis, Clinical Trial, Findings About, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1555974-1556011_27034_S1_M5_c4591001-safety-fa-eff-S-faho.xpt,c4591001 Safety Findings,2025-03-24,https://drive.google.com/file/d/1GMkBxBqNDJT0RcNeqMeZPRkHJFjWaDN2/view?usp=drivesdk,eua-051925,XPT,106,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Interventions, Safety, Regulatory Compliance, C4591001, M5, Adverse Events, Data Analysis, Clinical Trial, Study Data, Findings",False,False,False,True
FDA-CBER-2021-5683-1556644_27034_S1_M5_c4591001-safety-fa-eff-S-ie.xpt,c4591001 Safety and Efficacy Data,2020-11-19,https://drive.google.com/file/d/1aU1YumutspbBWStaI6X3xrQE1wBbt0-g/view?usp=drivesdk,eua-051925,XPT,6,M5,data,,"CBER, FDA Submission, Unique Subject Identifier, Study Identifier, Clinical Trial, Exclusion, Regulatory Compliance, M5, Inclusion Criteria, Efficacy Data, C4591001, Visit Information, Data Analysis, Safety Data, Exclusion Criteria",False,True,False,True
FDA-CBER-2021-5683-1556012-1556643_27034_S1_M5_c4591001-safety-fa-eff-S-ho.xpt,Healthcare Encounters,2025-03-24,https://drive.google.com/file/d/1nJyH1Ql7u04pLo7uvhoYKRR4SkvV3OG-/view?usp=drivesdk,eua-051925,XPT,1385,M5,data,,"Patient Records, FDA Submission, Safety Analysis, Study Data, Clinical Trials, Regulatory Compliance, Clinical Study, M5, Medical Encounters, Adverse Events, Pharmaceutical Research, Medical Data, Healthcare, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1556645-1558238_27034_S1_M5_c4591001-safety-fa-eff-S-is.xpt,Immunogenicity Specimen Assessment,2020-11-19,https://drive.google.com/file/d/14urjPBJyejyrxOdcykAE-3WBwI_MSy1Y/view?usp=drivesdk,eua-051925,XPT,3055,M5,data,,"Biomarkers, Medical Research, FDA Submission, Data Management, Pharmaceutical Development, Specimen Assessment, Regulatory Compliance, M5, Study Protocol, Clinical Trial, Laboratory Analysis, Safety Data, Immunogenicity, Quality Assurance",False,False,False,True
FDA-CBER-2021-5683-1558239-1559613_27034_S1_M5_c4591001-safety-fa-eff-S-lb.xpt,Laboratory Test Results,2025-03-28,https://drive.google.com/file/d/173dAms-4x8zzt2P-hEBoTTtvjfDcUKYQ/view?usp=drivesdk,eua-051925,XPT,3179,M5,data,,"Medical Research, Safety Analysis, Subject Identifiers, Numeric Findings, Standard Units, Laboratory Tests, Character Findings, M5, Clinical Trial, Efficacy Analysis, Study Data, Specimen Data, Test Results, Reference Ranges",False,False,False,True
FDA-CBER-2021-5683-1559614-1561992_27034_S1_M5_c4591001-safety-fa-eff-S-mb.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1M54q7PL-mmY3GDvWBuN5Ia0S382CxHO0/view?usp=drivesdk,eua-051925,XPT,4931,M5,data,,"Pharmaceutical, Sponsor Data, FDA Submission, Medical Research, Data File, Safety Analysis, C4591001, M5, Vaccine Development, Biostatistics, Clinical Trial, Efficacy Analysis, SAS Data, Microbiology",False,False,False,True
FDA-CBER-2021-5683-1561993-1561994_27034_S1_M5_c4591001-safety-fa-eff-S-mo.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1MZzo0X_HW8PXAOnPgBXk0wyObZqO18kx/view?usp=drivesdk,eua-051925,XPT,7,M5,data,,"Pharmaceutical, FDA Submission, Medical Research, Safety Analysis, Study Results, Drug Development, Regulatory Compliance, C4591001, M5, Biostatistics, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis",False,False,False,True
FDA-CBER-2021-5683-1561995-1562404_27034_S1_M5_c4591001-safety-fa-eff-S-pe.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1d2TZuDm3wSYzLUmDEWnoQBXk6hyDdiIm/view?usp=drivesdk,eua-051925,XPT,739,M5,data,,"Pharmaceutical, FDA Submission, Medical Research, Data File, Safety Analysis, Study Identifier, Unique Subject Identifier, Body System, C4591001, M5, Clinical Trial, Efficacy Analysis, SAS Data, Physical Examination",False,False,False,True
FDA-CBER-2021-5683-1562405_27034_S1_M5_c4591001-safety-fa-eff-S-pr.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1qvfynSmhPDlQH-Cq_5za3IdKBM9Vd3l2/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"CBER, FDA Submission, Safety Analysis, Subject Identifiers, C4591001, M5, Procedures, Clinical Trial, Efficacy Analysis, Study Data, SAS Data, Visit Information, Data Collection, Domain Data",False,False,False,True
FDA-CBER-2021-5683-1562485-1566322_27034_S1_M5_c4591001-safety-fa-eff-S-se.xpt,c4591001 Safety and Efficacy Analysis,2020-11-19,https://drive.google.com/file/d/1f8vj5P3gMFegzoMqYVljBMb4EEezfQt9/view?usp=drivesdk,eua-051925,XPT,4527,M5,data,,"CBER, FDA Submission, Safety Analysis, Domain Data, Regulatory Compliance, C4591001, M5, Study Identifiers, Clinical Trial, Efficacy Analysis, Study Data, SAS Data, Subject Data, Data Elements",False,False,False,True
FDA-CBER-2021-5683-1562406-1562484_27034_S1_M5_c4591001-safety-fa-eff-S-relrec.xpt,c4591001 Safety and Efficacy Related Records,2020-11-19,https://drive.google.com/file/d/1pPv18jmjVKpsbpkxGgjtWJF5YpxDjsJI/view?usp=drivesdk,eua-051925,XPT,74,M5,data,,"CBER, Related Records, Pharmaceutical, FDA, Safety, Study Data, C4591001, M5, Adverse Events, Data Analysis, Clinical Trial, Subject Identifiers, Medical Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1566323-1568841_27034_S1_M5_c4591001-safety-fa-eff-S-suppae.xpt,Supplemental Qualifiers for AE,2020-11-19,https://drive.google.com/file/d/1y4GokIWJvqbdf4Lkoe09a1eEixpJ9Hdm/view?usp=drivesdk,eua-051925,XPT,3102,M5,data,,"CBER, Supplemental Data, Qualitative Analysis, Pharmacovigilance, FDA Submission, Medical Terminology, Variable Definitions, Regulatory Compliance, C4591001, M5, Adverse Events, Clinical Trial, Safety Data, Data Dictionary",False,False,False,True
FDA-CBER-2021-5683-1568842-1576422_27034_S1_M5_c4591001-safety-fa-eff-S-suppce.xpt,Supplemental Qualifiers for CE,2020-11-19,https://drive.google.com/file/d/1OiD7KN6llYpREk94C-LPnKGd3sabHxtI/view?usp=drivesdk,eua-051925,XPT,12035,M5,data,,"SAS, Safety, Qualifiers, Clinical Study, M5, Data, Library, Linux, Dscrptr, Ce, C4591001, Member, Supplemental, Efficacy, Meddra",False,False,False,True
FDA-CBER-2021-5683-1576679-1577829_27034_S1_M5_c4591001-safety-fa-eff-S-suppdm.xpt,Supplemental Qualifiers for DM,2020-11-19,https://drive.google.com/file/d/1fUqYXVb-nRUYFUSvYMQUh2t21s8vVrff/view?usp=drivesdk,eua-051925,XPT,1598,M5,data,,"Case Flags, Derived Data, Data Management, FDA Submission, Qualifiers, Dm, Clinical Study, Regulatory Compliance, M5, Pharmaceutical Research, C4591001, Subject Identifiers, Study Sponsor, Supplemental Data",False,False,False,True
FDA-CBER-2021-5683-1576423-1576678_27034_S1_M5_c4591001-safety-fa-eff-S-suppcm.xpt,Supplemental Qualifiers for CM,2020-11-19,https://drive.google.com/file/d/1RimFdRJ9SYoUIvwdU6MMojNXgajmJu5e/view?usp=drivesdk,eua-051925,XPT,405,M5,data,,"SAS, Standardized Codes, WHO Dde, Qualifiers, Related Domains, Clinical Study, Evaluators, M5, Data Values, Medication Data, C4591001, Subject Identifiers, Linux, Data Dictionary",False,False,False,True
FDA-CBER-2021-5683-1577830-1579809_27034_S1_M5_c4591001-safety-fa-eff-S-suppds.xpt,c4591001 Safety and Efficacy Supplemental Data,2020-11-19,https://drive.google.com/file/d/1FJ-9AYjqg3aiAp5r37hwxtAsf-g_ji9j/view?usp=drivesdk,eua-051925,XPT,2087,M5,dataset,,"CBER, Supplemental Data, FDA, Medical Research, Vaccine, Clinical Trial, Safety, COVID-19, M5, BNT162B1, Regulatory, C4591001, Study Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1579810-1581339_27034_S1_M5_c4591001-safety-fa-eff-S-suppdv.xpt,c4591001 Safety and Efficacy Supplemental Data,2020-11-19,https://drive.google.com/file/d/18l1lSS6zXtvtmeGWvdEsiZ05SfVGm-5M/view?usp=drivesdk,eua-051925,XPT,1831,M5,data,,"CBER, FDA, Pharmaceutical, Medical Research, Exclusion, Safety, Data Set, C4591001, Regulatory, M5, Data Analysis, Clinical Trial, SAS, Supplemental Data, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1581340-1591988_27034_S1_M5_c4591001-safety-fa-eff-S-suppec.xpt,Supplemental Qualifiers for EC,2020-11-19,https://drive.google.com/file/d/1bHSffBg3R7qOdz3F0YhTF6kXH1bWrpYG/view?usp=drivesdk,eua-051925,XPT,14962,M5,data,,"Regulatory Submission, SAS Data, Ecobsv, Data File, Ecseq, Safety Analysis, Supplemental Qualifiers, Clinical Study, Ecdecod, M5, C4591001, Ecc, Eccd, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1591989-1602637_27034_S1_M5_c4591001-safety-fa-eff-S-suppex.xpt,Supplemental Qualifiers for EX,2020-11-19,https://drive.google.com/file/d/1qwO1w0qhpvKROA-v-QR-OUN9QmilYpsw/view?usp=drivesdk,eua-051925,XPT,14962,M5,data,,"Evaluator, Ex, Unique Subject Identifier, Study Identifier, Qualifier Variable, Supplemental Qualifiers, Observed Post Dose, Clinical Study, M5, Identifying Variable, Data Value, Origin, C4591001, Related Domain",False,False,False,True
FDA-CBER-2021-5683-1602638-1669107_27034_S1_M5_c4591001-safety-fa-eff-S-suppface.xpt,Supplemental Qualifiers for FACE,2020-11-19,https://drive.google.com/file/d/1Br4uy7K7JkZ8AskNMeUKrfPRpSVs5fFH/view?usp=drivesdk,eua-051925,XPT,99851,M5,data,,"Face Data, Unique Subject Identifier, Study Identifier, Qualifiers, Collection Type, Clinical Study, M5, Identifying Variable, Data Value, C4591001, Language Version, Related Domain, Diary Card, Subject Data",False,False,False,True
FDA-CBER-2021-5683-1669108-1669842_27034_S1_M5_c4591001-safety-fa-eff-S-suppho.xpt,Supplemental Qualifiers for HO,2020-11-19,https://drive.google.com/file/d/1ryuwCVPqHnX9G0uamCaEe10uWpaDOUj9/view?usp=drivesdk,eua-051925,XPT,903,M5,data,,"CBER, FDA, SAS, Clinical-trial, Respiratory, Vaccine, Safety, Illness, Qualifiers, M5, C4591001, Supplemental, Efficacy, Hospitalization",False,False,False,True
FDA-CBER-2021-5683-1669843_27034_S1_M5_c4591001-safety-fa-eff-S-suppie.xpt,Supplemental Qualifiers for IE,2025-03-27,https://drive.google.com/file/d/13Poc7OPjRdb5ToDl2ZPmyl6WsteSaa1B/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Evaluator, Unique Subject Identifier, Vaccine, Clinical Trial, Safety, Protocol Deviation, Exclusion, Qualifiers, M5, Data Value, Adverse Events, C4591001, Supplemental, Related Domain, Efficacy",False,True,False,True
FDA-CBER-2021-5683-1669844-1671437_27034_S1_M5_c4591001-safety-fa-eff-S-suppis.xpt,c4591001 Safety and Efficacy Supplemental Information,2020-11-19,https://drive.google.com/file/d/1naqGPA1tZn35lpZL0nHXYz5wKMRKzO1u/view?usp=drivesdk,eua-051925,XPT,1595,M5,data,,"CBER, Pharmaceutical, FDA, Study, Safety, Qualifiers, C4591001, Data, Variables, Subject, M5, Supplemental Information, Clinical Trial, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1671438-1674334_27034_S1_M5_c4591001-safety-fa-eff-S-supplb.xpt,Supplemental Qualifiers for LB,2020-11-19,https://drive.google.com/file/d/1Ly405h0ll0XKRyVC9KMamutlop87B8Ea/view?usp=drivesdk,eua-051925,XPT,3389,M5,data,,"Pharmaceutical, FDA, Variable Metadata, Medical Research, Lab Results, Supplemental Qualifiers, Clinical Study, M5, Linux, Lab Data, C4591001, Data File, SAS, Data Dictionary",False,False,False,True
FDA-CBER-2021-5683-1674335-1676725_27034_S1_M5_c4591001-safety-fa-eff-S-suppmb.xpt,c4591001 Safety and Efficacy Supplemental Data,2020-11-19,https://drive.google.com/file/d/1x83u0VfJFZm-GPdtFzlSkfG-R7oPQ_FR/view?usp=drivesdk,eua-051925,XPT,2498,M5,data,,"CBER, Pharmaceutical, FDA, Medical Research, Vaccine, Clinical Trial, Safety, Regulatory Compliance, Clinical Study, M5, Lab Data, C4591001, Supplemental Data, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1676726-1681443_27034_S1_M5_c4591001-safety-fa-eff-S-suppmh.xpt,Supplemental Qualifiers for MH,2020-11-19,https://drive.google.com/file/d/18IE3jU0IzZK3v6j9uO5DAZnDIwf3hE7R/view?usp=drivesdk,eua-051925,XPT,7234,M5,data,,"Pharmaceutical, Safety Analysis, Study Identifier, Subject Identifier, Qualifiers, Regulatory Compliance, Clinical Study, M5, Data Evaluation, Adverse Events, Data Values, C4591001, Data Origin, Medical Data, Data Dictionary, Meddra",False,False,False,True
FDA-CBER-2021-5683-1681444_27034_S1_M5_c4591001-safety-fa-eff-S-suppmo.xpt,Supplemental Qualifiers for MO,2020-11-19,https://drive.google.com/file/d/1YWMgaIJywyyWALQLXGgE9gzuAeTbwaUH/view?usp=drivesdk,eua-051925,XPT,4,M5,data,,"Subject-identifiers, Clinical-trial, Observations, Safety, Sas-data, Qualifiers, Regulatory-submission, M5, Adverse-events, Data-file, C4591001, Medical, Supplemental, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1681447-1681448_27034_S1_M5_c4591001-safety-fa-eff-S-supppr.xpt,Supplemental Qualifiers for PR,2020-11-19,https://drive.google.com/file/d/1EueD6uMXY3_7mCWCgddQXRX2xtGqLkSV/view?usp=drivesdk,eua-051925,XPT,4,M5,data,,"Evaluator, Unique Subject Identifier, Qualifier Variable, Body System, Clinical Study, M5, Identifying Variable, Data Value, C4591001, Linux, SAS Data, Prc4591001, Meddra, Organ Class",False,False,False,True
FDA-CBER-2021-5683-1681445-1681446_27034_S1_M5_c4591001-safety-fa-eff-S-supppe.xpt,Supplemental Qualifiers for PE,2020-11-19,https://drive.google.com/file/d/1cbdVuxgHlluURm6qEF5mzV0Ma8doG7Zn/view?usp=drivesdk,eua-051925,XPT,3,M5,data,,"Regulatory Submission, FDA, CBER, Pharmaceutical, Data Management, Data Qualifiers, Data Standards, Clinical Study, M5, Adverse Events, Data Analysis, Clinical Trial, Subject Identifiers, Safety Data, Data Dictionary",False,False,False,True
FDA-CBER-2021-5683-1681449-1687608_27034_S1_M5_c4591001-safety-fa-eff-S-suppvs.xpt,c4591001 Safety and Efficacy Supplemental Data,2020-11-19,https://drive.google.com/file/d/1Sor0yhZG-tNQrdNgT9_iOyh-lbwZWL7K/view?usp=drivesdk,eua-051925,XPT,8547,M5,data,,"Regulatory Submission, Data Variables, Data Origin, Study Identifier, Subject Identifier, Qualifiers, Clinical Study, M5, Data Evaluation, Data Values, Efficacy Data, C4591001, Data Collection, Safety Data, Supplemental Data",False,False,False,True
FDA-CBER-2021-5683-1687609-1690827_27034_S1_M5_c4591001-safety-fa-eff-S-sv.xpt,c4591001 Safety and Efficacy Data,2020-05,https://drive.google.com/file/d/1i0inc635NoFr8ZLoSrzfEms_MLN-zpeM/view?usp=drivesdk,eua-051925,XPT,3111,M5,data,,"CBER, Pharmaceutical, FDA Submission, Medical Research, Vaccine, Subject Visits, C4591001, M5, Adverse Events, Clinical Trial, Study Data, SAS Data, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1690828_27034_S1_M5_c4591001-safety-fa-eff-S-ta.xpt,C4591001 Trial Arms,2020-11-19,https://drive.google.com/file/d/10m3q7e0W8uYk_YQFbLNqX-HCH8F5dWEo/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"CBER, Follow-up, FDA, Vaccine, Safety, Randomization, BNT162B1, Phase 1, Arm Description, Screening, Vaccination, Study Design, Clinical Trial, M5, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1690829_27034_S1_M5_c4591001-safety-fa-eff-S-te.xpt,C4591001 Safety and Efficacy Trial Elements,2020-11-19,https://drive.google.com/file/d/1WJH3eeEviADttwXANAGvksf86phgvMHW/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"BNT162B2, Clinical Trial, Dose Levels, Follow-up Visit, M5, BNT162B1, Screening, Start Of Treatment, Vaccine Trial, Next Dose, C4591001, Safety Data, Efficacy Data, Informed Consent",False,False,False,True
FDA-CBER-2021-5683-1690830-1690832_27034_S1_M5_c4591001-safety-fa-eff-S-ti.xpt,Trial Inclusion/Exclusion Criteria,2020-11-19,https://drive.google.com/file/d/1flltkxWuGQ221ouKAauwmnU34My1UE_Y/view?usp=drivesdk,eua-051925,XPT,8,M5,data,,"C4591001 Trial, FDA Submission, Participant Eligibility, Exclusion, Regulatory Compliance, M5, Study Protocol, Inclusion Criteria, Medical Conditions, Safety Requirements, Vaccine Development, Clinical Trial, Data File, SAS Data, Exclusion Criteria",False,True,False,True
FDA-CBER-2021-5683-1690835_27034_S1_M5_c4591001-safety-fa-eff-S-tv.xpt,C4591001 Safety and Efficacy Trial Visits,2020-11-19,https://drive.google.com/file/d/1hsqjXcDp9PK763zlcKvrj5lkheypXIcf/view?usp=drivesdk,eua-051925,XPT,1,M5,data,,"Vaccine Study, Visit Rules, Study Identifier, Study Days, Planned Arms, M5, Visit Schedule, Screening, Vaccination, Clinical Trial, Visit Details, Safety Data, Efficacy Data, Post-vaccination",False,False,False,True
FDA-CBER-2021-5683-1690833-1690834_27034_S1_M5_c4591001-safety-fa-eff-S-ts.xpt,c4591001 Safety and Efficacy Trial Summary,2020-11-19,https://drive.google.com/file/d/1BT3kdQykO3koaWLCDn5YAt1KvftQ8R-r/view?usp=drivesdk,eua-051925,XPT,5,M5,report,,"Pharmaceutical, Data Reporting, FDA Submission, Medical Research, Clinical Trial, Safety, Trial Summary, Regulatory Compliance, Clinical Study, M5, Vaccine Development, Data Analysis, C4591001, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1690836-1699732_27034_S1_M5_c4591001-safety-fa-eff-S-vs.xpt,c4591001 Safety and Efficacy Data,2020-06,https://drive.google.com/file/d/154rAeWWh5FqdKYQswgnLjtsKu7lMt8GF/view?usp=drivesdk,eua-051925,XPT,24563,M5,data,"DK, DL, DM","Sponsor-defined Identifier, Investigator, Subject Identifier, Reference Id, Link Id, C4591001, M5, Screening, Vaccination, Domain, Clinical Trial, Body Mass Index, Vital Signs, Safety Data, Efficacy Data, Diastolic Blood Pressure",False,False,False,True
FDA-CBER-2021-5683-1699811-1701420_27034_S9_M5_c4591001-safety-fa-eff-S-is.xpt,Immunogenicity Specimen Assessment,2020-12-02,https://drive.google.com/file/d/1VYDeXO1XOgywyoeI_xlQx7OgE6sQi_RJ/view?usp=drivesdk,eua-051925,XPT,2918,M5,data,,"Pharmaceutical, Medical Research, FDA Submission, Data Management, Safety Analysis, Clinical Trial, Specimen Assessment, Regulatory Compliance, M5, Clinical Data, Biostatistics, Study Data, Immunogenicity, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1701421-1703030_27034_S9_M5_c4591001-safety-fa-eff-S-suppis.xpt,c4591001 Safety and Efficacy Supplemental Information,2020-12-02,https://drive.google.com/file/d/1bA0gDhkZrqiS-9QWKOXbm-f_kIfmI_Qn/view?usp=drivesdk,eua-051925,XPT,1611,M5,dataset,,"Supplemental Data, FDA, Pharmaceutical, Biomedical, Medical Research, Vaccine, Clinical Trial, Safety, Public Health, COVID-19, M5, Regulatory, Data Analysis, C4591001, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1704370-1704375_27034_S1_M1_fact-sheet-recipients-lab-1451-0-4.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1ykGPvbNEQteV_ztdwkVjNm8oBnG51nzx/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Emergency Use Authorization, FDA, M1, Vaccine, Safety, Public Health, Coronavirus, COVID-19, Medical Information, Recipients, Preventative Measures, Pfizer-biontech, Caregivers, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1704382-1704402_27034_S1_M1_pi-lab-1457-0-3.doc,FDA Submission - PI Lab 1457,2021,https://docs.google.com/document/d/1owy39qa5I87Ye_gWvOVMTSQjvOAHRAgF/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOC,0,M1,submission,,"CBER, FDA, Pharmaceutical, M1, Regulatory Filing, Quality Control, Medical Device, Lab Report, Research And Development, Clinical Trial, Product Development, Compliance, Product Information, Government Submission",False,False,False,True
FDA-CBER-2021-5683-1704350-1704359_27034_S1_M1_fact-sheet-healthcare-lab-1450-0-4.doc,Fact Sheet for COVID-19 Vaccination Providers,2021,https://docs.google.com/document/d/18krO45yhBk9-x7a5pxGtyMoIC2flLZzN/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOC,4,M1,fact sheet,,"Emergency Use Authorization, Reporting Requirements, Pandemic Response, M1, Vaccine, Vaccine Preparation, Public Health, COVID-19, Healthcare Professionals, Vaccine Storage, Vaccine Administration, Pfizer-biontech, Vaccine Distribution, Vaccination Providers",False,False,False,True
FDA-CBER-2021-5683-1711847-1711947_27034_S4_M1_vrbpac-bd.doc,"PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048) VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT",2020-12-10,https://docs.google.com/document/d/1Oq4dV8vs7j3QiEEimtf78zaxBAGWrICR/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOC,42,M1,report,,"Pandemic Response, Medical Research, M1, Vaccine, Advisory Committee, Safety, Public Health, Pharmaceutical Development, Clinical Trials, COVID-19, Regulatory, BioNTech, Pfizer, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1711800-1711822_27034_S4_M1_pi-lab-1457-0-4.docx,PFIZER-BIONTECH COVID-19 VACCINE FULL EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION,2021,https://docs.google.com/document/d/1bEkUz_zkUyuPcyMKHQuNqsn9VRUcAEQc/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,8,M1,prescribing information,,"Emergency Use Authorization, Pharmaceutical, M1, Vaccine, Safety And Precautions, Clinical Trial Results, Patient Counseling, Public Health, COVID-19, Medical Information, Regulatory, Adverse Events, Storage And Handling, Dosage And Administration",False,False,False,True
FDA-CBER-2021-5683-1712039-1712061_27034_S4_M1_pi-lab-1457-0-4-tracked.docx,PFIZER-BIONTECH COVID-19 VACCINE FULL EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION,2021,https://docs.google.com/document/d/1lwnFFGB87ptg5Y8VLdrlO_tR0udI7Tn2/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,8,M1,prescribing information,,"Emergency Use Authorization, Pharmaceutical, FDA, M1, Vaccine, Safety, Clinical Trial Results, Patient Counseling, COVID-19, Adverse Events, BioNTech, Storage And Handling, Pfizer, Dosage And Administration",False,False,False,True
FDA-CBER-2021-5683-1712062-1712162_27034_S6_M1_vrbpac-bd.doc,"PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048) VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT",2020-12-10,https://docs.google.com/document/d/1H9Jzx6h5RBcfW7_1dPVH5cWYPyoCcKPT/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOC,42,M1,report,,"Medical Research, M1, Vaccine, Advisory Committee, Safety, Public Health, Clinical Trials, COVID-19, Regulatory, BioNTech, Pfizer, Efficacy, Immunization, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712255_27034_S10_M1_covid-02.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1IWMct_0kAQj-K9J1_40fY-fMAW8tqSM0/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712256_27034_S10_M1_covid-03.jpg,COVID-19 Vaccine Preparation,2021,https://drive.google.com/file/d/1vTkgh8XUsEkCjBSttSMvrbJdsm2GKoy6/view?usp=drivesdk,eua-051925,JPG,1,M1,instructions,,"CBER, Pharmaceutical, FDA, Medical Preparation, M1, Vaccine, COVID-19, Clinical Trial, Sodium Chloride, Healthcare, Injection",False,False,False,True
FDA-CBER-2021-5683-1712257_27034_S10_M1_covid-04.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1UiqjsDU9hR_wa9jdFKckUaieqv5a7u6i/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712259_27034_S10_M1_covid-06.jpg,COVID-19 Vaccine Dilution Instructions,2021,https://drive.google.com/file/d/1SwUbCHJTYsdsmmEofScpV3Gcfua3YCeL/view?usp=drivesdk,eua-051925,JPG,1,M1,instructions,,"Medical Instructions, Pharmaceutical, FDA, CBER, M1, Vaccine, COVID-19, Dilution, Dosage, Healthcare, Expiration",False,False,False,True
FDA-CBER-2021-5683-1712260_27034_S10_M1_covid-07.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1XzSvgEwmu1Rz0tqOWDZ7hj9hAPwXpLub/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, Pandemic Response, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712258_27034_S10_M1_covid-05.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1KqJq9nEnXWdYJOR99klrLq_Qcx1lCzgb/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712261_27034_S10_M1_covid-08.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/19nXqruPXGWiRkVnDsJBE7HBereA975Ki/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712262_27034_S10_M1_covid-09.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1knQlRE1baMG8SW0robbE_1-djl3Hh_sh/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712264_27034_S10_M1_covid-11.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1c0lSQhhhl7tLF_8SAv9OP7MooMJJh81h/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712265_27034_S10_M1_covid-12.jpg,COVID-19 Vaccine Saline Solution,2021,https://drive.google.com/file/d/13JUTqfbUl012kkaUyHLuSR0Sj4cjawf5/view?usp=drivesdk,eua-051925,JPG,1,M1,technical specification,,"CBER, Pharmaceutical, FDA, M1, Medical Supplies, Vaccine, COVID-19, Regulatory, Healthcare, Sodium Chloride, Saline Solution, Injection",False,False,False,True
FDA-CBER-2021-5683-1712263_27034_S10_M1_covid-10.jpg,COVID-19 Temperature Storage Instructions,2021,https://drive.google.com/file/d/15_NDRg_KJqsdTrjugaUQLd813eMW-O3z/view?usp=drivesdk,eua-051925,JPG,1,M1,instructions,,"CBER, FDA, Pharmaceutical, M1, Vaccine, Instructions, Storage, COVID-19, Regulatory, Healthcare, Temperature",False,False,False,True
FDA-CBER-2021-5683-1712266_27034_S10_M1_covid-13.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/11YThW2VhcO5IOyYGDkqDGgj4S3JjYVIg/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712267_27034_S10_M1_covid-14.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1GSeE8I0DLl534G8WVtt7XhAy8gHhkiL3/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712269_27034_S10_M1_covid-16.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1o9xYVwr5HUCoAmDCmLxFBFcQsWzLFxjG/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial, Immunization",False,False,False,True
FDA-CBER-2021-5683-1712270_27034_S10_M1_covid-17.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1yktXkfLJaNw2k83v6SI4CXdtACnkMtC9/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712268_27034_S10_M1_covid-15.jpg,COVID-19 Vaccine Dilution Instructions,2021,https://drive.google.com/file/d/1fl8foibaxJo8bU5FxtiC4BKISI7SgpRh/view?usp=drivesdk,eua-051925,JPG,1,M1,instructions,,"CBER, Pharmaceutical, FDA, M1, Vaccine, COVID-19, Dilution, Dosage, Healthcare, Medical Instructions, Clinical Guidance",False,False,False,True
FDA-CBER-2021-5683-1712309_27034_S10_M1_covid-20.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1ftTjwPx18WqBDM-SEojPgcufabYUv78L/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Medical Research, Pandemic Response, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712271_27034_S10_M1_covid-18.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1GBlUzRvagG7AP_JrvVsPO1kQ8G2vuJXG/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712272_27034_S10_M1_covid-19.jpg,COVID-19 Vaccine Submission,2021,https://drive.google.com/file/d/1IhD63rsmycgHvt3OpIIxC_n0itnYgbp3/view?usp=drivesdk,eua-051925,JPG,1,M1,submission,,"CBER, FDA, Pharmaceutical, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Trial",False,False,False,True
FDA-CBER-2021-5683-1712311_27034_S10_M1_covid-22.jpg,Pfizer-BioNTech COVID-19 Vaccine,2021,https://drive.google.com/file/d/11XSQk41BaRE-g42kqlsDb2nUPMhU8LYt/view?usp=drivesdk,eua-051925,JPG,1,M1,product information,,"Pharmaceutical, FDA, M1, Vaccine, Administration, Storage, Public Health, COVID-19, Dosage, Regulatory, BioNTech, Medical, Pfizer",False,False,False,True
FDA-CBER-2021-5683-1712310_27034_S10_M1_covid-21.jpg,Pfizer-BioNTech COVID-19 Vaccine Information,2021,https://drive.google.com/file/d/1jBJ8DcFnU53V_fo2X6n49iymmSQflVhm/view?usp=drivesdk,eua-051925,JPG,1,M1,product information,,"Emergency Use Authorization, M1, Intramuscular, Vaccine, No Preservative, Storage, COVID-19, Dosage, Dilution, BioNTech, Pfizer",False,False,False,True
FDA-CBER-2021-5683-1712374-1712379_27034_S17_M1_fact-sheet-recipients-lab-1451-0-5.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1A5TCtLi9p2ffpqqVgSZJT0Mmzh_QqlXx/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, SARS-COV-2, M1, Vaccine Efficacy, Public Health, Vaccine Safety, Coronavirus, COVID-19, Vaccine Information, Vaccine Administration, Vaccine Caregivers, Vaccine Recipients, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712312_27034_S10_M1_covid-01.jpg,COVID-19 Vaccine Storage Instructions,2021,https://drive.google.com/file/d/1klBMf0hJOrbq85M64IK96OSuMT_693JZ/view?usp=drivesdk,eua-051925,JPG,1,M1,instructions,,"CBER, FDA, Pharmaceutical, M1, Vaccine, Storage, COVID-19, Regulatory, Guidelines, Medical, Healthcare, Temperature, Room Temperature",False,False,False,True
FDA-CBER-2021-5683-1712386-1712391_27034_S17_M1_fact-sheet-recipients-lab-1451-0-5-track.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/10M9RpIZuUgrNPLp5hhJ6dJQWdTrjzZ7C/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Symptoms, M1, Vaccine, Coronavirus, Caregiver Information, COVID-19, Respiratory Illness, Vaccination, Recipient Information, Pfizer-biontech, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712546-1712551_27034_S22_M1_fact-sheet-recipients-lab-1451-0-6-track.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1HsaMh2nTtEnOfkrj6zRv1R6xbqVj5Kkx/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, SARS-COV-2, M1, Vaccine Efficacy, Public Health, Vaccine Safety, Coronavirus, COVID-19, Vaccine Information, Vaccine Administration, Vaccine Caregivers, Vaccine Recipients, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712392-1712421_27034_S17_M1_hcp-fact-1450-0-5-pi-lab-1457-0-5-clean.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1EoJ1toNQNXV_pddniTbWelwf8zaHIxex/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Healthcare Providers, Intramuscular Injection, M1, Vaccine, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1712452-1712481_27034_S17_M1_hcp-fact-1450-0-5-pi-lab-1457-0-5-track.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1xoOQwoBLYjzK2cTdvMYEQwLfDNCSBJOI/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Healthcare Providers, Intramuscular Injection, M1, Vaccine, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1712583-1712588_27034_S24_M1_fact-sheet-recipients-lab-1451-0-7-clean.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1kVO2tbPgyMQwIPUqRwtOoHSpUh_lqCYx/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, M1, Vaccine, Preventative, Coronavirus, Pandemic, COVID-19, Recipients, EUA, Pfizer-biontech, Immunization, Caregivers",False,False,False,True
FDA-CBER-2021-5683-1712595-1712600_27034_S24_M1_fact-sheet-recipients-lab-1451-0-7-track.docx,FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE,2021,https://docs.google.com/document/d/1iDmBuLqRgiYFXcu4Mg380tzcX3rRQSig/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, FDA, SARS-COV-2, Caregiver Guidance, Pandemic Response, M1, Public Health, Coronavirus, COVID-19, Vaccination, Vaccine Information, Preventative Care, Recipient Guidance",False,False,False,True
FDA-CBER-2021-5683-1712552-1712582_27034_S22_M1_hcp-fact-1450-0-5-pi-lab-1457-0-6-track.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1f8be0z5SWdM8MB5hVt2KDS5G707w4ny9/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, SARS-COV-2, Healthcare Providers, Intramuscular Injection, Mandatory Requirements, Vaccine, M1, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1712659-1712687_27034_S24_M1_hcp-fact-1450-0-7-pi-lab-1457-0-7-track.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1ZjPDYSdSI_IjVDpCqyhLNadslO_Lj2Y1/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, Reporting Requirements, SARS-COV-2, Healthcare Providers, M1, Vaccine, Coronavirus, COVID-19, Vaccination, Adverse Events, Vaccine Administration, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1712630-1712658_27034_S24_M1_hcp-fact-1450-0-7-pi-lab-1457-0-7-clean.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1e4HQCH-Cn-ldh2Y_iIWdlddE_bPcQJXx/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, Reporting Requirements, SARS-COV-2, Healthcare Providers, M1, Vaccine, COVID-19, Respiratory Illness, Vaccination, EUA, Pfizer-biontech, Administration Instructions, Immunization, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712769-1712797_27034_S28_M1_hcp-fact-1450-1-0-pi-lab-1457-1-0-clean.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1TFeIAoP55Txul9sbqLNLKr1PJPECXTNe/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Healthcare Providers, Intramuscular Injection, M1, Vaccine, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1712757-1712762_27034_S28_M1_fact-sheet-recipients-lab-1451-1-0-clean.docx,Fact Sheet for Recipients and Caregivers - Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1YikmmnHAkyoOcN4rJM4BrPfenu-PVFtK/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,3,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Symptoms, M1, Two-dose Series, Vaccine, Coronavirus, COVID-19, Respiratory Illness, Vaccination, Recipient Information, Pfizer-biontech, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1712827-1712855_27034_S28_M1_hcp-fact-1450-1-0-pi-lab-1457-1-0-track.docx,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021,https://docs.google.com/document/d/1h1SVixL9ChVBGAKz3Y-XaJ6f1uMfRDpP/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-051925,DOCX,13,M1,fact sheet,,"Emergency Use Authorization, SARS-COV-2, Healthcare Providers, Mandatory Requirements, M1, Vaccine, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Vaccine Administration, Pfizer-biontech, Immunization, Respiratory Illness",False,False,False,True
FDA-CBER-2021-5683-1773308-1773320_Slipsheet.pdf,FOIA FDA/CBER Request #2021-5683,2021,https://drive.google.com/file/d/1empzoM72P7bttlP18rr89Xdca3R1dNTJ/view?usp=drivesdk,eua-063025,PDF,1,,slip sheet,,"CBER, FDA, Exemption 6, Data Redaction, FOIA Request, Personal Privacy, Public Disclosure, Regulatory Compliance, Exemption, Confidential Information, Document Withholding, Bates Numbers, Exemption 4, Government Records",True,False,False,True
17__09-Dec-2020 MICHAEL SMITH _UI_ UO_ UI_ UO_ PVP IR RE ANAPHYLACTIC REACTIONS - see EDR for full .pdf,EUA 27034: IR RE PVP,2020-12-09,https://drive.google.com/file/d/1iLI2UO7rRYUhH3nHAOzKxbQTBu0MJqiQ/view?usp=drivesdk,eua-063025,PDF,1,,email,"Michael Smith, Elisa Harkins Tull, Carmel Devlin, Ramachandra Naik","CBER, FDA, Potential Risk, COVID-19 Vaccine, Vaccine Safety, Pharmacovigilance Plan, Regulatory Review, Post-market Use, Adverse Events, Pfizer-biontech, December 2020, Anaphylactic Reactions, Information Request",False,False,False,True
14__06-Dec-2020 RAMACHANDRA NAIK _UC_ Request for submission of udated cross-reference document and.pdf,Request for submission of updated cross-reference document and EUA Request,2020-12-06,https://drive.google.com/file/d/1BJKnZuGXCHCJ30Vadx82TNbjL0iGZtQB/view?usp=drivesdk,eua-063025,PDF,2,,email,"Ramachandra Naik, Elisa Harkins Tull, Carmel M Devlin, Michael Smith, Donna Boyce","EUA 27034, Cross-reference Document, FDA Submission, Pfizer-biontech COVID-19 Vaccine, IND 19736, Facilities Information, Pharmacovigilance Plan, Regulatory Compliance, Needs-review, COVID-19 Response, Vaccine Development, Vaccine Adverse Event Reporting, CMC Information",False,False,False,True
13__05-Dec-2020 RAMACHANDRA NAIK _UC_ CBER comments on the Full EUA Prescribing Information include.pdf,EUA 27034 - Pfizer-BioNTech COVID-19 Vaccine - CBER comments on Full EUA PI and Fact Sheets,2020-12-05,https://drive.google.com/file/d/1XtlIGuooZGgwnaHlM2DyQTyhEjHoiEer/view?usp=drivesdk,eua-063025,PDF,43,,email,"Ramachandra Naik, Elisa Harkins Tull, Carmel Devlin, Michael Smith, Donna Boyce","CBER, FDA, Vaccine Recipients, Prescribing Information, Healthcare Providers, Vaccine, COVID-19, Regulatory, Fact Sheets, EUA, Pfizer-biontech, Vaccine Distribution, December 2020",False,False,False,True
12__3_26-Nov-2020_RAMACHANDRA_RAMACHANDRA__RE_ VRBPAC briefing document_ 508-compliant safety and e.pdf,VRBPAC Briefing Document,2020-11-26,https://drive.google.com/file/d/1v7piEGPOGT-faxMrLFS_PTX4wvFQjFGj/view?usp=drivesdk,eua-063025,PDF,2,,briefing,"RAMACHANDRA RAMACHANDRA, NAIK, RAMACHANDRA, SENN, KEVIN, SMITH, MICHAEL J, WOLLERSHEIM, SUSAN, LEE, LUCIA H, WANG, XIAO, MURATA, HARUHIKO, HUANG, LEI, ELEKWACHI, OLUCHI","FDA, SARS-COV-2, Pandemic Response, Vaccine, Safety, Public Health, COVID-19, IND, Regulatory, EUA, Pfizer-biontech, Efficacy, VRBPAC",False,False,False,True
16__08-Dec-2020 MICHAEL SMITH _UI_ UO_ UO_ UI_ IR RE FOUR SUBJECTS WITH BELL`S PALSY - LATERALITY O.pdf,IR regarding Bell's palsy,2020-12-08,https://drive.google.com/file/d/1uMZ_c6MtGtamTVizOWc7Jnz_YdOBkfy_/view?usp=drivesdk,eua-063025,PDF,1,,email,"Michael Smith, Elisa Harkins Tull, Carmel M Devlin, Ramachandra Naik","CBER, Vaccine Response, FDA Review, Vaccine Safety, Needs-review, Regulatory Affairs, Adverse Events, Vaccine Side Effects, Facial Paralysis, Clinical Data, Medical Review, Bell's Palsy, Pfizer",False,False,False,True
10__2_25-Nov-2020_RAMACHANDRA_RAMACHANDRA__RE_ Clarification to text in Section 11 Program schema r.pdf,Clarification to text in Section 11 Program schema,2020-11-25,https://drive.google.com/file/d/12LKoTD6iFQn2s08Z23yLFRYMhJNw05Wa/view?usp=drivesdk,eua-063025,PDF,1,,memo,"RAMACHANDRA, NAIK, RAMACHANDRA, SENN, KEVIN, SMITH, MICHAEL J","Government Contract, Pharmaceutical, Advanced Technology International, Vaccine, Administration, Shipment, Medical, COVID-19, Regulatory, MCDC, EUA, Pfizer-biontech, Program Schema",False,False,False,True
18A__BIMO Review Memo-EUA 27034_12_9_2020.pdf,BIMO Review Memo - EUA 27034,2020-12-09,https://drive.google.com/file/d/1s44H2roqIBPkjgP8mrhZWCGh9hblixZe/view?usp=drivesdk,eua-063025,PDF,3,,memo,"Ramchandra Naik, Susan Wollersheim, Dennis Cato, Carrie M. Mampilly, Mary A. Malarkey","EUA 27034, Data Review, Bioresearch Monitoring Branch, Pfizer-biontech COVID-19 Vaccine, Clinical Study Protocol C4591001, Vaccine Authorization, Division Of Inspections And Surveillance, Regulatory Compliance, Clinical Trial Inspection, COVID-19, Vaccine Development, Office Of Compliance And Biologics Quality, Bioresearch Monitoring",False,False,False,True
18__11_09-Dec-2020_BHANUMAHTI_BHANUMAHTI__RO_ BIMO preliminary inspection summary memo.pdf,BIMO preliminary inspection summary memo,2020-12-03,https://drive.google.com/file/d/1Jj2DJaof4gRQ2UxsAzsgtMlUfS-c1zz0/view?usp=drivesdk,eua-063025,PDF,1,,memo,"BHANUMAHTI KANNAN, NAIK, RAMACHANDRA, SENN, KEVIN, SMITH, MICHAEL J","Dis, SBU, Vaccine, BIMO, OVRR, COVID-19, Inspection, IND, Regulatory, EUA, Clinical Trial, Pfizer-biontech, Dvrpa, Sensitive Information",False,False,False,True
15__07-Dec-2020 MICHAEL SMITH _UO_ UI_ UI_ UO_ REQUEST FOR MILESTONE DATES FOR 3 ACTIVE SURVIELANCE.pdf,REQUEST FOR MILESTONE DATES FOR 3 ACTIVE SURVIELANCE,2020-12-07,https://drive.google.com/file/d/18lziYmduBiPyQJo0qs9YbFVUoXFfwdCo/view?usp=drivesdk,eua-063025,PDF,2,,memo,"Michael Smith, Elisa Harkins","CBER, FDA, Vaccine, Dod, Final Report, COVID-19, Healthcare Workers, Milestone Dates, Protocol, BioNTech, VA, Pfizer, Surveillance",False,False,False,True
11__2_EUA 27034_12-11-2020_Telecon_EUA OTHER _UO_.pdf,EUA 27034: PVP IR F/U,2020-12-11,https://drive.google.com/file/d/1_JFYckb_IfFwzS-KqheHaDsxKKcmzG4v/view?usp=drivesdk,eua-063025,PDF,2,,email,"Smith, Michael, Harkins Tull, Elisa, Devlin, Carmel M, Naik, Ramachandra","EUA 27034, CBER, Vaccine Safety, Pharmacovigilance Plan, Clinical Trials, Post-authorization, Regulatory Compliance, Needs-review, Adverse Events, Pfizer, Anaphylactic Reactions, FDA Review, Vaccine Monitoring",False,False,False,True
19736_S103_M5_bnt162-01-interim-report-body.pdf,Interim Clinical Study Report - BNT162-01,2020-09-23,https://drive.google.com/file/d/1_GXNFf-4XrxLYE283uomkK8QXf_N6r3h/view?usp=drivesdk,eua-063025,PDF,1115,M5,report,,"Investigational Medicinal Products, BNT162B2, T-cell Response, Exclusion, Safety, Reactogenicity, Intracellular Cytokine Staining, Clinical Study, Interim Report, BNT162B1, COVID-19, Younger Adults, Vaccine Development, M5, Immunogenicity",False,True,False,True
19736_S105_M2_introduction.pdf,BNT162b2 Module 2.6.1 Introduction,2020-09-29,https://drive.google.com/file/d/1JOCksncczKvyaqQqms_-Zrq6M2kzL9Z3/view?usp=drivesdk,eua-063025,PDF,2,M2,introduction,,"Lipid Nanoparticle, BNT162B2, SARS-COV-2, Pandemic Response, Global Health, M2, Vaccine, Public Health, COVID-19, Prefusion Conformation, Vaccine Development, Urgent Need, Rna-based, Spike Protein",False,False,False,True
19736_S103_M5_bnt162-01-interim-sap.pdf,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2020-09-04,https://drive.google.com/file/d/1Q4Yfwc81G3c7fG0RU8rjRzZV7ADrupe-/view?usp=drivesdk,eua-063025,PDF,33,M5,statistical analysis plan,Susanne Steinhauser,"BNT162B1, Bnt162c2, Immunogenicity, Bnt162a1, Cro, COVID-19, Regulatory, Sponsor, BNT162B2, Dose-escalation, RNA Vaccines, Protocol, Healthy Adults, SARS-COV-2, Eudract, Vaccine, Safety, WHO Utn, M5, Clinical Trial",False,False,False,True
19736_S105_M2_pharmacol-tabulated-summary.pdf,Pharmacology Tabulated Summary,2020-09-29,https://drive.google.com/file/d/1bR4GeDUUA9BOyoPsGIY_g7x9V84YWRiS/view?usp=drivesdk,eua-063025,PDF,1,M2,report,,"Antibody Response, BNT162B2, SARS-COV-2, M2, Vaccine, BALB/C Mice, Drug Development, Pharmacology, COVID-19, Rhesus Macaques, Neutralization Assay, Preclinical, Pfizer, Immunogenicity",False,False,False,True
19736_S105_M2_nonclinical-overview.pdf,Nonclinical Overview,2020-09-29,https://drive.google.com/file/d/15yjZ_NYIqMxCGqDlKv-JOriIugvcz7B0/view?usp=drivesdk,eua-063025,PDF,31,M2,report,,"FDA, BNT162B2, SARS-COV-2, M2, Vaccine, Nonclinical, Safety, Pharmacology, COVID-19, Regulatory, Toxicology, Immunogenicity, Efficacy, Preclinical",False,False,False,True
19736_S105_M2_nonclinical-overview-appendix.pdf,Nonclinical Overview Appendix,undated,https://drive.google.com/file/d/1-uq3fkN492g3s8932Wo-lvBAFBjc7_2W/view?usp=drivesdk,eua-063025,PDF,4,M2,report,,"BNT162B2, Im Administration, Excretion, M2, Pharmacology, GLP Studies, Vaccine Development, Pharmacokinetics, Nonclinical Studies, Iv Pk, WHO Guidelines, Toxicology, Metabolic Stability, Biotransformation, Novel Lipid Excipients",False,False,False,True
19736_S105_M2_pharmacol-written-summary.pdf,BNT162b2 Pharmacology Written Summary,2020-09-29,https://drive.google.com/file/d/1vLZAIgbiL035e-ouUn4RADMK89MesmQF/view?usp=drivesdk,eua-063025,PDF,40,M2,summary,,"BNT162B2, SARS-COV-2, M2, Vaccine, In Vitro, Pharmacology, COVID-19, Antigen, Biophysical, Regulatory, Preclinical, Immunogenicity, Confidential, Structural Characterization",False,False,False,True
19736_S105_M2_pharmkin-tabulated-summary.pdf,Pharmacokinetics Tabulated Summary,2020-09-29,https://drive.google.com/file/d/1X2-3nGPHejuCLgwnJbsAGMGr0ygxn08I/view?usp=drivesdk,eua-063025,PDF,10,M2,report,,"Metabolism, BNT162B2, FDA Submission, Adme, M2, Drug Development, LNP Formulation, Distribution, Regulatory, Pharmacokinetics, Excretion, Tabulated Summary, Preclinical, Confidential",False,False,False,True
19736_S105_M2_pharmkin-written-summary.pdf,BNT162b2 Module 2.6.4. Pharmacokinetics Written Summary,2020-09-29,https://drive.google.com/file/d/1-6KgBzM-RDkvdhsN6i27z6j5Dz84yrVg/view?usp=drivesdk,eua-063025,PDF,9,M2,report,,"Written Summary, FDA, BNT162B2, CBER, Absorption, Metabolism, M2, Pharmaceutical Development, Drug Interactions, Distribution, Clinical Data, Pharmacokinetics, Excretion, Confidential",False,False,False,True
19736_S105_M2_toxicology-written-summary.pdf,Toxicology Written Summary,2020-09-29,https://drive.google.com/file/d/1mUcuhQsqLrZ-5fwx_PIFYvn3RVLbd1vm/view?usp=drivesdk,eua-063025,PDF,16,M2,report,,"Animal Studies, Single-dose, BNT162B2, FDA, Wistar Han Rats, M2, Vaccine, Viral Proteins, Biontech/pfizer, Lnp-formulated RNA, Toxicology, Confidential, Preclinical, Repeat-dose",False,False,False,True
19736_S105_M2_toxicology-tabulated-summary.pdf,Toxicology Tabulated Summary,2020-09-29,https://drive.google.com/file/d/1wLjmKY1kclxn-7Op86AZHLfWa-k7F2yv/view?usp=drivesdk,eua-063025,PDF,28,M2,report,,"Animal Studies, Regulatory Submission, BNT162B2, M2, Vaccine, Safety, Pharmaceutical Development, 2020, Reproductive Toxicity, GLP Compliance, Repeat-dose Toxicity, Toxicology, Pfizer, Preclinical",False,False,False,True
19736_S105_M4_r-20-0085.pdf,COVID-19: Immunogenicity Study of the LNP-Formulated mRNA Encoding the Viral S Protein -V9,2020-09-24,https://drive.google.com/file/d/1lwAsFGW30ozS3wo9G6lSGFCLmYiSGfq4/view?usp=drivesdk,eua-063025,PDF,94,M4,report,,"Lipid Nanoparticle, M4, Mouse, Vaccine, Atm Material, Viral Protein, R&d, Study, Coronavirus, modRNA, COVID-19, BioNTech, Preclinical, Immunogenicity",False,False,False,True
19736_S105_M4_vr-vtr-10671.pdf,BNT162b2 (V9) Immunogenicity and Evaluation of Protection against SARS-CoV-2 Challenge in Rhesus Macaques,2020-09-29,https://drive.google.com/file/d/1FkWpkwc6JlXOcMaOM0JsmEqvsBIkcK5a/view?usp=drivesdk,eua-063025,PDF,27,M4,report,"(b) (6), (b) (6), (b) (6), (b) (6), (b) (6)","M4, BNT162B2, SARS-COV-2, Neutralizing Antibodies, Vaccine, Vaccine Efficacy, COVID-19, Challenge Study, Animal Study, T Cell Response, Rhesus Macaques, Preclinical, Pfizer, Immunogenicity",False,False,False,True
19736_S136_M5_c4591001-interim-protocol.pdf,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2020-10-29,https://drive.google.com/file/d/1hSWzpOR7ghhhb1Wz-1FKOKzu-3nm_vCD/view?usp=drivesdk,eua-063025,PDF,1413,M5,protocol,,"Vaccine, Exclusion, Safety, Tolerability, Healthy Individuals, COVID-19, BNT162, M5, PF-07302048, Clinical Trial, Rna-based, Pfizer, Immunogenicity, Efficacy, BioNTech",False,True,False,True
19736_S120_M1_response-05oct2020-clinical.pdf,"COVID-19 Vaccine (BNT162, PF-07302048) Response to CBER Guidance on EUA Request",2020-10,https://drive.google.com/file/d/1VMOIoV2iYdodW45eQjr1N9wk7A6o8VwV/view?usp=drivesdk,eua-063025,PDF,18,M1,report,,"Effectiveness, CBER Guidance, M1, Vaccine, Bb-ind 19736, EUA Request, Safety, Nonclinical, Clinical Trials, COVID-19, BNT162, Regulatory, PF-07302048, Bioassays",False,False,False,True
19736_S136_M5_c4591001-interim-report-body.pdf,"Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2020-11-12,https://drive.google.com/file/d/1ys9yVjt1ak3MuMYPsEG-HFvpvkqWxtkc/view?usp=drivesdk,eua-063025,PDF,1206,M5,report,"Stephen Thomas, John L. Perez, Kenneth Koury","SARS-COV-2, COVID-19 Vaccine, BNT162 Rna-based COVID-19 Vaccines, Safety, Tolerability, Phase 1/2/3 Clinical Trial, Healthy Individuals, Clinical Study, Interim Report, M5, Vaccine Development, PF-07302048, Immunogenicity, Efficacy",False,False,False,True
19736_S139_M5_bnt162-01-protocol.pdf,A multi-site Phase I/II trial investigating the safety and effects of four BNT162 vaccines against COVID-19 in healthy and immunocompromised adults,2020-10-28,https://drive.google.com/file/d/1RpQps9hiYz-rtPJvkgx4ODExVhXgbv1g/view?usp=drivesdk,eua-063025,PDF,112,M5,protocol,"Dr. Dr. med. Armin Schultz, Özlem Türeci","Healthy Adults, SARS-COV-2, Phase I/ii, Safety, RNA Vaccines, Gcp, Regulatory Compliance, COVID-19, BNT162, Declaration Of Helsinki, Dose Escalation, M5, Clinical Trial, Immunocompromised Adults, Immunogenicity",False,False,False,True
19736_S136_M5_c4591001-interim-sap.pdf,Protocol C4591001 (PF-07302048) Statistical Analysis Plan,2020-11-02,https://drive.google.com/file/d/1Nt7SYVzb_sPCG9V4trx8PmmP-vszL2Bt/view?usp=drivesdk,eua-063025,PDF,59,M5,plan,,"Statistical Analysis, SARS-COV-2, Vaccine, Safety, Tolerability, Healthy Individuals, COVID-19, M5, Interim, Regulatory, Protocol, Clinical Trial, Immunogenicity, Efficacy",False,False,False,True
19736_S141_M4_20gr142-protocol.pdf,17-DAY INTRAMUSCULAR TOXICITY STUDY OF B NT162B2 (V9) AND BNT162B3C IN WISTAR HAN RATS WITH A 3 -WEEK RECOVERY,2020-11-13,https://drive.google.com/file/d/1n7uE4IM2-UGDZtySRfbreYa5hXqCYKLj/view?usp=drivesdk,eua-063025,PDF,598,M4,report,"(b) (6), Regulatory Quality Assurance -Good Laboratory Practices, Pfizer, Groton CT","M4, BNT162B2, Wistar Han Rats, Intramuscular, COVID-19 Vaccine, GLP, Toxicity Study, Recovery, Regulatory, Bnt162b3c, Pharmaceutical Research, Preclinical, Pfizer, Drug Safety",False,False,False,True
19736_S1_M4_38166.pdf,Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms,2020-04-16,https://drive.google.com/file/d/1YSkiYJ7SdSGwbvFWXjTQI8pw5RXYcOa7/view?usp=drivesdk,eua-063025,PDF,910,M4,report,"BioNTech RNA Pharmaceuticals, LPT Laboratory of Pharmacology and Toxicology GmbH & Co. KG","M4, Wistar Han Rats, RNA, Preclinical Study, LNP, Pharmacology, Interim Report, Intramuscular Administration, Mainz, Germany, Viral Proteins, Pharmaceutical Research, GmbH, Toxicology, Hamburg",False,False,False,True
19736_S1_M4_r-20-0072.pdf,R&D STUDY REPORT No. R-20-0072,2020-04-16,https://drive.google.com/file/d/1i177_OOENyJ6KMRbdEgLhrPlcJUU3jiK/view?usp=drivesdk,eua-063025,PDF,37,M4,report,,"M4, Mouse, Gmp-ready, Biodistribution, Confidential, R&d, Bioluminescence Assay, Acuitas LNP Formulation, modRNA, COVID-19, Germany, BioNTech, Pharmaceuticals, Luciferase",False,False,False,True
19736_S33_M4_38166-final.pdf,Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral Proteins,2020-07-01,https://drive.google.com/file/d/182NJnm5OgJRkWNY9cTEkmIg0NVZXBSR6/view?usp=drivesdk,eua-063025,PDF,2243,M4,report,"(b) (4), (b) (6)","M4, Wistar Han Rats, Pharmaceutical Development, Toxicity Study, Vaccine Candidate, LPT Laboratory, Pharmacology, Safety Evaluation, Intramuscular Administration, Viral Proteins, BioNTech, Lnp-formulated RNA, Toxicology, Preclinical Research",False,False,False,True
19736_S77_M1_ib-summ-change.pdf,Comparison Table of Changes to COVID-19 Vaccine (BNT162) IB,2020-08,https://drive.google.com/file/d/1QgHxnuxRSxo-ckxxVNbU1Q977ZcS5_Sr/view?usp=drivesdk,eua-063025,PDF,78,M1,report,,"Toxicity, Lipid Nanoparticle, Immune Response, Pharmaceutical, M1, Vaccine, Safety, mRNA, COVID-19, BNT162, Investigator's Brochure, Regulatory, Animal Study, Preclinical, Inflammation",False,False,False,True
19736_S77_M1_ib-track.pdf,Investigator's Brochure BNT162/C4591001 PF-07302048,2020-07-12,https://drive.google.com/file/d/1UnJSudOvblL_DYUDUfzvYWzKpFefHIzT/view?usp=drivesdk,eua-063025,PDF,123,M1,brochure,,"M1, Investigational Medicinal Product, Pharmaceutical Development, Vaccine Candidate, Clinical Trials, Non-clinical Data, BNT162, COVID-19, Safety Information, Regulatory, PF-07302048, C4591001, BioNTech RNA Pharmaceuticals, Confidential",False,False,False,True
19736_S77_M1_inv-brochure.pdf,Investigator's Brochure,2020-08-12,https://drive.google.com/file/d/1KT0grbMd2Iodoe8TIAtCdHDXFu-n-AXx/view?usp=drivesdk,eua-063025,PDF,87,M1,brochure,,"Pharmaceutical, Non-clinical, M1, Investigational Medicinal Product, Vaccine, RNA, Safety, Clinical Trials, BNT162, PF-07302048, Immunotoxicology, Toxicology, Confidential, BioNTech",False,False,False,True
1A__CBER Memo for Pfizer re EUA and NEPA 12-8-2020s.pdf,"NEPA, CEQ, and Emergency Use Authorizations",2020-12-11,https://drive.google.com/file/d/1VaBZIoo2UaDv1oycJr9oopDesOP9mpRs/view?usp=drivesdk,eua-063025,PDF,3,,memo,"Marion Gruber, PhD","CBER, NEPA, FDA, Vaccine, Exclusion, Categorical Exclusion, OVRR, Environmental Impact Statement, Fd&c Act, COVID-19, CEQ, Environmental Assessment, EUA, BioNTech, Federal Action, Pfizer, Environmental Impact",False,True,False,True
19__22-Nov-2020 MICHAEL SMITH _UI_ UO_ UI_ UO_ IR regarding differences in three 25-pack carton lab.pdf,Differences in Three 25-Pack Carton Labels,2020-11-22,https://drive.google.com/file/d/1C77lIK6Tnyh1GxjzqHmLRfj3YzjGdZmp/view?usp=drivesdk,eua-063025,PDF,1,,email,"Ramachandra Naik, Elisa Harkins Tull, Michael Smith, Carmel Devlin","EUA 27034, FDA, Vaccine Distribution, COVID-19 Vaccine, Quality Control, Regulatory Review, Needs-review, Label Differences, Vaccine Packaging, Product Information, Carton Labels, Pfizer",False,False,False,True
1__0_09-Dec-2020_RAMACHANDRA_RAMACHANDRA__RA_ OVRR Office Director`s memo that addresses obligation.pdf,1  0 09-Dec-2020 RAMACHANDRA RAMACHANDRA  RA  OVRR Office Director`s memo that addresses obligation,undated,https://drive.google.com/file/d/1L_MpTncqOoAbmklv8HGGXXzrQXlde_FP/view?usp=drivesdk,eua-063025,PDF,2,,document,,"FDA, Review-needed, Vaccine, 2020, COVID-19, Data",False,False,False,True
2.5A__EUA 27034_Pfizer-COVID-19 Vaccine Statistical Memo signed.pdf,Pfizer-COVID-19 Vaccine Statistical Memo,2020-12-11,https://drive.google.com/file/d/1xAT4HfqwxmrBXMjq7uYhT2tSdagrP9Lh/view?usp=drivesdk,eua-063025,PDF,41,,memo,"Lei Huang, Tsai-Lien Lin, John Scott, Ramachandra Naik, Michael Smith","CBER, FDA, Statistical Analysis, Emergency Use Authorization, SARS-COV-2, Data Review, Vaccine, Clinical Trial, Coronavirus, COVID-19, Epidemiology, EUA, Biostatistics, Pfizer, Immunization",False,False,False,True
2.5__0_11-Dec-2020_LEI_LEI__RS_.pdf,2.5  0 11-Dec-2020 LEI LEI  RS ,undated,https://drive.google.com/file/d/1VpdgP3gDQKqrJQebNZHsv-iI5Tq_JYcq/view?usp=drivesdk,eua-063025,PDF,2,,document,,"FDA, Review-needed, Vaccine, 2020, COVID-19, Data",False,False,False,True
22__23-Nov-2020 MICHAEL SMITH _UI_ UO_ UO_ UI_ Asymptomatic shell table and questions - see EDR for.pdf,Asymptomatic shell table and questions,2020-11-23,https://drive.google.com/file/d/1erl2kFIhnJDcAtsM_1S3PcmV5Q2CvQwi/view?usp=drivesdk,eua-063025,PDF,3,,email,"Michael Smith, Elisa Harkins Tull, Carmel Devlin, Ramachandra Naik","CBER, FDA, Asymptomatic, Follow-up, Vaccine, Data Request, Usphs, Severe Cases, COVID-19, Regulatory, Clinical Data, Pfizer, Immunogenicity",False,False,False,True
21__23-Nov-2020 MICHAEL SMITH _UE_ UO_ UE_ UO_ F-U T-CON TO DISCUSS THE SAFETY POP TO BE INCLUDED I.pdf,21  23-Nov-2020 MICHAEL SMITH  UE  UO  UE  UO  F-U T-CON TO DISCUSS THE SAFETY POP TO BE INCLUDED I,undated,https://drive.google.com/file/d/14RWdVGI0ZSHoCTfhaCYdgq0UDM2JHajP/view?usp=drivesdk,eua-063025,PDF,4,,document,,"FDA, Clinical, Review-needed, Vaccine, 2020, COVID-19, Data, Research",False,False,False,True
20__23-Nov-2020 MICHAEL SMITH _UC_ UO_ UO_ UC_ 508-COMPLIANT SAFETY AND EFFICACY TABLES WITH   43K .pdf,508-Compliant Safety and Efficacy Tables,2020-11-23,https://drive.google.com/file/d/1KmPv_yDG4uhjvsSRoYwgWZiFDpeHChFV/view?usp=drivesdk,eua-063025,PDF,1,,email,"Fink, Doran, Boyce, Donna","Subgroup Analysis, Follow-up, Safety, Data Cutoff, Population, Regulatory, Tables, Clinical Trial, Medical Data, Pfizer, Compliance, Efficacy, Review",False,False,False,True
24__25-Nov-2020 MICHAEL SMITH _UK_ UK_.pdf,Emergency Use Authorization Acknowledgment,2020-11-25,https://drive.google.com/file/d/1rGwKJZo1Z2mfFdJvf8pGaieRREAcFCbd/view?usp=drivesdk,eua-063025,PDF,4,,letter,"Michael Smith, Kevin Senn, R. Naik, E. Sutkowski, K. Prutzman, C. Collazo, Elisa Harkins","CBER, FDA, Pharmaceutical, Pandemic Response, Vaccine, Public Health, Authorization, Acknowledgment, COVID-19, Exemption, Regulatory, EUA, BioNTech, Medical, Pfizer",True,False,False,True
23__24-Nov-2020 MICHAEL SMITH _UI_ UO_ UO_ UI_ DISCUSSION POINTS FOR 11-25 T-CON ON DATASETS - see .pdf,DISCUSSION POINTS FOR 11-25 T-CON ON DATASETS,2020-11-24,https://drive.google.com/file/d/19JpSocmIYDDSnxWXALY1cc_CLg6JK1J6/view?usp=drivesdk,eua-063025,PDF,4,,memo,"Michael Smith, Elisa Harkins","CBER, FDA, Teleconference, Vaccine, Datasets, Clinical Trials, COVID-19, Regulatory, IND, EUA, BioNTech, Pfizer, Safety Data",False,False,False,True
26__27-Nov-2020 MICHAEL SMITH _UO_ UI_ UO_ UI_ 5 CLINICAL QUESTIONS - see EDR for full communicatio.pdf,EUA 27034: IR with 5 Clinical Questions,2020-11-27,https://drive.google.com/file/d/1iiUEWhnIG3S6HE62QaT6s9ge-3_q0Utz/view?usp=drivesdk,eua-063025,PDF,2,,email,"Michael Smith, Elisa Harkins Tull, Carmel Devlin, Ramachandra Naik","Medication Error, FDA, CBER, SARS-COV-2, Follow-up Period, Vaccine, Serious Adverse Events, COVID-19, Database Variables, Dose 1, Adverse Events, Safety Population, Clinical Questions, Dose 2, Pfizer, Safety Data, Cutoff Date",False,False,False,True
25_25-Nov-2020 RAMACHANDRA NAIK _UI_ CBER comments on Pharmacovigilance Plan were sent in an email .pdf,CBER comments on Pharmacovigilance Plan,2020-11-25,https://drive.google.com/file/d/1zxtOxXU3KYLmHT-6_Ro-rxJ_N0P4_THY/view?usp=drivesdk,eua-063025,PDF,2,,memo,"Ramachandra Naik, Elisa Harkins","CBER, FDA, Post-authorization Surveillance, Vaccine Safety, Regulatory Review, COVID-19, Vaccine Development, Adverse Events, BioNTech, Multisystem Inflammatory Syndrome, Pfizer, Pharmacovigilance, Vaccine-associated Enhanced Disease",False,False,False,True
27034_S11_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-03,https://drive.google.com/file/d/1sUH9ehxMm7cC9pU7xNc4SZBKh5wIbcRl/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Public Health, Medical Countermeasures, Needs-review, COVID-19, Biologics, Regulatory, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S10_M1_cover.pdf,Request for Emergency Use Authorization (EUA) 27034,2020-12-03,https://drive.google.com/file/d/18O8TIzN5p09aBZg2gydyK0nEwL0_0j2_/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkinstull","FDA, Emergency Use Authorization, Prescribing Information, Pandemic Response, M1, Vaccine, Public Health, COVID-19, Biologics, Regulatory, Vaccine Development, BioNTech, Vaccine Distribution, Pfizer",False,False,False,True
27034_S11_M1_financial-cert-3454.pdf,Financial Certification 3454,2021,https://drive.google.com/file/d/102Ax-WG40IVY9XUR3ZsaQ9o8PkUhsg2I/view?usp=drivesdk,eua-063025,PDF,71,M1,certification,(b) (6),"CBER, FDA, Pharmaceutical, M1, Government Oversight, Medical Device, Product Approval, Regulatory Compliance, Needs-review, Regulatory Affairs, Clinical Trial, Safety Data, Financial Certification, Quality Assurance",False,False,False,True
27034_S11_M1_financial-cert-3455.pdf,Financial Certification 3455,undated,https://drive.google.com/file/d/1aS4ELE3HzFyO-qLulHJEKcUVlv2SEaml/view?usp=drivesdk,eua-063025,PDF,11,M1,certification,,"Financial Procedures, Financial Oversight, M1, Financial Policies, Financial Controls, Financial Certification, Regulatory, Internal Controls, Financial Reporting, Corporate Governance, Accounting, Compliance, Risk Management, Audit",False,False,False,True
27034_S11_M1_financial-cert-bias.pdf,Financial Certification and Disclosure - Bias Statement,2021-03,https://drive.google.com/file/d/1_iR9WPxhd7AjDDXraPFTxJbylY9FhSpL/view?usp=drivesdk,eua-063025,PDF,2,M1,report,,"Randomized Trial, Data Monitoring Committee, SARS-COV-2, M1, Clinical Research, Regulatory Compliance, COVID-19, Vaccine Development, Bias Statement, PCR Testing, Clinical Trial, Financial Disclosure, Pfizer, Blinding",False,False,False,True
27034_S11_M1_financial-cert-summary.pdf,Financial Certification and Disclosure Summary,2020-12-01,https://drive.google.com/file/d/14UueOrVfmYbigsIhLwBx3VH0T4caLTbG/view?usp=drivesdk,eua-063025,PDF,2,M1,summary,,"BNT162B2, M1, Payments, Vaccine, Equity Interest, Proprietary Interest, Clinical Trials, Regulatory Compliance, COVID-19, BioNTech, Clinical Investigators, Financial Disclosure, Pfizer, 21 Cfr Part 54",False,False,False,True
27034_S12_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-03,https://drive.google.com/file/d/1VYmQ04-qjIld6JtwP0av5n5gYZ05pISg/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D.","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine Research And Review, Vaccine, Public Health, Medical Countermeasures, COVID-19, Center For Biologics Evaluation And Research, Regulatory Affairs, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S12_M1_response-25-nov-2020-bimo.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/1JChVnjz3DlmI3vc16bPOOcMLmmexEPie/view?usp=drivesdk,eua-063025,PDF,5,M1,response,"Michael Smith, Elisa Harkins","Emergency Use Authorization, M1, Vaccine, BIMO, Pharmaceutical Development, Regulatory Compliance, COVID-19, December 2020, Adverse Events, Clinical Trial, Pfizer, Safety Data, FDA Information Request, BioNTech",False,False,False,True
27034_S13_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-04,https://drive.google.com/file/d/1bnDN-9M6HStrw0Z53HE5_WfqE_estZRe/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","FDA, Emergency Use Authorization, Bell's Palsy, Pregnancy Exposure, M1, Vaccine Research And Review, Vaccine, Active Surveillance, COVID-19, Biologics, Regulatory, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S13_M1_response-2-dec-2020-preg.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/1I7PscqdPY3F0ElMuC0IYBecCUIWxWUqg/view?usp=drivesdk,eua-063025,PDF,3,M1,response,"Michael Smith, Elisa Harkins","CBER, Emergency Use Authorization, FDA, M1, Vaccine, Reported Pregnancies, Clinical Trial, Safety, COVID-19, Regulatory, BioNTech, Pfizer, December 2020, Information Request",False,False,False,True
27034_S13_M5_c4591001-pregnancy-exp-date.pdf,Clinical Trial C4591001 Pregnancy Exposure Data,2020-12-04,https://drive.google.com/file/d/1tGZazZOsnxWrzNw58iMyHEnsQYhOlhjR/view?usp=drivesdk,eua-063025,PDF,5,M5,report,,"BNT162B2, Safety Monitoring, Pregnancy Exposure, FDA Submission, Maternal Exposure, Vaccine, Medical Events, Regulatory Compliance, M5, Patient Data, Adverse Events, Clinical Trial, Placebo, Pregnancy Outcomes",False,False,False,True
27034_S13_M1_response-2-dec-2020-bp-act-surv.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/19Zoaskz4lrF-stwtKzwRyoe5KqP5ruos/view?usp=drivesdk,eua-063025,PDF,14,M1,response,,"FDA, Bell's Palsy, M1, Vaccine, Active Surveillance, Clinical Trial, Safety, COVID-19, Regulatory, EUA, BioNTech, Pfizer, December 2020, Information Request",False,False,False,True
27034_S14_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-04,https://drive.google.com/file/d/1uFTwFlIrj39TfLIMaQiGjs8-Ydcu3F65/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","CBER, Emergency Use Authorization, FDA, Global Health, M1, Vaccine Research And Review, Vaccine, Medical Product Development, Public Health, COVID-19, Biologics, Regulatory, BioNTech, Pfizer, Pandemic",False,False,False,True
27034_S14_M5_c4591001-508-compliant-tables.pdf,c4591001-508-Compliant Tables,2014-S14,https://drive.google.com/file/d/1_Ggu52PvZws2le7IrqbUDcQpr_P_ez8C/view?usp=drivesdk,eua-063025,PDF,44,M5,report,,"Phase 2, Vaccine Trials, BNT162B2, Exclusion, Safety, Subject Disposition, COVID-19, Regulatory Compliance, Clinical Overview, Phase 1, Phase 3, Clinical Data, M5, Immunogenicity, Efficacy",False,True,False,True
27034_S15_M1_cover.pdf,Pfizer-BioNTech COVID-19 Vaccine VRBPAC Presentation,2020-12-04,https://drive.google.com/file/d/1jkRo1bxKN83OQNIPvi3vbYoOM-scLo__/view?usp=drivesdk,eua-063025,PDF,2,M1,presentation,"Marion Gruber, Ph.D., Elisa Harkins","FDA, Emergency Use Authorization, Pandemic Response, M1, Vaccine, Public Health, Clinical Trials, COVID-19, Biologics, Vaccine Development, Regulatory Affairs, BioNTech, Pfizer, VRBPAC",False,False,False,True
27034_S16_M1_cover.pdf,Request for Emergency Use Authorization (EUA) 27034 - Updated Pharmacovigilance Plan,2020-12-07,https://drive.google.com/file/d/1ynA7mtrKdxoFGhmQEcQNraNl9kNMSsnv/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkinstull","FDA, Safety Monitoring, Emergency Use Authorization, M1, Vaccine, Clinical Trials, COVID-19, Regulatory Affairs, Adverse Events, BioNTech, Product Development, Pfizer, Pharmacovigilance, Post-marketing Surveillance",False,False,False,True
27034_S16_M1_data-capture-aid-clean.pdf,Pfizer-BioNTech COVID-19 Vaccine Data Capture Aid,2020-12-07,https://drive.google.com/file/d/1iHD6h8-Oolas8EvCyAx3Mp0CAvuEjhtX/view?usp=drivesdk,eua-063025,PDF,7,M1,form,,"Adverse Event Reporting, Follow-up Questions, Data Capture, Medical Reporting, Vaccine, M1, Vaccine Safety, Patient Demographics, COVID-19, Clinical Details, Vaccine Effectiveness, BioNTech, Pfizer, Product Information",False,False,False,True
27034_S16_M1_pharmacovigilance-plan-clean.pdf,PHARMACOVIGILANCE PLAN FOR EMERGENCY USE AUTHORIZATION # 27034 OF PFIZER-BIONTECH COVID-19 VACCINE,2020-12-05,https://drive.google.com/file/d/1VVty24esWtjBV82iKN0mZKnByNiGar4P/view?usp=drivesdk,eua-063025,PDF,77,M1,plan,,"Emergency Use Authorization, Medical Product Safety, M1, COVID-19 Vaccine, Safety Specification, Public Health, Post-authorization, Clinical Trials, Regulatory Compliance, Adverse Events, Pfizer-biontech, Pharmacovigilance, Risk Management, Vaccine Monitoring",False,False,False,True
27034_S16_M1_pharmacovigilance-plan-track.pdf,Pharmacovigilance Plan for Emergency Use Authorization # 27034 of Pfizer-BioNTech COVID-19 Vaccine,2020-11-19,https://drive.google.com/file/d/1Nftfc7nne4HPnUonx9kgW4FEatg2aRHc/view?usp=drivesdk,eua-063025,PDF,77,M1,plan,,"Emergency Use Authorization, M1, Vaccine, Safety Specification, Public Health, Post-authorization, Clinical Trials, Regulatory Compliance, COVID-19, Adverse Events, Pfizer-biontech, Pharmacovigilance, Surveillance, Risk Management",False,False,False,True
27034_S17_M1_cover.pdf,Response to FDA 5 December 2020 Comments on the Full EUA Prescribing Information and Fact Sheets,2020-12-07,https://drive.google.com/file/d/1x-CZHhNSlAjS-YS4h70m0yDXmZmKu-TJ/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","Pfizer-biontech Vaccine, Emergency Use Authorization, FDA Comments, Prescribing Information, M1, Biologics Evaluation And Research, COVID-19, Vaccine Licensing, Confidential Information, Fact Sheets, Vaccine Development, Vaccine Registration, Vaccine Research And Review, Global Product Development",False,False,False,True
27034_S16_M1_data-capture-aid-track.pdf,Pfizer-BioNTech COVID-19 Vaccine Data Capture Aid,2020-12-05,https://drive.google.com/file/d/1PqIZsETQfs-ioRb9xZr-vKmokheU8-dK/view?usp=drivesdk,eua-063025,PDF,6,M1,form,,"Adverse Event Reporting, M1, Data Capture, Medical Reporting, Vaccine, Vaccine Safety, Patient Demographics, Regulatory Compliance, COVID-19, Clinical Details, Vaccine Effectiveness, Healthcare Provider, Pharmacovigilance, Product Information",False,False,False,True
27034_S17_M1_fact-sheet-recipients-lab-1451-0-5-annotated.pdf,Fact Sheet for Recipients and Caregivers - Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/16RdEN8CTdUTFtJ5U7jPccJZMkLTNf67K/view?usp=drivesdk,eua-063025,PDF,6,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, FDA, SARS-COV-2, Symptoms, M1, Coronavirus, COVID-19, Respiratory Illness, Vaccination, Recipients, Vaccine Information, Caregivers, Pandemic",False,False,False,True
27034_S18_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-07,https://drive.google.com/file/d/1nBRf3VS7toANk9usv9RIX-4o-qpCt1Ys/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","FDA, Emergency Use Authorization, Pandemic Response, M1, Vaccine Research And Review, Vaccine, Public Health, COVID-19, Biologics, Regulatory Affairs, Vaccine Registration, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S17_M1_hcp-fact-1450-0-5-pi-lab-1457-0-5-annotated.pdf,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/1mdedjAQegghVSFBy9uj-a0Htuf8VB9Tl/view?usp=drivesdk,eua-063025,PDF,33,M1,fact sheet,,"Emergency Use Authorization, SARS-COV-2, Healthcare Providers, Intramuscular Injection, Two-dose Series, Vaccine, M1, Pandemic, Clinical Trials, COVID-19, Vaccination Program, Adverse Events, Multisystem Inflammatory Syndrome, Respiratory Illness",False,False,False,True
27034_S18_M1_response-4-dec-2020-biostat.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/1vhppfPY7MMmNfxyNSbPFVzq0cS7l5t4H/view?usp=drivesdk,eua-063025,PDF,11,M1,response,"Michael Smith, Elisa Harkins","Emergency Use Authorization, FDA, Pharmaceutical, M1, Vaccine, Safety Analysis, Variable Derivation, Dataset, COVID-19, Regulatory, BioNTech, Medical, Pfizer, December 2020",False,False,False,True
27034_S19_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-08,https://drive.google.com/file/d/1xVywv7cegas_o20bKyzB50kC6r-0ox8-/view?usp=drivesdk,eua-063025,PDF,2,M1,correspondence,"Marion Gruber, Ph.D.","Emergency Use Authorization, FDA, Healthcare Providers, Vaccine Education, M1, Vaccine, Public Health, COVID-19, Biologics, Regulatory, Vaccine Administration, BioNTech, Vaccine Distribution, Pfizer, Pandemic",False,False,False,True
27034_S1_M1_bnt-25pk-carton-wave2-kzoo5.pdf,Pfizer-BioNTech COVID-19 Vaccine,2020-11-19,https://drive.google.com/file/d/16KKM53MSbXaUWkfuGzbogkkwUEEEM-Lt/view?usp=drivesdk,eua-063025,PDF,1,M1,product information,"Pfizer Inc, BioNTech Manufacturing GmbH","Emergency Use Authorization, M1, Intramuscular Injection, Sterile Saline Diluent, COVID-19 Vaccine, Medical Product Labeling, Storage Requirements, Multiple Dose Vials, BioNTech, Vaccine Distribution, Pfizer, Suspension, Dosage And Administration, Pharmaceutical Manufacturing",False,False,False,True
27034_S1_M1_bnt-25pk-carton-wave2-puurs5.pdf,Pfizer-BioNTech COVID-19 Vaccine Carton,2020-11-19,https://drive.google.com/file/d/1u74Uyo46qxgv6LE7Amg-jjmydok57LlB/view?usp=drivesdk,eua-063025,PDF,1,M1,packaging,,"Emergency Use Authorization, Manufacturing Information, Intramuscular Injection, Product Labeling, Vaccine, Puurs, M1, Storage Requirements, Carton Packaging, COVID-19, BioNTech, Pfizer, Dosage And Administration, Multiple Dose",False,False,False,True
27034_S1_M1_c4591011-draft-protocol.pdf,Pfizer-BioNTech COVID-19 Vaccine C4591011 Non-Interventional Study Protocol,2020-11-18,https://drive.google.com/file/d/1kSPEotJzYrZNkoTrpR6Grj-3RshQcOez/view?usp=drivesdk,eua-063025,PDF,26,M1,protocol,,"Emergency Use Authorization, M1, Safety Surveillance, Vaccine Utilization, COVID-19 Vaccine, Real-world Data, Incidence Rates, Healthcare System, Vaccine Enhanced Disease, Adverse Events, Department Of Defense, Pfizer-biontech, FDA Review, Secondary Data Collection",False,False,False,True
27034_S1_M1_c4591012-draft-protocol.pdf,Post-Emergency Use Authorization Active Surveillance of Adverse Events of Special Interest among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2020-11-18,https://drive.google.com/file/d/1LFdZFACuaU8lQRk8p3AmzczRGvqE2JiJ/view?usp=drivesdk,eua-063025,PDF,35,M1,study protocol,,"BNT162B2, Medical Research, M1, Veteran's Affairs Health System, COVID-19 Vaccine, Post-authorization Surveillance, Vaccine Utilization, Vaccine Safety, Incidence Rates, Clinical Events, Adverse Events, Vaccine Effectiveness, Public Health Monitoring, FDA Review",False,False,False,True
27034_S1_M1_c4591008-draft-protocol.pdf,Post-Emergency Use Authorization Observational Cohort Study to evaluate the safety of SARS-COV-2 RNA Vaccine in Healthcare Workers,2020-11-19,https://drive.google.com/file/d/1V3GPWdkb4i2xOBbpipsB4hTurmsSiTRy/view?usp=drivesdk,eua-063025,PDF,30,M1,protocol,,"SARS-COV-2, M1, Observational Study, Vaccine Utilization, Exclusion, Active Surveillance, Real-world Data, Vaccine Safety, Post-authorization, COVID-19, Adverse Events, Pfizer-biontech, Primary Data Collection, Healthcare Workers, FDA Review",False,True,False,True
27034_S1_M1_cross-reference.pdf,Cross-Reference to Previously Submitted Information,2020-11,https://drive.google.com/file/d/1PZ82ORj04ZU1oOy_zQUUJ7bCCf4DDjZo/view?usp=drivesdk,eua-063025,PDF,3,M1,report,,"CMC Amendment, Pfizer Confidential, M1, Nonclinical Overview, Vaccine, EUA Application, Pharmacology, COVID-19, Regulatory, Pharmacokinetics, Cross-reference, Toxicology, Ind019736, Investigational Drug",False,False,False,True
27034_S1_M1_cover.pdf,Request for Emergency Use Authorization 27034,2020-11-20,https://drive.google.com/file/d/1OnT0qBXgdS1-jlXZBjb-iyTIdD6jlSKT/view?usp=drivesdk,eua-063025,PDF,2,M1,request,"Marion Gruber, Ph.D.","FDA, Emergency Use Authorization, SARS-COV-2, Pandemic Response, M1, COVID-19 Vaccine, Pharmaceutical Development, Public Health, Clinical Trials, Biologics, Vaccine Licensing, Regulatory Affairs, Infectious Disease, Pfizer-biontech",False,False,False,True
27034_S1_M1_data-capture-aid.pdf,BNT162b2 Vaccine Data Capture Aid,2020-11-19,https://drive.google.com/file/d/1ZOO-SobDb66VyKMsQ28Xi-rmfIdbRnEW/view?usp=drivesdk,eua-063025,PDF,6,M1,form,,"Pharmaceutical, Internal Use, M1, Vaccine, Vaccine Safety, Adverse Event, Regulatory Compliance, COVID-19, Product Details, Clinical Details, Vaccine Effectiveness, Data Collection, Reporter Details, Patient Information",False,False,False,True
27034_S1_M1_eua.pdf,Pfizer-BioNTech EUA for Pfizer-BioNTech COVID-19 Vaccine,2020-11-20,https://drive.google.com/file/d/1LZI_oEzNiYTlcyHxuwcs-nJutowGk2sD/view?usp=drivesdk,eua-063025,PDF,215,M1,request,,"Emergency Use Authorization, M1, Manufacturing, Vaccine, Clinical Studies, Coronavirus, COVID-19, Regulatory, Unmet Need, BioNTech, Preclinical Studies, Pfizer, Spike Glycoprotein, Rna-lipid Nanoparticle",False,False,False,True
27034_S1_M1_paa156051-vial.pdf,Pfizer-BioNTech COVID-19 Vaccine Vial Label,2011-06-08,https://drive.google.com/file/d/1nNV97aYOiJiL8x30nkvq6w5nZTMWdd-g/view?usp=drivesdk,eua-063025,PDF,1,M1,label,,"Emergency Use Authorization, NDC, M1, Intramuscular, Vaccine, Expiration, Vial, COVID-19, Dilution, Barcode, Label, Lot Number, BioNTech, Pfizer",False,False,False,True
27034_S1_M1_meeting-correspondence-pre-eua-responses.pdf,Pre-EUA Meeting Correspondence for COVID-19 Vaccine,2020-11-17,https://drive.google.com/file/d/1rvimdqcnxZOLLvJw19-UunCvoPq1IiSt/view?usp=drivesdk,eua-063025,PDF,8,M1,meeting correspondence,"Elisa Harkins, Ramachandra Naik, Meghna Alimchandani, Maria Allende, Brenda Baldwin, Anissa Cheung, Carmen Collazo, Oluchi Elekwachi, John Eltermann, Karen Farizo, Doran Fink, Theresa Finn, Laura Fontan, Sara Gagneten, Ravi Goud, Martin (Dave) Green, Marion Gruber","FDA, Clinical, SARS-COV-2, Pandemic Response, M1, Vaccine, Nonclinical, Public Health, Pharmaceutical Development, COVID-19, BNT162, Pre-eua, Regulatory, Lipid Nanoparticles, Labeling, Active Immunization",False,False,False,True
27034_S1_M1_paa160560-carton.pdf,Pfizer-BioNTech COVID-19 Vaccine Carton,2011-06-08,https://drive.google.com/file/d/1hvF5jUExLxpMlbEuwfpQN_QQwGMhRdHP/view?usp=drivesdk,eua-063025,PDF,1,M1,label,,"Emergency Use Authorization, Pharmaceutical, M1, Vaccine, Administration, Storage, Carton, COVID-19, Dosage, Packaging, Healthcare, BioNTech, Medical, Pfizer",False,False,False,True
27034_S1_M1_paa156052-carton.pdf,Pfizer-BioNTech COVID-19 Vaccine Carton Label,2011-06-08,https://drive.google.com/file/d/19zzqfmGdijdoQYhGkFkg-KC3goaHfCMi/view?usp=drivesdk,eua-063025,PDF,1,M1,label,,"Emergency Use Authorization, Pharmaceutical, M1, Intramuscular Injection, Vaccine, Administration, Storage, Multiple Dose Vials, COVID-19, Dosage, BioNTech, Medical, Pfizer, Suspension",False,False,False,True
27034_S1_M1_pharmacovigilance-plan.pdf,Pharmacovigilance Plan for Emergency Use Authorization # 27034 of Pfizer-BioNTech COVID-19 Vaccine,2020-11-19,https://drive.google.com/file/d/1LTtDh6DLKsplk_PmhNDC77vaJ7Wjqtpq/view?usp=drivesdk,eua-063025,PDF,72,M1,plan,,"Emergency Use Authorization, M1, COVID-19 Vaccine, Safety Specification, Vaccine Safety, Post-authorization, Public Health, Regulatory Compliance, Clinical Data, Adverse Events, Pfizer-biontech, Pharmacovigilance, Surveillance, Risk Management",False,False,False,True
27034_S1_M1_response-18nov2020-ir-vrbpac.pdf,"COVID-19 Vaccine (BNT162, PF-07302048) Response to FDA Information Request",2020-11-18,https://drive.google.com/file/d/163qUZB8LNqRbPSzgcBnOMI_VqQtvKpNa/view?usp=drivesdk,eua-063025,PDF,5,M1,response,,"Pfizer Confidential, November 2020, M1, Vaccine, Bb-ind 19736, Clinical Trials, Regulatory Compliance, COVID-19, BNT162, VRBPAC Meeting, Vaccine Development, PF-07302048, Pharmaceutical Research, FDA Information Request",False,False,False,True
27034_S1_M1_pi-lab-1457-0-3-annotated.pdf,PFIZER-BIONTECH COVID-19 VACCINE FULL PRESCRIBING INFORMATION,2021,https://drive.google.com/file/d/1xDOJZGTvpttPkgIKQbsot01_X5HI5xsy/view?usp=drivesdk,eua-063025,PDF,22,M1,prescribing information,,"Emergency Use Authorization, Pharmaceutical, M1, Vaccine, Safety, Clinical Trial Results, Patient Counseling, Public Health, COVID-19, Medical Information, Regulatory, Adverse Events, Storage And Handling, Dosage And Administration",False,False,False,True
27034_S1_M1_safety-surveillance-plan.pdf,BNT162b2 (COVID-19 Vaccine) Emergency Use Authorization Safety Surveillance Study Plan,2020-10-19,https://drive.google.com/file/d/1qqxIBbS1bx84fjTVEQn7vIxJqEIUBOap/view?usp=drivesdk,eua-063025,PDF,8,M1,study plan,,"Emergency Use Authorization, BNT162B2, United States, Pharmacovigilance, Safety Surveillance, M1, COVID-19 Vaccine, Public Health, Post-authorization, Regulatory Compliance, Adverse Events, Pfizer, Non-interventional Study, Vaccine Monitoring",False,False,False,True
27034_S1_M5_c4591001-safety-listing-ae.pdf,Listing of Adverse Events – All Subjects,2020-11-19,https://drive.google.com/file/d/1_KhSjFOI7zJwofEtAgWuUmfACSaeTzXA/view?usp=drivesdk,eua-063025,PDF,1933,M5,report,,"Vaccine, Subject Information, Safety, Case Report, Drug Development, Regulatory Compliance, M5, Adverse Events, Medical Review, Clinical Trial, Pharmaceutical Research, Medical Data, Health Monitoring, Patient Outcomes",False,False,False,True
27034_S1_M5_bnt162-list-of-invest-cvs-providers.pdf,BNT162 Interim Clinical Study Report,2020-09-08,https://drive.google.com/file/d/1-Mvyi8gc2BySu7UosZckseRax01XJXhv/view?usp=drivesdk,eua-063025,PDF,2,M5,report,"Dr. Dr. med. Armin Schultz, Dr. med. Sybille Baumann, Dr. med. Matthias Berse, Manuela Casjens MD, Dr. med. Friedeborg Seitz","Statistics, Cro, Investigators, Medical Monitoring, COVID-19, BNT162, Interim Report, Clinical Study, M5, Vaccine Development, Pharmaceutical Research, Clinical Trial, Confidential, Central Laboratory",False,False,False,True
27034_S1_M5_c4591001-safety-listing-demographic.pdf,Listing of Demographic Characteristics – All Subjects,2020-07-28,https://drive.google.com/file/d/1PEU04saBgqsr_7N9exFbZkCMomFftf-L/view?usp=drivesdk,eua-063025,PDF,3118,M5,report,,"Sex, Race, Medical Research, Weight, Safety Listing, Height, BMI, Subject Characteristics, Ethnicity, M5, Demographic Data, Age, Clinical Trial, Informed Consent",False,False,False,True
27034_S1_M5_c4591001-safety-listings.pdf,Safety Listings for c4591001 Study,2021,https://drive.google.com/file/d/1CDesSV5NpL9GjmVBH7nyX3lqjsJHgkzT/view?usp=drivesdk,eua-063025,PDF,278,M5,report,,"Phase 2/3 Analysis, Safety Listings, Vaccine Study, Exclusion, Reactogenicity, Multiple Site Enrollment, Regulatory Compliance, C4591001, M5, Medication Errors, Adverse Events, Subject Withdrawals, Clinical Trial, Safety Population, Safety Data",False,True,False,True
27034_S20_M1_cover.pdf,Request for Emergency Use Authorization (EUA) 27034,2020-12-08,https://drive.google.com/file/d/11y76LJP06lwyj0Xlga0b-n6YKV7Vgx5m/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","FDA, Emergency Use Authorization, Vaccine Presentation, M1, Vaccine, Vaccine Efficacy, Vaccine Safety, COVID-19, Biologics, Vaccine Data, Vaccine Development, BioNTech, Pfizer, VRBPAC",False,False,False,True
27034_S21_M1_cross-reference-track.pdf,Cross-Reference to Previously Submitted Information,2021-01,https://drive.google.com/file/d/1iLR20S3mUTcUfDkV3HW2yZtKXFYNQRc6/view?usp=drivesdk,eua-063025,PDF,3,M1,report,,"CMC Amendment, Clinical Trial Data, M1, Nonclinical Overview, Pharmaceutical Development, Investigational Brochure, EUA Application, Pharmacology, Regulatory Compliance, Needs-review, Pharmacokinetics, Toxicology, Ind019736",False,False,False,True
27034_S21_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-09,https://drive.google.com/file/d/1N_ewjGFkfi4K5gYU3lzmZlqm9EG4oHXc/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Vaccine Efficacy, Public Health, Vaccine Safety, Clinical Trials, COVID-19, Biologics, Regulatory Affairs, Vaccine Development, BioNTech, Pfizer",False,False,False,True
27034_S21_M1_eua-track.pdf,Pfizer-BioNTech EUA for Pfizer-BioNTech COVID-19 Vaccine,2020-12-08,https://drive.google.com/file/d/1kEy2auVB351K4KfqA33DhUEkMIMoui6L/view?usp=drivesdk,eua-063025,PDF,215,M1,request,,"Emergency Use Authorization, M1, Manufacturing, Vaccine, Clinical Studies, Coronavirus, COVID-19, Regulatory, Unmet Need, BioNTech, Preclinical Studies, Pfizer, Spike Glycoprotein, Rna-lipid Nanoparticle",False,False,False,True
27034_S21_M1_cross-reference.pdf,Cross-Reference to Previously Submitted Information,2021,https://drive.google.com/file/d/1weuMVR0x3JzCzvAeA9UJq9M4Eo4kW4l5/view?usp=drivesdk,eua-063025,PDF,3,M1,report,,"CMC Amendment, M1, Nonclinical Overview, COVID-19 Vaccine, EUA Application, Pharmacology, Regulatory, 2021, Pharmacokinetics, Cross-reference, Toxicology, Clinical Development, Ind019736, Pfizer",False,False,False,True
27034_S21_M1_eua.pdf,Pfizer-BioNTech EUA for Pfizer-BioNTech COVID-19 Vaccine,2020-12-07,https://drive.google.com/file/d/1hBu3O4xPTP2pwEcQrOYDWevkvn1ikhwy/view?usp=drivesdk,eua-063025,PDF,215,M1,request,,"Emergency Use Authorization, FDA, M1, Vaccine, Safety, Public Health, Coronavirus, Clinical Trials, COVID-19, EUA, BioNTech, Pfizer, Efficacy, Pandemic",False,False,False,True
27034_S22_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-09,https://drive.google.com/file/d/1tvzbd1ARtr4tIxUyJovhms6A6nGNSDEc/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Michael Smith, Ramachandra Naik","Emergency Use Authorization, FDA, Pharmaceutical, Healthcare Providers, Medical Research, M1, Vaccine, Public Health, COVID-19, Biologics, Regulatory, Clinical Data, Fact Sheet, BioNTech, Pfizer, Pandemic",False,False,False,True
27034_S22_M1_fact-sheet-recipients-lab-1451-0-6-annotated.pdf,Fact Sheet for Recipients and Caregivers - Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/1qbqPAO9itKz2eQhZpLwkC19e5-VikQnP/view?usp=drivesdk,eua-063025,PDF,6,M1,fact sheet,,"Emergency Use Authorization, FDA, SARS-COV-2, Symptoms, M1, Vaccine, Coronavirus, Pandemic, COVID-19, Respiratory Illness, Vaccination, Recipients, Pfizer-biontech, Caregivers",False,False,False,True
27034_S22_M5_c4591001-adr.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034,2020-12,https://drive.google.com/file/d/1tR2kCSZ6n43UdnDlGwFk6mURgpTCKFog/view?usp=drivesdk,eua-063025,PDF,4,M5,amendment,,"Emergency Use Authorization, Intensive Care, Healthcare Providers, Vaccine, Prescribers, Clinical Information, Severe Cases, CDC Definition, COVID-19, M5, Regulatory, Mechanical Ventilation, Hospitalization, Efficacy Analysis, December 2020",False,False,False,True
27034_S22_M1_hcp-fact-1450-0-5-pi-lab-1457-0-6-annotated.pdf,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers),2020-12,https://drive.google.com/file/d/1lRJq4SX3TZJV_3Rnj6VKPTNZE3mN30nU/view?usp=drivesdk,eua-063025,PDF,31,M1,fact sheet,,"Emergency Use Authorization, Healthcare Providers, M1, Vaccine, Public Health, Medical Guidance, Coronavirus, Clinical Trials, COVID-19, Regulatory, Vaccination, Pfizer-biontech, Immunization, Pandemic",False,False,False,True
27034_S23_M1_response-y-dec-2020-act-surv.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA27034 Response,2020-12,https://drive.google.com/file/d/1acihrAOxfCxtap-usX3wEgkihTlIOZG4/view?usp=drivesdk,eua-063025,PDF,4,M1,response,"Captain Michael Smith, Elisa Harkins","FDA, M1, Protocol Submission, Vaccine, Active Surveillance, Veterans Health Administration, Final Report, COVID-19, Needs-review, Milestone Dates, EUA, Department Of Defense, Study Completion, Healthcare Workers",False,False,False,True
27034_S23_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-09,https://drive.google.com/file/d/1HWzBKM9qsy-wZzv0zAU3tJvLyJEVzDaR/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Public Health, Medical Countermeasures, COVID-19, Regulatory, Vaccine Development, BioNTech, Pfizer, Global Product Development, Active Surveillance Studies",False,False,False,True
27034_S24_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-10,https://drive.google.com/file/d/1MSeEYnptb6zXbJF6XA95aCxUkrSVo0Ag/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","Emergency Use Authorization, FDA, Medical Products, Pandemic Response, M1, Vaccine, Public Health, COVID-19, Biologics, Regulatory Affairs, Healthcare, BioNTech, Pfizer, Pharmaceuticals",False,False,False,True
27034_S24_M1_hcp-fact-1450-0-7-pi-lab-1457-0-7-annotated.pdf,Fact Sheet for Healthcare Providers Administering Vaccine,2020-12,https://drive.google.com/file/d/1PoyiuXJgbAcK1TjrLNXMX4MI4p5Wfqt7/view?usp=drivesdk,eua-063025,PDF,30,M1,fact sheet,,"Emergency Use Authorization, Healthcare Providers, M1, Vaccine, Public Health, Medical Guidance, Coronavirus, Regulatory Compliance, COVID-19, Vaccination Program, Adverse Events, Pfizer-biontech, Immunization, Pandemic",False,False,False,True
27034_S24_M1_fact-sheet-recipients-lab-1451-0-7-annotated.pdf,Fact Sheet for Recipients and Caregivers - Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine,2020-12,https://drive.google.com/file/d/1uNrhebrfWN3S1P8BmvcWGVAyuolVYDos/view?usp=drivesdk,eua-063025,PDF,6,M1,fact sheet,,"Pfizer-biontech Vaccine, Emergency Use Authorization, M1, Vaccine Efficacy, Public Health, Medical Guidance, Coronavirus, Vaccine Safety, Disease Prevention, COVID-19, Recipients, Vaccine Information, Caregivers, Pandemic",False,False,False,True
27034_S25_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-11,https://drive.google.com/file/d/1nShiJkSKAPRodZdRM185w5gsDxlHe-2D/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Public Health, Needs-review, COVID-19, Biologics, Regulatory Affairs, Vaccine Development, BioNTech, Pfizer, Pharmacovigilance",False,False,False,True
27034_S25_M1_response-9-dec-2020-pvp-appendix1.pdf,CIOMS FORUM SPECIAL DRUG SAFETY UPDATE,2020-12-09,https://drive.google.com/file/d/1ovyb8h5HiVzbe2Dc8IpFGLJp4ihVTQ6Y/view?usp=drivesdk,eua-063025,PDF,8,M1,report,,"M1, CIOMS, Clinical Trials, Regulatory Compliance, Patient Safety, Medical Information, Pharmaceutical Industry, Adverse Events, Data Analysis, Healthcare, Pharmacovigilance, Risk Management, Post-marketing Surveillance, Drug Safety",False,False,False,True
27034_S25_M1_response-9-dec-2020-pvp.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12-11,https://drive.google.com/file/d/1TVSps5RWrEFxe14Yon2Uiu6xBD5CkfDV/view?usp=drivesdk,eua-063025,PDF,9,M1,response,,"Emergency Use Authorization, FDA, Allergic Reactions, M1, Vaccine, Clinical Trial, Safety, Exclusion, COVID-19, Adverse Events, EUA, BioNTech, Pfizer, Pharmacovigilance, Anaphylaxis",False,True,False,True
27034_S26_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-11,https://drive.google.com/file/d/1QG6wTEYjl0CpTwirNAAq8GYgKUh6XB-t/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D.","Emergency Use Authorization, FDA, Pharmaceutical, Pandemic Response, M1, Vaccine Research And Review, Vaccine, Public Health, COVID-19, Biologics, Regulatory Affairs, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S28_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-11,https://drive.google.com/file/d/1Xqc034x87pBR2bGARh8vgz3IDvPQcYgP/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Michael Smith, Ramachandra Naik","FDA, Emergency Use Authorization, Healthcare Providers, Pandemic Response, M1, Vaccine, COVID-19, Biologics, Regulatory, Recipients, Vaccine Development, Fact Sheet, BioNTech, Pfizer, Caregivers",False,False,False,True
27034_S26_M1_response-10-dec-2020.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/1BTQ-3u_1nZWUN6MZAvFTTHuvZjn0CirI/view?usp=drivesdk,eua-063025,PDF,4,M1,response,"Ramachandra S. Naik, Elisa Harkins","EUA 27034, FDA, CBER, M1, Oversight, Manufacturing, Vaccine, Public Health, mRNA, Coronavirus, COVID-19, Collaboration Agreement, Regulatory, BioNTech, Pfizer, Information Request, Pandemic",False,False,False,True
27034_S27_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-11,https://drive.google.com/file/d/1mz1tY33UxULbUUQJmtLmpyZ_l4lHuIEH/view?usp=drivesdk,eua-063025,PDF,2,M1,presentation,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Needs-review, COVID-19, Biologics, Regulatory Affairs, Vaccine Development, BioNTech, Pfizer, Global Product Development, VRBPAC",False,False,False,True
27034_S28_M1_hcp-fact-1450-1-0-pi-lab-1457-1-0-annotated.pdf,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers),2020-12,https://drive.google.com/file/d/1q9Q-eUGYi8xoaGBcnDBdYXj9uHz6VmxC/view?usp=drivesdk,eua-063025,PDF,29,M1,fact sheet,,"Emergency Use Authorization, Reporting Requirements, SARS-COV-2, Healthcare Providers, Intramuscular Injection, M1, Vaccine, Coronavirus, COVID-19, Vaccination, Adverse Events, Pfizer-biontech, Immunization, Pandemic",False,False,False,True
27034_S2_M1_cover.pdf,Request for Emergency Use Authorization 27034,2020-11-23,https://drive.google.com/file/d/15W2MnBmJYxR_DDCcdsUD35yegAu5tU8M/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Ramachandra Naik","CBER, FDA, Emergency Use Authorization, Regulatory Submission, Product Labeling, Pandemic Response, M1, Vaccine, Public Health, COVID-19, Biologics, Adverse Events, BioNTech, Product Development, Pfizer",False,False,False,True
27034_S3_M1_cover.pdf,Request for Emergency Use Authorization 27034,2020-11-25,https://drive.google.com/file/d/1fWPFLpXA8KdKsSOvLrAHDxnu4CWAt5tA/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, Vaccine Amendment, M1, COVID-19 Vaccine, Vaccine Efficacy, Vaccine Safety, Vaccine Documentation, Vaccine Program, Vaccine Submission, Vaccine Licensing, Regulatory Affairs, Vaccine Development, Vaccine Registration, Pfizer-biontech, Vaccine Distribution",False,False,False,True
27034_S2_M5_c4591001-narratives.pdf,Pfizer COVID-19 Vaccine Clinical Trial Narratives,2020-11-22,https://drive.google.com/file/d/1mUznjCCh7Z8KA8CI8Ob8KQufQx67QlqH/view?usp=drivesdk,eua-063025,PDF,1050,M5,report,,"Subject Narratives, Vaccine, Safety, Serious Adverse Events, COVID-19, M5, Regulatory, Protocol, Subject Withdrawals, Adverse Events, EUA, Clinical Trial, Medical Review, Pfizer",False,False,False,True
27034_S3_M1_eua-amend-sec-11.pdf,Amendment to Pfizer-BioNTech COVID-19 Vaccine EUA,2020-11-25,https://drive.google.com/file/d/1XQkOKoQP6p0z142A-0mJvzl3LDrcVTVG/view?usp=drivesdk,eua-063025,PDF,3,M1,amendment,,"Emergency Use Authorization, Advanced Technology International, Pharmaceutical, M1, Vaccine, Bulk Shipment, Contract, COVID-19, Finished Doses, Regulatory, MCDC, EUA, BioNTech, Pfizer, United States Government, Program Schema",False,False,False,True
27034_S4_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-11-25,https://drive.google.com/file/d/1_cafqzz_-7-asNc86Dfmu_x3ztQ784ty/view?usp=drivesdk,eua-063025,PDF,2,M1,briefing,"Marion Gruber, Ph.D.","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Medical Product Development, Public Health, Clinical Trials, COVID-19, Biologics, Regulatory Affairs, BioNTech, Pfizer, VRBPAC",False,False,False,True
27034_S4_M1_response-17-and19-nov-2020.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-11,https://drive.google.com/file/d/1UfHjPn3OR1tx6AGsulHhf-ilayFc_FR7/view?usp=drivesdk,eua-063025,PDF,13,M1,response,,"CBER, Emergency Use Authorization, FDA, November 2020, M1, Vaccine, Safety, COVID-19, Clinical Data, EUA, BioNTech, Pfizer, Information Request, Efficacy",False,False,False,True
27034_S4_M1_pi-lab-1457-0-4-annotated.pdf,PFIZER-BIONTECH COVID-19 VACCINE FULL PRESCRIBING INFORMATION,2021,https://drive.google.com/file/d/1O4-vhnqChlAF4ZgIHB3MPjPxhOw5bW5E/view?usp=drivesdk,eua-063025,PDF,24,M1,prescribing information,,"Emergency Use Authorization, SARS-COV-2, M1, Vaccine, Administration, Safety, Clinical Trials, COVID-19, Dosage, Adverse Events, BioNTech, Pfizer, Immunization, Pandemic",False,False,False,True
27034_S5_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-11-27,https://drive.google.com/file/d/1e6H0lt9KrzEHWFjNVRCAo9gP2mRbM8Wy/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D.","CBER, Emergency Use Authorization, FDA, Regulatory Submission, Pandemic Response, M1, Vaccine, Public Health, Data Discussion, COVID-19, Biologics, Clinical Data, BioNTech, Pfizer, Information Request",False,False,False,True
27034_S4_M5_c4591001-508-compliant-tables.pdf,c4591001-508-Compliant Tables,2020-11-25,https://drive.google.com/file/d/1AAosum5oigifO33cDMVVB-cJ6Zqat2aX/view?usp=drivesdk,eua-063025,PDF,45,M5,report,,"FDA, BNT162B2, Pharmaceutical, Vaccine, Exclusion, Safety, Clinical Trials, Subject Disposition, COVID-19, Randomized, Regulatory Compliance, M5, Adverse Events, Immunogenicity, Efficacy",False,True,False,True
27034_S5_M1_response-23-nov-2020-appendix-1.pdf,Vaccine Efficacy - First COVID-19 Occurrence,2020-11-27,https://drive.google.com/file/d/1gG9DvwXg0yml0bPcI0i2HApvZX1QcQmz/view?usp=drivesdk,eua-063025,PDF,4,M1,report,,"CBER, FDA, Asymptomatic, M1, Serostatus, Vaccine Efficacy, Vaccine Group, COVID-19, Surveillance Time, Dose 1, Dose 2, Control Group, Clinical Trial, RT-PCR",False,False,False,True
27034_S5_M1_response-23-nov-2020.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-11-23,https://drive.google.com/file/d/1cWLGVz1YRyDq80rewjOCeCGjo6quxFFK/view?usp=drivesdk,eua-063025,PDF,11,M1,response,,"Emergency Use Authorization, FDA, Pharmaceutical, November 2020, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Data, BioNTech, Pfizer, Information Request, Pandemic",False,False,False,True
27034_S5_M1_response-24-nov-2020.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-11,https://drive.google.com/file/d/11cv1f-ILsqxosEC1h5ybJvFC0LqEmorO/view?usp=drivesdk,eua-063025,PDF,28,M1,response,,"Emergency Use Authorization, FDA, Pharmaceutical, November 2020, M1, Vaccine, COVID-19, Regulatory, Clinical Data, EUA, BioNTech, Medical, Pfizer, Information Request",False,False,False,True
27034_S6_M1_cover.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA Request,2020-11-30,https://drive.google.com/file/d/1TBUX6579qMucAupglp3argYJRZs6h1sn/view?usp=drivesdk,eua-063025,PDF,2,M1,briefing,"Marion Gruber, Ph.D.","Emergency Use Authorization, Vaccine Approval, Pandemic Response, M1, COVID-19 Vaccine, Vaccine Efficacy, Vaccine Safety, Biologics, Vaccine Advisory Committee, Vaccine Development, Vaccine Review, BioNTech, Vaccine Distribution, Pfizer",False,False,False,True
27034_S7_M1_eua-amend-sec-13-2.pdf,Amendment to EUA 27034 for Pfizer-BioNTech COVID-19 Vaccine,2020-11-30,https://drive.google.com/file/d/1qeFqpUFsgoViTDYwPWnOOKNQUUEcOp26/view?usp=drivesdk,eua-063025,PDF,4,M1,amendment,,"Emergency Use Authorization, Adverse Event Reporting, M1, Vaccine, Public Health, COVID-19, Regulatory, Healthcare, EUA, BioNTech, Medical, Pfizer, VAERS, Pandemic",False,False,False,True
27034_S7_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-11-30,https://drive.google.com/file/d/1LIZAfBx-9PzekDhDWs3n6osyGGQO9k5Q/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Global Product Development, Pandemic Response, Medical Research, M1, Vaccine, Public Health, COVID-19, Biologics, Regulatory Affairs, BioNTech, Pfizer, Pharmacovigilance",False,False,False,True
27034_S8_M1_response-27-nov-2020.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-11,https://drive.google.com/file/d/1IkbSx24c3mBU8AnlDywEMBbJ4llXylng/view?usp=drivesdk,eua-063025,PDF,10,M1,response,,"EUA 27034, Emergency Use Authorization, Pharmaceutical, Pandemic Response, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Clinical Data, BioNTech, Pfizer, FDA Information Request",False,False,False,True
27034_S7_M1_response-25-nov-2020-pvp.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-11-30,https://drive.google.com/file/d/1j7izk7U3Sqa7u5Q8BwvvvteIFyofaUVY/view?usp=drivesdk,eua-063025,PDF,5,M1,response,,"FDA, M1, Vaccine, Clinical Trial, Safety, Pediatric Age Groups, COVID-19, Regulatory, EUA, BioNTech, Multisystem Inflammatory Syndrome, Pfizer, Pharmacovigilance, Information Request",False,False,False,True
27034_S8_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-01,https://drive.google.com/file/d/1tTtYjJ-JKfzt_9vwjdvrFscEDyM5wZKR/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Pandemic Response, M1, Vaccine, Public Health, Medical Countermeasures, Needs-review, COVID-19, Biologics, Regulatory, BioNTech, Pfizer, Global Product Development",False,False,False,True
27034_S8_M5_c4591001-table-rr-508-8-15.pdf,Listing of Subjects With Symptoms of COVID-19 but not Confirmed Cases by PCR - Dose 1 All-Available Efficacy Population,2020-11-30,https://drive.google.com/file/d/11y1dNm16062nvKGV0227D58nQv4frpeW/view?usp=drivesdk,eua-063025,PDF,398,M5,report,"C4591001 1001 10011096, C4591001 1001 10011108, C4591001 1001 10011111, C4591001 1001 10011118, C4591001 1001 10011125, C4591001 1001 10011126, C4591001 1001 10011129, C4591001 1001 10011131","Pandemic Response, Public Health, Needs-review, COVID-19, SARS-COV-2 NAAT, Clinical Study, Dose 1, M5, Symptom Listing, Vaccine Trial, Adverse Events, Medical Data, Healthcare, Efficacy Population",False,False,False,True
27034_S9_M1_response-01-dec-2020-stat.pdf,Pfizer-BioNTech COVID-19 Vaccine EUA 27034 Response,2020-12,https://drive.google.com/file/d/12b4ROLTZwE5eG0Lrn2H8yG8fZT75_czY/view?usp=drivesdk,eua-063025,PDF,4,M1,response,"Michael Smith, Elisa Harkins","Emergency Use Authorization, FDA, M1, Vaccine, Clinical Trial, Safety, Dataset, Regulatory Compliance, COVID-19, Data Analysis, BioNTech, Pfizer, December 2020, Information Request",False,False,False,True
27034_S9_M1_cover.pdf,Request for Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine,2020-12-02,https://drive.google.com/file/d/1T8wO3-_NYzpcLkl84WRbafAm0pmXiHqD/view?usp=drivesdk,eua-063025,PDF,2,M1,letter,"Marion Gruber, Ph.D., Elisa Harkins","Emergency Use Authorization, FDA, Pharmaceutical, Pandemic Response, M1, Vaccine Research And Review, Vaccine, Public Health, COVID-19, Center For Biologics Evaluation And Research, Regulatory Affairs, BioNTech, Pfizer, Global Product Development",False,False,False,True
29__EUA 27034_12-09-2020_Telecon_EUA ADVICE _UC_.pdf,EUA 27034 - Pfizer-BioNTech COVID-19 Vaccine - CBER comments on Fact Sheets,2020-12-09,https://drive.google.com/file/d/1EWnO3n31vb0vzPG0QPIN3G0zRD5c6ikm/view?usp=drivesdk,eua-063025,PDF,49,,email,"Naik, Ramachandra, Harkins Tull, Elisa, Devlin, Carmel M, Smith, Michael (CBER), Boyce, Donna","EUA 27034, FDA, Vaccine, COVID-19, Regulatory, Recipients And Caregivers, Fact Sheets, Vaccine Information, CBER Comments, Pfizer-biontech, Vaccine Distribution, December 2020, Vaccination Providers",False,False,False,True
27__27-Nov-2020 RAMACHANDRA NAIK _UC_ Clarification to comment 2 on PVP sent on 11-25-2020 was sent.pdf,Clarification to comment 2 on PVP,2020-11-27,https://drive.google.com/file/d/1sPvSdWaUh1xaBZOPRObgqZzi8gLRR0Yd/view?usp=drivesdk,eua-063025,PDF,2,,email,"Ramachandra Naik, Elisa Harkins Tull, Carmel M Devlin, Michael Smith, Donna Boyce","FDA, Vaccine, Clarification, Pharmacovigilance Plan, Needs-review, COVID-19, Regulatory, EUA, Pediatric Age Groups, Missing Information, Pfizer, Comment Response, BioNTech",False,False,False,True
28__EUA 27034_11-25-2020_Telecon_EUA INFORMATION REQUE.pdf,28  EUA 27034 11-25-2020 Telecon EUA INFORMATION REQUE,undated,https://drive.google.com/file/d/1uHEQASqw2iiSbsrkr-woKTPnMNTjoDHj/view?usp=drivesdk,eua-063025,PDF,11,,document,,"FDA, Review-needed, Vaccine, Study, Exclusion, 2020, COVID-19, Data",False,True,False,True
2A__EUA review Pfizer Facility Section 2020.12.10.pdf,EUA review Pfizer Facility Section,2020-12-10,https://drive.google.com/file/d/1wTdgFJadmO-XDW9nINwLGnB_NvObe5oP/view?usp=drivesdk,eua-063025,PDF,8,,report,"Laura Fontan, Christine Harman, Kathleen R. Jones, Carolyn Renshaw, John Eltermann, Mary A. Malarkey, Ramachandra Naik, Haruhiko Murata, Xiao Wang, Lori Peters, Deborah Trout","Pfizer Facility, Emergency Use Authorization, BNT162B2, OCBQ/DMPQ/MRBI, COVID-19 Vaccine, Drug Product, Ovrr/dvp/ldv, Quality Control, Container Closure, Manufacturing Review, Quality Systems, Ocvrr/dvrpa/cmc3, Drug Substance",False,False,False,True
2__0_11-Dec-2020_KATHLEEN_KATHLEEN__RP_ DMPQ Discipline Review for EUA of BNT162b2.pdf,DMPQ Discipline Review for EUA of BNT162b2,2020-12-11,https://drive.google.com/file/d/1zZ6TDqfJEScWZwbVd1-iqKXcNpyMoE6q/view?usp=drivesdk,eua-063025,PDF,2,,review,"KATHLEEN KATHLEEN, NAIK, RAMACHANDRA, WOLLERSHEIM, SUSAN, LEE, LUCIA H, NAIR, NARAYAN, ELEKWACHI, OLUCHI, KANNAN, BHANUMAHTI, BALDWIN, BRENDA, FONTAN, LAURA, WANG, XIAO, WELSH, KERRY, STEWART, DAPHNE, MURATA, HARUHIKO","BNT162B2, SARS-COV-2, Clinical Development, IND 27034, Vaccine, COVID-19, Prevention, Regulatory, Lipid Nanoparticles, EUA, Drug Manufacturing, Pfizer-biontech, Spike Protein, Dmpq Review",False,False,False,True
30__EUA 27034_12-10-2020_Telecon_EUA INFORMATION REQUE.pdf,EUA 27034 - Pfizer-BioNTech COVID-19 Vaccine - Request for Pfizer-BioNTech relationship letter,2020-12-10,https://drive.google.com/file/d/1tIUeuE_gxl_dgQ_qqUvjq2XxwRLaIhLb/view?usp=drivesdk,eua-063025,PDF,1,,email,"Naik, Ramachandra, Harkins Tull, Elisa, Devlin, Carmel M, Smith, Michael (CBER), Boyce, Donna","EUA 27034, Pfizer-biontech Relationship, Pfizer-biontech COVID-19 Vaccine, Pharmaceutical Collaboration, Vaccine Authorization, Manufacturing Oversight, COVID-19 Pandemic, Regulatory Compliance, FDA CBER, Regulatory Request, Biologic Product, Vaccine Development, Vaccine Manufacturing",False,False,False,True
32__EUA 27034_12-11-2020_Letter_EUA AUTHORIZED _UA_.pdf,EUA Authorization Letter for Pfizer-BioNTech COVID-19 Vaccine,2020-12-11,https://drive.google.com/file/d/1FQ0RJSphby7_1uMc8qlxJlHXlHxLk8P2/view?usp=drivesdk,eua-063025,PDF,9,,letter,Ms. Elisa Harkins,"Emergency Use Authorization, FDA, SARS-COV-2, Vaccine, Public Health, Clinical Trials, COVID-19, Regulatory, EUA, Pfizer-biontech, December 2020, Immunization, Pandemic",False,False,False,True
31__EUA 27034_12-10-2020_Telecon_EUA OTHER _UO_.pdf,EUA 27034 - Pfizer-BioNTech COVID-19 Vaccine - Request for Pfizer-BioNTech relationship letter,2020-12-10,https://drive.google.com/file/d/12jIBcOl1hPAOaoAu5ok1CIIKUZ7_6E8v/view?usp=drivesdk,eua-063025,PDF,1,,email,"Ramachandra Naik, Elisa Harkins Tull, Carmel Devlin, Michael Smith, Donna Boyce","EUA 27034, CBER, Fda-cber, Pharmaceutical Partnership, Pfizer-biontech COVID-19 Vaccine, Manufacturing Oversight, OVRR, FDA Communication, Regulatory Compliance, Biologics Evaluation, Vaccine Development, Vaccine Research And Review, December 2020",False,False,False,True
34__EUA 27034_12-11-2020_Telecon_EUA ADVICE _UC_.pdf,EUA Advice Telecon,2020-12-11,https://drive.google.com/file/d/1GCH9e_sHWk5-xlWLsogEKPXDYNg9A8Pe/view?usp=drivesdk,eua-063025,PDF,41,,email,"Marion Gruber, Donna Boyce, Ramachandra Naik, Michael Smith","Emergency Use Authorization, FDA, Letter Of Authorization, Vaccine, Needs-review, COVID-19, Recipients, Fact Sheet, Pfizer, Vaccination Providers, Caregivers",False,False,False,True
33__EUA 27034_12-11-2020_Memo_EUA - OTHER _UO_.pdf,Emergency Use Authorization (EUA) for an Unapproved Product,2020-12-11,https://drive.google.com/file/d/1ukD_4RJqGAOJ5kd2m4LAkAF6ISUFDhVI/view?usp=drivesdk,eua-063025,PDF,57,,memo,"Marion F. Gruber, Ramachandra Naik, Michael Smith, Susan Wollersheim, Nabil Al-Humadi, Lei Huang, Haruhiko Murata, Xiao Wang, Laura Fontan, Kathleen Jones, Kerry Welsh, Narayan Nair, Brenda Baldwin, Bhanumathi Kannan, Oluchi Elekwachi","Emergency Use Authorization, FDA, Pandemic Response, Vaccine, Clinical Trial, Safety, Public Health, Regulatory Review, COVID-19, BioNTech, Pfizer, Efficacy, Immunization",False,False,False,True
5__1_23-Nov-2020_RAMACHANDRA_RAMACHANDRA__RE_ Narratives and CRFs for all SAEs and Study discontinu.pdf,Narratives and CRFs for all SAEs and Study discontinuations,2020-11-23,https://drive.google.com/file/d/1Wl1_CJWJx4IiDpGo6rFE8Kt7XsQl1jCi/view?usp=drivesdk,eua-063025,PDF,1,,memo,"RAMACHANDRA RAMACHANDRA, NAIK, RAMACHANDRA, WOLLERSHEIM, SUSAN, SENN, KEVIN, SMITH, MICHAEL J","Review, Narratives, Serious Adverse Events, Clinical Trials, COVID-19, IND, Regulatory, EUA, Study Discontinuations, Spike Protein, CRFS, Submission, BioNTech, Pfizer, Amendment, SARS-COV-2, Vaccine, Adverse Events, Lipid Nanoparticles",False,False,False,True
3__01-Dec-2020 MICHAEL SMITH _UI_ UI_ UO_ UO_ STATISITCAL IR REGARDING DATASETS - see EDR for full .pdf,CBER Comments regarding datasets - Assigning subjects with N-binding Antibody Neg at Visit 1 Flag,2020-12-01,https://drive.google.com/file/d/1rhDfsWhXemt5YJHK0T5Pt4EaQ9OOJLLk/view?usp=drivesdk,eua-063025,PDF,2,,memo,"Michael Smith, Elisa Harkins","CBER, FDA, SARS-COV-2, Vaccine, Clinical Trial, Dataset, Antibody, COVID-19, Regulatory, IND, Data Analysis, BioNTech, Pfizer",False,False,False,True
4__01-Dec-2020 MICHAEL SMITH _UO_ UO_ UI_ UI_ IR   response RE QC REVIEWED FINAL DRAFT REPORT FOR D.pdf,EUA 27034 - Pfizer-BioNTech COVID-19 Vaccine - Timeline to submit the QC reviewed DART study report,2020-12-01,https://drive.google.com/file/d/1iVN726xI1b8dZjxqfDkY0kTFwFrCfoON/view?usp=drivesdk,eua-063025,PDF,2,,email,"Elisa Harkins Tull, Ramachandra Naik, Michael Smith, Carmel Devlin","EUA 27034, FDA Submission, Pfizer-biontech COVID-19 Vaccine, DART Study Report, Clinical Trials, Developmental And Reproductive Toxicology, Needs-review, Vaccine Development, Regulatory Affairs, December 2020, Pregnancy, QC Review",False,False,False,True
8__02-Dec-2020 MICHAEL SMITH _UI_ UO_ UI_ UO_ IR regarding Bell`s palsy and the Active surveillance.pdf,Bell's Palsy and Active Surveillance for COVID-19 Vaccine,2020-12-02,https://drive.google.com/file/d/1M8CkoNcGxA6SuL-XaP4Pgd_C3rWNVLHG/view?usp=drivesdk,eua-063025,PDF,3,,memo,"Michael Smith, Elisa Harkins","Vaccine Research, COVID-19 Vaccine, Active Surveillance, Public Health, Vaccine Safety, Clinical Trials, Regulatory Affairs, Adverse Events, Vaccine Development, Pfizer-biontech, Bell's Palsy, FDA Review, Vaccine Monitoring",False,False,False,True
7__1_EUA_20-Nov-2020 MICHAEL SMITH _UI_ UO_ UO_ UI_ REQUEST FOR A STATUS UPDATE WHEN SARS-COV-2 NAA.pdf,REQUEST FOR A STATUS UPDATE WHEN SARS-COV-2 NAA,2020-11-20,https://drive.google.com/file/d/1QA65vcKOtN-eAlNuiZdxC76_dxvXbZpW/view?usp=drivesdk,eua-063025,PDF,1,,email,"Michael Smith, Elisa Harkins Tull, Carmel Devlin, Ramachandra Naik","FDA, SARS-COV-2, Illness Samples, Data Request, Visit Samples, NAAT Data, COVID-19, Molecular Testing, Status Update, Vaccine Development, Regulatory Affairs, Clinical Trial, Pfizer",False,False,False,True
6__1_EUA 27034_12-11-2020_Telecon_EUA OTHER _UO_.pdf,EUA 27034 - Pfizer-BioNTech - LOA and final Fact Sheets and EUA Full PI,2020-12-11,https://drive.google.com/file/d/1N6XtiqWHz3-Gz2-Nal8Ploex6sICA6A5/view?usp=drivesdk,eua-063025,PDF,41,,email,"Ramachandra Naik, Elisa Harkins Tull, Michael Smith, Carmel Devlin, Paul Rohlfing, Donna Boyce","EUA 27034, FDA, CBER, EUA Full Pi, Healthcare Providers, Letter Of Authorization, COVID-19 Vaccine, Vaccine Caregivers, Vaccine Safety, Regulatory, Fact Sheets, Vaccine Information, Vaccine Administration, Pfizer-biontech, Vaccine Distribution, Vaccine Recipients",False,False,False,True
9__02-Dec-2020 MICHAEL SMITH _UI_ UO_ UO_ UI_ BiMO Information Request _missing information_ - see .pdf,BiMO Information Request,2020-12-02,https://drive.google.com/file/d/1QT9P1UWTMW0v8LtSTgk5kvS5KxVpeLUK/view?usp=drivesdk,eua-063025,PDF,2,,information request,"Michael Smith, Elisa Harkins","CBER, FDA, Vaccine, Clinical Trial, Medical Information Request, Regulatory Compliance, COVID-19, Needs-review, Adverse Events, Missing Data, BioNTech, Pfizer",False,False,False,True
FDA-CBER-2021-5683-1788582-1788585_27034_S5_M1_response-23-nov-2020-appendix-1.docx,COVID-19 Vaccine Efficacy Analysis,2020-11-23,https://docs.google.com/document/d/1Qeh16wKQOvw8PxqXgA3p5hXe3n2bwDkK/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-063025,DOCX,1,M1,report,,"CBER, FDA, Immune Response, Medical Research, M1, Vaccine, Public Health, COVID-19, Regulatory, Data Analysis, Clinical Trial, Infection, Efficacy, Pandemic",False,False,False,True
FDA-CBER-2021-5683-1788479-1788523_27034_S4_M5_c4591001-508-compliant-tables.docx,Clinical Overview,2021,https://docs.google.com/document/d/1KDhrJ2TKje8SFSzblDbssJmCOmvOpjfk/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-063025,DOCX,2,M5,report,,"Primary Endpoint, BNT162B2, FDA Submission, Vaccine, Demographic Characteristics, Clinical Trials, Subject Disposition, COVID-19, Regulatory Compliance, M5, Safety Population, Secondary Efficacy, Efficacy Results, Evaluable Efficacy",False,False,False,True
FDA-CBER-2021-5683-1789170-1789213_27034_S14_M5_c4591001-508-compliant-tables.docx,c4591001 COVID-19 Vaccine Efficacy Tables,2021,https://docs.google.com/document/d/1dxPHSGJiTgGtxD_fo7xLLlLKGVi3Ojky/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-063025,DOCX,2,M5,tables,,"CBER, FDA, Primary Endpoint, Medical Research, COVID-19 Vaccine, Safety, Subject Disposition, Regulatory Compliance, M5, Demographics, Secondary Endpoint, Clinical Trial, Data Analysis, Efficacy",False,False,False,True
FDA-CBER-2021-5683-1790070-1794788_27034_S1_M5_c4591001-safety-fa-eff-A-admh.xpt,c4591001 Safety and Efficacy Analysis,2021-06-05,https://drive.google.com/file/d/1LLOTRB1XARcr1UyYgO6twpoYcJw3edeM/view?usp=drivesdk,eua-063025,XPT,38088,M5,data,,"CBER, FDA Submission, Safety Analysis, Vaccine, Regulatory Compliance, COVID-19, C4591001, Medical History, M5, Adverse Events, Data Analysis, Clinical Trial, Efficacy Analysis, Pharmaceutical Research",False,False,False,True
FDA-CBER-2021-5683-1794789-1799444_27034_S1_M5_c4591001-ia efficacy-S-mh.xpt,c4591001 Vaccine Efficacy Data,2021-06-05,https://drive.google.com/file/d/1_gDsgqm6SvJT5VbvVVKiFUvEZ1r1-hxc/view?usp=drivesdk,eua-063025,XPT,19434,M5,data,,"CBER, FDA, Vaccine, Redacted, Medical History, C4591001, Data, M5, Study Id, Adverse Events, Clinical Trial, SAS, Efficacy, Subject Id",False,False,False,True
FDA-CBER-2021-5683-1799445-1804163_27034_S1_M5_c4591001-safety-fa-eff-S-mh.xpt,c4591001 Safety and Efficacy Data,2021-06-05,https://drive.google.com/file/d/1OvvQjAryQ_NMLGeeh6U0iOz9t3Twd2qg/view?usp=drivesdk,eua-063025,XPT,19697,M5,data,,"Pharmaceutical, FDA Submission, Medical Research, Vaccine, Public Health, Regulatory Compliance, COVID-19, C4591001, M5, Biostatistics, Data Analysis, Clinical Trial, Safety Data, Efficacy Data",False,False,False,True
FDA-CBER-2021-5683-1804341-1804342_22A__EUA 27034 asymptomatic table for Pfizer.docx,EUA 27034 Asymptomatic Table for Pfizer,2021,https://docs.google.com/document/d/1q5QPQtamRI_iVGEd24AWoLXP4Ot32B8y/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,eua-063025,DOCX,1,,report,,"CBER, FDA, BNT162B2, Severe Cases, COVID-19, Regulatory, Vaccine Data, Prior Infection, Clinical Trial, Efficacy Analysis, Pfizer, Cmi Data, Immunogenicity",False,False,False,True
